¥xÆW¥¼¤W¥«ªÑ²¼ °]¸gºô 

¥¼¤W¥«  

¥¼¤W¥«ªÑ²¼¦æ±¡,¿³ÂdªÑ²¼¶R½æ,¥¼¤W¥«ÂdªÑ²¼¬d¸ß,§Ö³t´x´¤¥¼¤W¥«ªÑ²¼¶R½æ¯ß°Ê

Åwªï¨Ó¨ì¥²´Iºô ¤â¾÷ª© ¥[¤J·|­û µn¤J ­º­¶
¥¼¤W¥«ÂdªÑ²¼¦æ±¡¬d¸ß,¥¼¤W¥«ªÑ²¼¶R½æ¹L¤á,¿³ÂdªÑ²¼¦æ±¡¬d¸ß¡ã§K¥I¶O±M½u¡G0800-035-178
°Q½×°Ï>ÃĵØÂåÃÄ
ªø´Á«ù¦³¥Ø¼Ð»ù500¤¸¥H¤W     µoªí·s¸ÜÃD ¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¥ý¶i10000164  µoªí®É¶¡:2014/7/22 ¤W¤È 09:05:58
ÃÒ¥æ©Ò­«¤j°T®§¤½§i

(6446)ÃĵØÃĤ½§i¥»¤½¥q¦V¬ü°êFDA¥Ó½ÐP1101¥Î©óªvÀø¯u©Ê¬õ¦å²y¼W¥Í¯g(Polycythemia Vera)¤§²Ä¤T´ÁÁ{§É¸ÕÅç¡A¤wÀòFDA®Ö­ã¡C

1.¨Æ¹êµo¥Í¤é:103/07/21

2.¤½¥q¦WºÙ:ÃĵØÂåÃĪѥ÷¦³­­¤½¥q

3.»P¤½¥qÃö«Y(½Ð¿é¤J¥»¤½¥q©ÎÁpÄݤ½¥q):¥»¤½¥q

4.¬Û¤¬«ùªÑ¤ñ¨Ò(­Y«e¶µ¬°¥»¤½¥q¡A½Ð¶ñ¤£¾A¥Î):¤£¾A¥Î

5.µo¥Í½t¥Ñ:¥»¤½¥q¦V¬ü°êFDA¥Ó½ÐP1101¥Î©óªvÀø¯u©Ê¬õ¦å²y¼W¥Í¯g(Polycythemia Vera)¤§²Ä¤T´ÁÁ{§É¸ÕÅç(IND½s¸¹119047)¡A¤wÀòFDA¥¿¦¡³qª¾¥i«ö­pµe¶i¦æ(¥ç§Y¬ü°êFDA®Ö­ã±µ¨ü¦b¼Ú¬w¶i¦æ¤§²Ä¤T´ÁÁ{§É¸ÕÅç­pµe)¡C

6. ¦]À³±¹¬I:¶i¦æ¤½§i¡C

7.¨ä¥LÀ³±Ô©ú¨Æ¶µ:

(1)¥»¤½¥q«e©ó102¦~9¤ë26¤é»P¬ü°êFDA¶i¦æPre-IND meeting¡A·|¤¤FDA©x­û«Øij¥»¤½¥q¥i¿ï¾Ü¶È¥H¦b¼Ú¬w¶i¦æ¤§PROUD-PV trail(§YP1101¥Î©óªvÀø¯u©Ê¬õ¦å²y¼W¥Í¯g²Ä¤T´ÁÁ{§É¸ÕÅç)¼Æ¾Úµ²ªG¡A³w°e¬ü°êFDA¥Ó½ÐÃÄÃÒ¡C

(2)PROUD-PV trail«Y¥»¤½¥q±ÂÅv(Out-Licensing)¹Ù¦ñAOP¤½¥q¦b¼Ú¬w¶i¦æ¤§²Ä¤T´ÁÁ{§É¸ÕÅç¡F¸g»PAOP¤½¥q¨ó°Ó«áij©w¡A¥Ñ¥»¤½¥q©e°UAOP¤½¥q¾á¥ôCROÅU°Ý¡A¨ó§U¬ü°êIND¥Ó½Ð°e¥ó¨Æ©y¡C



¶}ª©·|­û¡u¥ý¶i¡v½Ðºô¤Íµo¨¥µÛ­«©ó²z©Ê°Q½×·sÃĶi«×¡AµL¿×¤£²z©Êªº¥´À£¡A½Ð¦Ü¨ä¥Lª©°Ï¡A¤À¬y¬O¬°¤F¦³§Q§ë¸ê¤H·j´M

·|­û¡G§ë¸ê¬ö«ß10145266  µoªí®É¶¡:2018/6/27 ¤W¤È 11:30:03²Ä 4669 ½g¦^À³
¸É¥R¡G

¦]¬°AOP«ùÄò­A¤p¤â¬q

¦b°ê»Ú³q°Ó(¦³Â×´I¥òµô¸gÅç¤SÀ´ÂåÃÄ)«Øij¤U¡A¦h¦¸±Hµoĵ§i¨ç

¦ýAOP¤´¥¼¥æ»ô¸ê®Æ¤©ÃĵØÃÄ¡AÄÝÄY­«¹H¬ù

³Ì«á¦b«ß®v«Øij¤U»PAOP¸Ñ°£¦X¬ù

¦ý¦]¬°¸â¸³©À¤Î»PAOP¤w¦X§@8~9¦~¤§¤[

¬G¸Ñ¬ù¦P®É¡A¥çªþ¤W·s¦X¬ùµ¹AOP¡AÅýÂù¤è¯àÄ~Äò¦X§@

«ß®vµû¦ô¡A¥Ø«e¬Ý¨Ó¥òµô®×¹ïÃĵØÃĸû¦³§Q

¦]¬°AOP¥òµôªº¶D¨D¬O®³¤£¨ìEMAÃÄÃÒ«e´£¤U¡A±N¦VÃĵØÃįÁ°Q20¦~ªº½æÃÄ·l¥¢

¦ýEMAÃÄÃҥثe¬Ý°_¨Ó¨S°ÝÃD

¦]¬°AOP­t³dªº³¡¥÷¬OÁ{§É¡A¤w§â¸ê®Æ´£¥æEMA¡A¦ÓÃĵØÃÄ­t³dªº¬OCMC¡A¥ç¤w±N¸ê®Æ°eµ¹EMA

EMA­Y¹ïCMC¦³ºÃ°Ý¡AÃĵØÃĤ@©w·|¸É¥¿¨ì¨S°ÝÃD¬°¤î

©Ò¥H¤£·|¦³AOP©Ò¿×®³¤£¨ìEMAÃÄÃÒªº«e´£

¦ÓÃĵØÃÄ´£¥Xªº¤Ï¥òµô¡A¬O«ü·s¦X¬ù

¦pªG¤Ï¥òµô¤£©¯¤¤ªº¤£©¯¿é¤F¡A´N¬O¨«¦^¦X¬ù

³Ñ¤Uªº´N¥u¬OÂù¤è¥òµô©Ò­nªá¶Oªº¶O¥Î

¥H¤W»¡©ú­Y»P¤½¥q·s»D½Z¦³¥X¤J¡A½Ð¥H¤½¥q¬°¥D¡AÁÂÁÂ

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GAnderson10143089  µoªí®É¶¡:2018/6/27 ¤W¤È 11:24:22²Ä 4668 ½g¦^À³
¦b°Ó¨¥°Ó¡AAOP¤]¤£¬O¦ò¤ß¨Óªº¡A¨âÃä³£·Q¬°ªÑªFª§¨ú³Ì¤j§Q¯q¡AµL¥i«p«D¡C
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GÃƪѥÁ10147162  µoªí®É¶¡:2018/6/27 ¤W¤È 10:59:23²Ä 4667 ½g¦^À³
·P®¦~~ AOP¬°¤F©ê¬ü°ê¾P°âÅv¤§¤³, ¤p¤â¬qÁÙ¯u¦h...ª±¥@¬É¬×ªº¹ï¤âÁ`¬O·|¤ñ¸û±j, ¥[ªoêy
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤p¥øÃZ10142872  µoªí®É¶¡:2018/6/27 ¤W¤È 10:57:56²Ä 4666 ½g¦^À³
³£­n¶}½æ¤F

¨â¤è²{¦b¤~¶}©l¶i¦æ©Ò¿×ªºªk«ß¥òµô

¨ä¹êÂù¤è³£¤£¬O²Â³J

¥u¬O¬°¤F¯u¥¿¤W½Í§P®à¤W¥ý©ñ¸Ü

¥u¬O¬°¤F±N¦Û¤vªº§Q¯q·¥¤j¤Æªºµ¦²¤

³oºØ¸ò¹q¤l·~ªº±M§Q¶D³^, §¹¥þ¤£¦P

©Ò¥H¤£¥Î¤Ó¾á¤ß

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G§ë¸ê¬ö«ß10145266  µoªí®É¶¡:2018/6/27 ¤W¤È 10:54:06²Ä 4665 ½g¦^À³
ªL°õ¦æªøªº·N«ä¬O

AOP³v¦¸µ¹ªº¸ê®Æ¥Ø«e¨¬°÷»PFDA½Í±µ¤U¨ÓªºCSR¶¥¬q

¦ý¥¼¨Ó­n®³¨ìÃÄÃÒ¡A¸ê®ÆÁÙ¬O¤£»ô

¦]¬°FDA¦Û¤v¦³¤ÀªR¸ê®Æªº¤è¦¡

©Ò¥H¤~»Ý­n¸É»ôRaw Data°e¥æFDA¤ÀªR

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GÃƪѥÁ10147162  µoªí®É¶¡:2018/6/27 ¤W¤È 10:27:13²Ä 4664 ½g¦^À³
¦³°Ñ»PªÑªF·|ªºªB¤Í·Q½Ð±Ð¤@¤U

´N§ÚÅ¥¨ìªLÁ`»¡¥Ø«eFDAªº¸ê®Æ¤j­P¤WAOP³£µ¹¤F, ¦ýÁٻݤֳ¡¤À, ¤£­«­n¦ý¥¼¨Ó°e¥óÁÙ¬O»Ý­n?

¨º¤£´N¥NªíÁÙ¬O±o¹GAOP§â¸ê®Æ®³¥X? ¦pªG¥òµô®×«ùÄò, ¸ê®ÆµLªk¨ú±o, ¨º¤£¬O¤S·|©ì¨ì¬ü°êªº®Éµ{?

¤w¸g§ë¸ê¶W¹L3¦~¥H¤W, ¤]³£¦³¦bÅ¥¨ú¤j®aªºµo¨¥, ªñ´Á·Pı¤½¥q¦³ºØ¼·¶³¨£¤éªº·Pı.....

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GºÖ«°10145527  µoªí®É¶¡:2018/6/27 ¤W¤È 10:06:21²Ä 4663 ½g¦^À³
­A¼L¯¥.......

¯u¥®¸X.......

ÃĵØÃĺ¦........

¦Y¨ý´N¨Ó¶Ã........

¦ó¥²°Ç..............

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤p¥øÃZ10142872  µoªí®É¶¡:2018/6/27 ¤W¤È 10:04:41²Ä 4662 ½g¦^À³
700¤¸¶R¤j¥ß¥úªºªB¤Í, »¡³oÀɬO¦nªÑ²¼

6000¶R¤j¥ß¥úªºªB¤Í, »¡³oÀɬOÄêªÑ²¼

¦ý¨S¤H»¡¥L¬OÄꤽ¥q

HTC §ó¬O¸g¨å

¤j®a³£¬O¨ÓÁȸꥻ§Q±oªº

¤£¬O·Q­n±µ¤J¸gÀç©Î¬O·í¸³ºÊ¨Æ

¶R½æ¤~¬O¨M©wÁȽß

¨ä¥L³£¬O¹Lµ{

ª÷¿Ä¥«³õ«Ý¶V¤[

¶Vı±o¥«³õ®ø®§¶Ç»Dµê°²©~¦h

6446 ³s­É¨é©ñªÅ³£µLªk°µ

·|¦³¤H³o»ò¦n¤ß´£¿ô¤j®a¤£­n¶R

¯u¬O¦ò¤ß¨Óªº

§Ú¬O«Øijª©¥D

ºû«ù½×¾Âªº«ÈÆ[©Ê

¤j®a®³¥ô¦ó¦hªÅÃÒ¾Ú¦õÃÒ³£¥i¥H

¤£»Ý­n¤f¤ô¾Ô

§ó¤£»Ý­n´£¨Ñ¶R½æ«Øij

¦A»¡¤@¦¸

¤j®a³£¬O¨ÓÁȸꥻ§Q±oªº

¤£¬O·Q­n±µ¤J¸gÀç©Î¬O·í¸³ºÊ¨Æ

¶R½æ¤~¬O¨M©wÁȽß

¨ä¥L³£¬O¹Lµ{

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GRussell10140734  µoªí®É¶¡:2018/6/27 ¤W¤È 08:55:05²Ä 4661 ½g¦^À³
­«­nªº¨Æ¤Ï¦Ó§Ñ¤F´£¡K

·PÁ¦U¦ì¤j¤jµL¨pªº¤À¨É!!

·Ó¤j®a´£¨Ñªº¸ê°T¬Ý¨Ó¡A

Ãĵزæ­L´«°©¡K´N¬Ý³o­Ó´»°²¤F¡K

Ãĵإ[ªo!!

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GRussell10140734  µoªí®É¶¡:2018/6/27 ¤W¤È 08:19:28²Ä 4660 ½g¦^À³
«¢~

¬P¬P¤p¶R­Ó´X±i¡A¥u¬°¤F©Î³\¦³½t°Ñ¥[¨ÖÁʲ±¨Æ¡A

¸ò«ù¦³ªº¤¤¸Î¡BÃĵؤñ¡A¤£¹L¤E¤û¤@¤ò¡C

¬Ý¬Ý¤H®aªº§V¤O¡A§Ú­Ì¸òµÛ§ë¾÷/§ë¸ê¤@¤U¡K

¦Aµ¥Â½µPÅo¡I

¨ä¹ê¸Ü»¡¦^¨Ó¡A¤j®a¹ï·sÃĪѦU¦³°¾¦n¡K

¤j®a¤@°_¥[ªo¹ªÀy¤£¬O«Ü¦n¡K

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GÂyªÌ10142287  µoªí®É¶¡:2018/6/27 ¤W¤È 08:02:35²Ä 4659 ½g¦^À³
«¢«¢¡ã

§A­Ì¦b¶D»¡¦Û¤v¶Ü¡H

Ây¤H°O±o⋯,§A¦Û¤v¡uµVµV¡v¤]ª¼§ë¡]¸¨¤J

°é®M¡^¡A©Î³\Ãĵؤ]§Y±N¨B¤J«á¹Ðªº¡A

§O·W⋯,ºCºC¨É¨ü®M¨cªº´þ¨ý⋯,®ÉÁÙ¦³º©º©ªø¸ô

­n¨«ªº⋯¡I

¦Ü©ó¯E¹©¡B¤¤¸Î¡A«ùªÑ³£¤»¦~¥H¤W¤F⋯,

¨SÔ£·Pıªº⋯,¦³¨Çº¦5­¿⋯,¦³¨Ç¤p½ß´X¤Q¢H⋯,

´N⋯,·Ó±`¥´Ây¹L¤é¤l°Ú⋯,

¤£¿ù⋯,¤d¸U§O©ã¨­®a⋯,

¤×¨äµVµV¡BÃĵØ⋯,­n¤£µM·|´¨¤ß¨xªº⋯!

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GRussell10140734  µoªí®É¶¡:2018/6/27 ¤W¤È 07:11:36²Ä 4658 ½g¦^À³
¥i´c¤§¤H¥²¦³¥i¼¦¤§³B¡K

·í¦~¯E¹©¤@§Ð¡A¤Ó¦h¤H©ã¨­®a¡A

¬Æ¦Ü³sªk³W¤Wªº¥¢±Ñ¡K³£¤´¤£Ä@¾A®É¤U¨®¡C

°í«ùµÛ¬ì¾Çªº¦¨¥\¡C

­ü¡K·í§½ªÌ¬O¯uªºÀ³¸Ó¤ß¦sµ½©À¡K

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G·s¶i10143606  µoªí®É¶¡:2018/6/26 ¤U¤È 10:49:52²Ä 4657 ½g¦^À³
¨Ì¾ÚªÑªF·|«á¡A³\¦hªÑªF³òµÛ¶ÀÁ`¦³°Ý³o­Ó°ÝÃD¡A¶ÀÁ`ªº¦^µª¬O7 8¤ë°eFDAªº¬OCSR¸ê®Æ¡AÁÙ¦³¸òFDA¶}¤F¥|¦¸·|ij¡AFDA³£¨S¦³´£¨ìÁ{§Éªº¨Æ¡A¬Æ¦Ü¦b²Ä¥|¦¸FDA³Bªø¥X®u®ÉÁÙ¥D°Ê½Í¨ì¥é³æ¼ÐÅÒªº¨Æ¡C

¥i¯à¬O³o¼Ë...©Ò¥HªÑªF·|®ÉªL°õ¦æªø¤~»¡À³¸Ó¬O©ú¦~«á¥b¦~·|¦³¾÷·|¨ú±o¬ü°êÃÄÃÒ¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¶È¨Ñ°Ñ¦Ò10146497  µoªí®É¶¡:2018/6/26 ¤U¤È 10:37:33²Ä 4656 ½g¦^À³
§Ú¬ðµM¦³ÂI¦P±¡ÂyªÌ¤j¤F¡A§Ú¥»·Q¬JµM¬O¤s¤W¥´¤s½Þªº¡A·F¹À¨Ó¨ì¤Z¶¡¬°®`¶m¥Á¡A¥»·Q¤£²z¥Lªº¡A¤]ı±o¤j®a·F¹À­n¸ò¥L¤@¯ë¨£ÃÑ

¥i§Ú²{¦b¤~ª¾¡AÂyªÌ¤j¤]¬OªÑ¥«ªåªå²³¥Í¤¤´¿¸g¨ü¶Ë¤£¤Öªº§ë¸ê¤H¡A¤~·|¤£®É¨ì¦U³B½Î½Î§i»|¤j®a¡A

­ü..¬J´¿¬O¤Ñ²P²_¸¨¤H¡A¤j®a´N¥ô¾Ì¥L§a

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GÂyªÌ10142287  µoªí®É¶¡:2018/6/26 ¤U¤È 10:15:45²Ä 4655 ½g¦^À³
·í¦³¤H¬Ý¹Ï¶Ã»¡¬G¨Æ¡A·N¹Ï§l¤Þµ½·N§ë¸ê¤H¡u¤W·í¡v¡A

枱­±¤W¤j§j¤j¾Ý¡A­I¦a𥚃ªÑ²¼¤j©ñ°e®É¡A

Ây¤H´N·|¾A®É¼å§N¤ô¡A

Åý¤@¨Ç¤H¡A§O¤W鈎·íªÎ¦Ï¡A

¦Ü©ó¨º¤äÃĪ«¦¨¤£¦¨¥\¡A¦ó®É¦¨¥\¡A

ÃöÂy¤H¦ó¨Æ¡I

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GRussell10140734  µoªí®É¶¡:2018/6/26 ¤U¤È 09:39:03²Ä 4654 ½g¦^À³
¬ÝµÛ¤H®a³q©¹¦¨¥\ªº¹D¸ô¡A

§Y¨Ï¤£Ä@¥[¤J¦¨¬°¹Ù¦ñ¦ý¤´µ¹¤©¯¬ºÖ¡K

«ÜÃø¶Ü¡H

ÁÙ¬O¨º¥y¸Ü¡K

·sÃĬO¬ì¾Ç!!

§Ú¹ç¥i¬Û«H¦å²G¦~·|¤Wªº¾ÇªÌ±M®a»PKOL¡K

©Î³\§Ú­Ì¬O²Â³J¡A

¦ýEMA¸òFDA¥i¤£¬O¶Ì¥Ê!!

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡Gavandia10146474  µoªí®É¶¡:2018/6/26 ¤U¤È 08:58:29²Ä 4653 ½g¦^À³
ªü¤¤¤j½Ð°Ý

¬ü°ê¤è­±¹w­p7¤ë©³(¥t¤@¦ìª©¤Í»¡¤K¤ë©³)¸É¥ó ¬O«ü pre-BLA meeting ­n¨Dªº CSR ¸ê®Æ¶Ü

¦~©³«e°e¥ó ¬O«ü°e NDA/BLA ?

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GÂyªÌ10142287  µoªí®É¶¡:2018/6/26 ¤U¤È 08:10:20²Ä 4652 ½g¦^À³
§O¶^­Ó´X¤¸¡A´N«ö­@¤£¦í¤F¡A¤f¥X´c¨¥¡A

Ây¤H¬Oµ½·N´£¿ô¡A

§O⋯,

­n¤£µM¡AªÑ»ù­Ë°hÃr®É¡A¤@¤Ñ¶^­Ó¤Q¨Ó¤¸®É¡A

·|ºÎ¤£µÛıªº¡A

¥h¬Ý¬Ý¥H«eªºµVµVª©¡A

Ây¤H¬Ý¨ì¤F¡A¡u¤H®a¡vÄw½X¤j©ñ°e¡A

¬P¬Pª©³y¯«ªÌ¨Ì½sÅÖ¡u¬ü¹Ú¡v¡A

«uïÔ¤H¦b80¡B¡]¶^¨ì52¤¸¡^68¤¸¡]¶^¨ì51¤¸¡^66¤¸¡A¡]¥Ø«e¤£¨ì54¡^

³sÄò¤T¦¸¥Üĵ¡A

¦³Äµ覚ªº¤H¡A¦¨¥»¦­减¥b¤F¡A

¤£¹L⋯,¥_·¥¯uªº¨S¦³µVµV¡A¥u¦³¥_·¥ºµªº

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤p¶Â10145930  µoªí®É¶¡:2018/6/26 ¤U¤È 07:35:09²Ä 4651 ½g¦^À³
²Î¤@¡K¶R5±i.½æ16±i

ª£®a.°ª°ª¤â.¹Ú¤Û°ª¤â.¥Ñ½L¤U8¤¸¦h©Ô¤W¬õ½L.¤Ñ¶ò¤U¨Ó.²Î¤@°ª¤â¼µµÛ¡K.

¬¡¨£°­¤F.

³£¤£ª¾¹D§A¬O¦b§@¹ÚÁÙ¬O¼g¤p»¡?

¤H°Ú¡K«p¹DÂI.¤£­n¬°¤F¤@ÂI¤p§Q.·l¤F¤l®]³±¼w.

¤£­n¦Ñ·R´²¼½ÁÁ¨¥.

¤£­n¦Ñ·R´²¼½¨S¦³®Ú¾Ú.¦Û¤v½M²qªº¨¥½×

(¦Û¤v½M²qªº¨Æ±¡.§ä­Óµ§°O¥»°O¿ý.¯dµÛ¦Û¤v¥¼¨ÓÅçÃÒ´N¦n..¨Ä~~~)

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤p¥¿¥¿10141351  µoªí®É¶¡:2018/6/26 ¤U¤È 07:09:28²Ä 4650 ½g¦^À³
Interferon Changes Life of Cancer Patient, Karrie Schwartz

MPN News | June 25, 2018

www.mpnresearchfoundation.org/news

Stories like Karrie¡¦s are the reason MPNRF is dedicated to investing time and resources into opportunities for repurposing existing drugs and figuring out the mechanisms of action that lead to results.

Watch the video below from news outlet ABC 7 Chicago and learn about how Interferon changed the life of cancer patient, Karrie Schwartz. Interferon is an off-label drug that is currently the only treatment to provide disease-altering effects for MPN patients. However, we don¡¦t understand why it works and why it works for some patients and not others. In an attempt to answer these question, MPN Research Foundation launched a multi-center partnership last year called the Interferon Initiative. The goal of the initiative is to explore the use of Interferon in MPN patients.

Stories like Karrie¡¦s are the reason MPNRF is dedicated to investing time and resources into opportunities for repurposing existing drugs and figuring out the mechanisms of action that lead to results. It is our hope that the Interferon Initiative will help pave the way for better interferon compounds and will bring new treatments to light for MPN patients.

¤zÂZ¯À§ïÅܤFÀù¯g±wªÌªº¥Í¬¡¡AKarrie Schwartz

MPN·s»D| 2018¦~6¤ë25¤é

¹³Karrie¡¦s³o¼Ëªº¬G¨Æ¬OMPNRF­P¤O©ó§ë¤J®É¶¡©M¸ê·½¨Ó­«·s§Q¥Î²{¦³ÃĪ«¨Ã§ä¥X¾É­Pµ²ªGªº¦æ°Ê¾÷¨îªº­ì¦]¡C

Æ[¬ÝABC 7·s»D¥Xª©ªÀªºµøÀW¡A¤F¸Ñ¤zÂZ¯À¦p¦ó§ïÅÜÀù¯g±wªÌªº¥Í¬¡¡AKarrie Schwartz¡C¤zÂZ¯À¬O¤@ºØ¤£¦X®æÃĪ«¡A¥Ø«e¬O°ß¤@¯à°÷¬°MPN±wªÌ´£¨Ñ§ïÅܯe¯f®ÄªGªºªvÀøÃĪ«¡C¦ý¬O¡A§Ú­Ì¤£©ú¥Õ¥¦¬°¤°»ò¥i¦æ¡A¬°¤°»ò¥¦¾A¥Î©ó¬Y¨Ç±wªÌ¦Ó¤£¬O¨ä¥L±wªÌ¡C¬°¤F¦^µª³o¨Ç°ÝÃD¡AMPN¬ã¨s°òª÷·|¥h¦~µo°_¤F¤@­ÓºÙ¬°°®ÂZ¯À­Òijªº¦h¤¤¤ß¦X§@¹Ù¦ñÃö«Y¡C¸Ó­Òijªº¥Ø¼Ð¬O±´¯Á¦bMPN±wªÌ¤¤¨Ï¥Î°®ÂZ¯À¡C

¹³Karrie¡¦s³o¼Ëªº¬G¨Æ¬OMPNRF­P¤O©ó§ë¤J®É¶¡©M¸ê·½¨Ó­«·s§Q¥Î²{¦³ÃĪ«¨Ã§ä¥X¾É­Pµ²ªGªº¦æ°Ê¾÷¨îªº­ì¦]¡C§Ú­Ì§Æ±æ¤zÂZ¯À¦æ°Ê¯à°÷¬°§ó¦nªº¤zÂZ¯À¤Æ¦Xª«¾Q¥­¹D¸ô¡A¨Ã¬°MPN±wªÌ±a¨Ó·sªºªvÀø¤èªk¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¦B«B10138946  µoªí®É¶¡:2018/6/26 ¤U¤È 04:54:23²Ä 4649 ½g¦^À³
¬ü°ê¤è­±½T»{¬O8¤ë©³¸É¥ó....
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡Gavandia10146474  µoªí®É¶¡:2018/6/26 ¤U¤È 01:37:16²Ä 4648 ½g¦^À³
ªÅ¤âªº¤H¬Ý°IªÑ²¼ ·Q¥H§C»ù¶R¨ì¤D¤H¤§±`±¡

¥¿©Ò¿×¶û³f¤~¬O¶R³f¤H

§_«h¥xªÑ¦³¤d¦ÊÀɪѲ¼ ©ú©ú¦Û¤v¬O4147ªÑªF

«o¦¨¤Ñ¦b§O¤H®aª©¤W¶¢®Ì¥á¤H²{²´ ©Ò¿×¦ó¨Ó?

¬Ý°I¹j¾À¤½¥q ¼J¯º¹j¾À®aªÑªF

¬O²`©È¦Û®a·sÃĪѥ¿¶ÀºXªZªL·ù¥Dªº¦a¦ì³Q¾Ù°Ê¶Ü

4147 ªÑªF¯uªº¦n¥Í©È©È ¤ñ¤­¤ë¥÷À禬¬O0ÁÙ¥O¤Hºò±i

³o§Ú´N¯u¤ß¤£¯à²z¸Ñ¦¹µ¥¥®¸X¤§¤Hªº¤ßºA¬°¦ó¤F

·íµM¦³¨Ç¤H¥H¬°¦Û¤v¬OÄw½X°ª¤â

¤@¬Ý³o¤@©P ¨é°Ó¶i¥X¤ÀÂI

°¨¤W±oª¾ª£§@°ª¤â°ª°ª¤â¨Ó¦Û²Î¤@ÃÒ

®í¤£ª¾ Äw½X¦A©ñªø»·¤@¬Ý

¥~¸ê³o¤@¦~¨Ó¦­´NÀqÀq¶R¶W 6446 ¦X­p¤­¤d¦h±i¤F

¯u­n»¡­I«á¦³¤@°¦¤â

¨º³o°¦¤â¤]¯uªº¤Ó¦h¤F¤@ÂI

Ãø¹DÃĵØÃÄ«e¨­¤D¤d¤âÆ[­^?

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G±i±M­û10145380  µoªí®É¶¡:2018/6/26 ¤U¤È 01:22:58²Ä 4647 ½g¦^À³
Ây¤jÀ³¸Ó¬OªÅ¤â²´¬õ¨£¤£±o¤H®a¦n¡Aªp¥BÃĵؤS¤£¯à©ñªÅ¦ó­Wª½°Û°I¤¤¸Î¡AÃĵØ?

®M¥ÎÀs¤¶¥Pªº«Z»y~§O¤H£°ÉÆ©ñ§¾·í«¨¤j¡F¨¿£°¦_©ñ§¾¸zªüÄê¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤p¶Â10145930  µoªí®É¶¡:2018/6/26 ¤U¤È 12:22:59²Ä 4646 ½g¦^À³
­ì¨Ó³o´N¬OÀt³À¤G¥Pªº¬Ý½L¼h¯Å..

¦ü¬O¦Ó«D+¥ª¥k°{¸ú

Á¿°ò¥»­±.¦ü¬O¦Ó«D.¥ß½×µL¾Ú¡K«ç¤@­Ó¯ä¦r¤F±o

Á¿Äw½X­±¡K§A»{ÃѲΤ@ªº¤j¤á°Ú?³Ìªñªº²Î¤@´N¬OÃĵإD¤O?½T»{¤F¦Aµo¨¥¹À.

¨SÃÒ¾Ú§A´N¬O¦b½M²q.§A´N¬O¦b´²¼½ÁÁ¨¥¡K.³s¹Ú¤Û°ª¤â³£¨Ó¤F

Á¿¤F´NÁ¿¤F.ÁÙ¦A©^¤W­Ó¶P³ß¤j®a.«ç»ò¤F.©ÈÁ¿¿ù.¥ý°Q©ç?«ç»ò³sÂIGUTS³£¨S¦³©O?

¯u¬O²´·ú·~»Ù­«.ÂI¶}´N¬Ý¨ì³oºØ¨SÀç¾iªºµo¨¥

¤£ºÞ§A¬OÀt¥ý¥ÍÁÙ¬O³À¥ý¥Í.¦æ¦æ¦n¡K

1.¼g§¹¯d¨¥.Àˬd¤@¤U.¤£­n§O¦r¨º»ò¦h

2.³ßÅwµo¨¥.´N¦A¥h¶}­Ó·sª©¡K.

¥\¼wµL¶q°Ú....

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GÂyªÌ10142287  µoªí®É¶¡:2018/6/26 ¤W¤È 11:05:10²Ä 4645 ½g¦^À³
¥B¡A³Ì­«­nªº¬O¡A

¦¹ºØ¹Ú¤Û°ª¤â¡A·U¦b½L¶Õª^³ò¤£¨Î®É¡A

¶V·|§@°f¶Õ¡A¥Hªí¥Ü¸ÓªÑ¡uí°·±j¶Õ¡v¡A

¯uªº¡A¦A¦¸¶PÁH¤j®a¡A

·Q¥²¥i°ªªEµL¼~¡A

¦]¬°¤Ñ¶ò¤U¨Ó¡A¦³²Î¤@ªº°ª¤â¼µµÛ

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GÂyªÌ10142287  µoªí®É¶¡:2018/6/26 ¤W¤È 10:32:43²Ä 4644 ½g¦^À³
¹LÁ¿¤F¡A

¤@Ã䶰¤¤¶R¶i¡B¤@¤â¹J¥Î¥~资户ÀY¡A

§l¤Þ¥«Ô·ª`¥Øªº°ª¤â¡A«D±`¤H¯à­@©Ò¤Î¡A

¯uªº°J¤ß¯¬¥ñ¤j®a¡A

¤×¨ä¦b¦¹ºØÉ]Ô·¥æ©ö®ñª^¡A

¤´µM将¥¦¥Ñ·ù¤U8¶ô¦h¡A

©Ô¤W¬õ½L¡A

Ãĵت£®a¡A¯uªº³ô称°ª¤â¤¤ªº°ª°ª¤â°Õ

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GAnderson10143089  µoªí®É¶¡:2018/6/26 ¤W¤È 10:12:45²Ä 4643 ½g¦^À³
«z¡A³o¶æ¥\°ª²`¡A¥O§Ú¤]±o°hÁפTªÙ¡C
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GÂyªÌ10142287  µoªí®É¶¡:2018/6/26 ¤W¤È 08:46:35²Ä 4642 ½g¦^À³
«z«z¡ã¤£±o¤F¡A

¦b³QÂy¤H¨Ï¥X¡u¿E±Nªk¡v«á¡A

²Î¤@ªºª£®a¡A­á©Ù±ø¤F¡A

¨Ï«l¥þ¤O¶R¶i⋯,

²{¦b¸Õ¶}½L220¤¸¤F⋯,

§A­Ì¡uºÖ¡v®ð°Õ¡A

«¢¡ã

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡Gttseng1310145885  µoªí®É¶¡:2018/6/26 ¤W¤È 07:26:34²Ä 4641 ½g¦^À³
¦U¦ì¥ý¶i¡A¬Q¤Ñ½Ð±Ð¹LAlan¤j¤§«á¡A­Ó¤H»{¬°

¬ü°êªº³¡¤À¬Ò¦b©ó¡§¤@¤Á¶¶§Q¤U¬°«e´£¡¨¡A¹w­p©ú¦~©³¥i¯à¨ú±oÃÄÃÒ

²´¤U§Æ±æ¢Ï¢Ý¢Þ¯à°÷ºÉ§Ö»PÃĵبú±o¦@ÃÑ¡A¨Ã¨ú±o©Ò¦³ÃöÁä¸ê®Æ

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡Gªü¤¤10143502  µoªí®É¶¡:2018/6/26 ¤W¤È 07:17:34²Ä 4640 ½g¦^À³
¨º¬OªL°õ¦æªø³o¼Ë»¡

¹w­p

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GRussell10140734  µoªí®É¶¡:2018/6/26 ¤W¤È 07:12:18²Ä 4639 ½g¦^À³
ªü¤¤¤j¡K½Ð°Ý¡K

¬ü°ê¤è­±¹w­p7¤ë©³¸É¥ó,¦~©³«e°e¥ó,¶¶§Q©ú¦~¤U¥b¦~¨úÃÒ!!

³o¬Oªk»¡·|³zÅSªº°T®§¶Ü¡H

¦pªG¯uªº¡K¯uªº¬O¸ó¥X¤@¤j¨B!!

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡Gªü¤¤10143502  µoªí®É¶¡:2018/6/26 ¤W¤È 06:51:47²Ä 4638 ½g¦^À³
³ºµMÁÙ´£¥X¸U¤@ÃÄÃÒ¨S¹L,­n6446¥I¾á¥þ³¡Á{§É¶O¥Î

6446«ç¥i¯à·|¦P·N

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GKid10147031  µoªí®É¶¡:2018/6/26 ¤W¤È 06:37:46²Ä 4637 ½g¦^À³
pchome.m.megatime.com.tw/news/cat1/20180619/9700006446201806191.html

Ãa¤]¨SÃö«Y¡A·Ó¦X¬ù¨Ó¡A¦Ó¥BaopÁÙ¤£¦p»°§Ö¶R¶WÃĵءAÂùĹ·|¤ñ¸û¦n

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡Gªü¤¤10143502  µoªí®É¶¡:2018/6/26 ¤W¤È 06:33:09²Ä 4636 ½g¦^À³
aop«ÜÃa

¤£¶È·Q°½p1101§Þ³N©e°U¥N¤u¼t¥Í²£,¥N¤u¼t½T»{6446±M§Q¤£´±¸I

Á{§É¼Æ¾Ú«D6446´£¸Ñ¬ù«Â¯Ù,¤£µM®Ú¥»¤£´£¨Ñµ¹6446

©Ò¥H­Ó¤H»{¬°´£¤Ï¥òµô¬O¹ïªº

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡Gªü¤¤10143502  µoªí®É¶¡:2018/6/26 ¤W¤È 06:23:24²Ä 4635 ½g¦^À³
¼Ú¬w¤è­±¸ò³ø¯È»¡±o®t¤£¦h

¬ü°ê¤è­±¹w­p7¤ë©³¸É¥ó,¦~©³«e°e¥ó,¶¶§Q©ú¦~¤U¥b¦~¨úÃÒ

­Ó¤H»{¬°¸òfda·¾³q¤£¬O°ÝÃD,FDAÀ³¸Ó¬O§Æ±æ6446»°§Ö°e¥ó,­ì¦]¥d¦bAOP³ö¨Ñ¤§«eÁ{§É¼Æ¾Ú¤£¥þ

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GRussell10140734  µoªí®É¶¡:2018/6/25 ¤U¤È 08:01:35²Ä 4634 ½g¦^À³
¬Û«H¤j®a³£¹ï¹L¥h¤@¦~¦h¨Óªº°í«ù·P¨ìªY¼¢¡K

¸ôÁ٫ܪø¡A¤j¥ë°ª¿³¤@¤U´N¦n¡C

­«ÂI¨Ó¤F¡K

¤£ª¾¦³¨S¦³°Ñ¥[ªÑªF·|ªº¤j¤j¡A

¥i§_¤£§[¤À¨É»P·|ªº­«ÂIºK­n!

ÁÂÁ¡K

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GRookie10143115  µoªí®É¶¡:2018/6/25 ¤U¤È 06:56:52²Ä 4633 ½g¦^À³
°J¤ß·PÁÂRussell¤j¡A¥H¤Î´¿¦b¦¹ª©´£¨Ñ¬ÛÃö¥¿­±°T®§©Î¬Ýªkªº¦U¦ì¤j¤j¡A

¤p§Ì2¦~«eÅ¥¤FªL°õ¦æªø¦bÃĵؤWÂd«e·~ÁZµoªí·|ªº¤@µf¨¥½×¡A¤@ªÑ¸£½Ä¤F¶i¥h¶R¶i¡Aµ²ªG¤@¸ô½L¶^¨ì140¡AÁöµM¤U¶^ªº¹Lµ{Ãø§K·|¦³®£·W¡A¦ý¦]¬°¦³§A­Ì¤@²¼µØ¤Í¡AÅý§Ú¹ïÃĵط|¦¨¥\ªº¬Ýªk©l²×¨S¦³§ïÅÜ¡A¤]¤£Â_¦V¤U©Ó±µ¡A¨ì¤µ¤Ñ¦¬½L»ù½Ä¹L¤F§Ú©Ò¦³´¿¶R¶i¹Lªº»ù¦ì¡AÁ`ºâ¦u±o¶³¶}¨£¤ë©ú¡A¤]§Æ±æÃĵدà«ùÄò¦³¦n®ø®§¡A¤]³\¯u¦³¤@¤Ñª©¥D¼ÐÃDªº»ù¦ì«Ü§Ö´N·|¨ì¨Ó¡A³Ì«á¯¬¦U¦ìµØ¤Í¾Þ§@¶¶§Q¡A¤@¤Á¶¶¤ß

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GRussell10140734  µoªí®É¶¡:2018/6/25 ¤U¤È 05:42:57²Ä 4632 ½g¦^À³
¤j¤j«È®ð¤F¡K

¨ä¹ê¤º¤ß¯u¬O§Æ±æ120¥ý¨ì¡A

·Ç³Æ¤@¨Ç¤l¼u¥´ºâ¨Ó­Ó³Ì«áªºshow hand¡K

¥u¬O¨º¤ä¬Ý¤£¨£ªº¤â¤£µ¹¾÷·|ÅoXD¡K

ªÑ»ù±q170¶^¦Ü140®É³£¤@¸ô¸òªB¤Í±ÀÂË

¶R¶iÃĵثù¦³¤T¨ì¤­¦~¡KÁ`ºâ¹ï±o°_ªB¤Í

¤½¥q¥[ªo!!

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤p¶Â10145930  µoªí®É¶¡:2018/6/25 ¤U¤È 05:27:47²Ä 4631 ½g¦^À³
·PÁª©¤WµL¨p©^Äm+¥ß½×¦³¾Úªº¦U¦ì¤j¤j

(­n·PÁªº¦n¤H¤Ó¦h¤F.±ÚÁc¤£¤Î³Æ¸ü)

Åý§Ú¯à°í«ù¨ì³o

¯S§O·PÁÂR¤j

¯uªº¦p±z¹w¨¥200¥ý¨ì.(120¡K¨S¬Ý¨ì!!!)

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤p¥¿¥¿10141351  µoªí®É¶¡:2018/6/25 ¤U¤È 02:54:07²Ä 4630 ½g¦^À³
ªÑªF·|¡þÃĵØÃÄ ·sÃĦ³±æ¶i­x¼Ú·ù

ÃĵØÃÄ ¡]6446¡^¤µ¤ÑªÑªF·|¡A³q¹L¤£°tµoªÑ§Q¡A¦ý¶Ç¨Ó³ß°T¡G¸Ó¤½¥q¥Î©óªvÀø¨u¨£¦å²G¯e¯fªºP1101¡A¦b¼Ú¬w¤w±Ò°Ê·sÃĪº¼f®Ö¡A¬d¼tµ²ªGµL­«¤j¯Ê¥¢¡A¥x¤¤¼t¤Î¥x¥_¸Õ¶q²£¹êÅç«Ç§¡¤wÀòEMA»{©w³q¹LÀu¨}»s³y³W½d¡]GMP¡^ÃҮѡF¦pªG¤@¤Á¶i®i¶¶§Q±N¦b¤µ¦~¤U¥b¦~¨ú±o¼Ú·ù¤W¥«®Ö­ã¡C

ÃĵØÃÄ©Ò¬ãµo·sÃÄ P1101¡A°£¦b¼Ú·ù¤Î¬ü°ê¬ÛÄ~Àò±o©t¨àÃÄ»{ÃÒ¥~¡A¥h¦~9¤ë¤@¦¸³q¹L¼Ú·ù EMA¬d®Ö¨Ã¨ú±oGMP»{ÃÒ¡A¦¨¬°¥xÆW²Ä¤@®a³q¹LEMA»{ÃÒªº³J¥Õ½èÃļt¡A¥[¤W¤½¥qGMP³J¥Õ½èÃļt©Ð«Y¬[ºc¦b©t¨àÃĬÛÃöªk®×¤§¤U¡A¦]¦¹¹ï©t¨àÃĬãµo¦æ¾P·~°Èªº±À®i¡A¬Û¸û©ó¨ä¥L¥Í§Þ¦P·~¡A§¡¨ã¦³¬Û·íªºÀu¶Õ¡C

ÃĵØÃĪº·~°È¦æ¾P­±¤w³°Äò¦b¬ü°ê¡B¤é¥»»P¤¤°ê³]¥ß¤l¤½¥q¡A±À°Ê¬ÛÃöÁ{§É¸ÕÅç¡B°Ñ»PÂå¾Ç¬ã°Q·|©M¯f±wÃöÃhµ¥¦U¶µ¬¡°Ê¨Ó¶i¦æ²£«~±À¼s¡A¨ÃÂǥѦb¦a¤Æªº±M·~¦æ¾P¹Î¶¤»Pµ¦²¤Áp·ùªº¨ÑÀ³Ãì¡A¥H«Ø¸m¥þ²yÃÄ«~¨ÑÀ³¡B¦æ¾P©M¾P°â³q¸ô¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¦V¿ú¨«10137837  µoªí®É¶¡:2018/6/25 ¤U¤È 01:02:09²Ä 4629 ½g¦^À³
¤É¯}196¤¸,®¥³ß¦¨¥\´«¤â
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡Gonly10135877  µoªí®É¶¡:2018/6/25 ¤W¤È 12:14:44²Ä 4628 ½g¦^À³
§Æ±æ¤µ¤Ñ¦³¥hªÑªF·|ªº¤j¤j,¯à¦³¿ý­µ©M¤À¨É,ÁÂÁÂ
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤pªL10142678  µoªí®É¶¡:2018/6/24 ¤U¤È 07:38:43²Ä 4627 ½g¦^À³
Repurposed drug gives woman with cancer the gift of life

abc7chicago.com/health/repurposed-drug-gives-woman-with-cancer-gift-of-life/3633457/

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¶È¨Ñ°Ñ¦Ò10146497  µoªí®É¶¡:2018/6/24 ¤W¤È 02:44:25²Ä 4626 ½g¦^À³
·Q¥²±z¬O»~·|§Ú©Ò»¡¥ýª¾ªº·N«ä¬O¤]¡A¥ýª¾ªÌ¤D¤ñ¤@¯ë¤H¥ýª¾¹D¤@¨Ç®ø®§­±©Î¤º¹õªÌ¦Ó¨¥¡A³q±`·|¬O¤º³¡¤H¤jªÑªF¤§Ãþ¡AÁÙ¦³¨ä©PÃ䤧¤H¬O¤]¡F¦ý¥ýª¾¹D¤º¹õ®ø®§ªÌ¡A¤£¤@©w´N³£¯à§@¥X¥¿½T¤§§PÂ_¡A¦]¥i¯à¹ï¨Æ±¡¤§¤F¸ÑÁÙ¤£°÷²`¤J¡A³q±`¼h¯Å¶V°ªªÌ¡A©Ò§@¤§§PÂ_¶Vºë·Ç¡A¦]ª¾¹D¤§±¡§Î¶V¸Ô²Ó²`¤J¬O¤]¡F¦ý§Y¨Ï¦p¦¹¡AÁÙ¬O¥Rº¡³\¦h¥¼ª¾ªºÅܼơA¦ý«o¤ñ¤@¯ë¤H§ó¯àÁͦNÁפ¿¤F¡A¦p°ò¥»­±¤£¿ù®É¡A·í¤@¯ë§ë¸ê¤H¦b¸ê°T¸¨«á¡A¦Ó¤S¦³¹w´Á¤ß²z¤§¤U¡A¥i¯à´N·|¶¶¶Õ¬°¨ä©Ò¥Î¡A¦b®ø®§­±©|¥¼Ãn¥ú«e¡A¶X¹w´Á¤§§Q¦hªÑ»ù½Ä°ª®É­Ë³fµ¹§A¡A«Ý®ø®§¤½¥¬¤£¦p¹w´Áµ¥§CÀɦA±µ¦^¨Ó¡F«á­±´N¬O¬Ý¹Ï»¡¬G¨Æ¤F¡A±z»¡12/15«e¤@¤ë¥¿¬O®ø®§­±³Ì®t¡A¦ýªÑ»ù¤]¥¿³B©ó¬Û¹ï§CÀɤ§®É¡A¤@¯ë´²¤á¬O¤£¤Ó´±¤¶¤Jªº¡A§Y¨Ï¤¶¤J¤]¤£¤Ó´±¶R¦h¡A´±¶R¶iªÌ¡A¥²¬Oªø½u§ë¸êªÌ¡A¶X«K©y¶R¶i¡A·Ç³Æªø´Á§Ü¾Ô¡A¥t¥~¥²¬O®ø®§­±ÆF³q¡A¦Ó¤S¹ï¤º±¡ª¾¤§¬Æ¸Ô¤§½ú¡A³q±`³£¬O¤£Â²³æ¤§¤H¡A¤¤¶¡2¤ë¥÷ªÑ»ù½Ä°ª¡A¥¿¬O´CÅé¬ÆÄ۹ФW»¡»PFDA¨ó°Ó¹w´Á¼ÖÆ[¡A¦~«á¶R³£¶R¤£¨ì¤§®É¬O¤]¡A¦Ó¤@¤ù¬Ý¤j¦n¤§¤U¡AªÑ»ù«o²ö¦Wµ¹§A±þ¥X¤@®Ú¤¤ªø¶Â¡Aµ²§ôº¦¶Õ¡A¤j®aªº¸ÑŪ¬O»â¨ìÃÄÃÒÁÙ¦­¡A®í¤£ª¾¬O¥t¦³Áô±¡¡A·íµM¤jªÑªF½è©ãªº°Ê§@¡A¬O±aµ¹¥«³õ¤£¤Ö«H¤ß¡A¦]¦¹¤]¦b¥L½è©ãªÑ²¼ªþªñ¤§«eªº»ù¦ì§@¤î¶^¡A¦]¬°¤jªÑªF¬O³Ì¯à¥ª¥kªÑ»ù¤§¤H¬O¤]¡A¤@­±¦³º¡¤âªÑ²¼¡A¤@­±¤S¹ï°ò¥»­±ÁA­Y«ü´x¡AÁٯ౱¨î¤½¥q®ø®§­±¤§µo¥¬¡A¬O¤j®a³Ì·Q¾aÃl¤§¤H¡C±z»¡¸É°e¸ê®Æ«eªº¦^ÀÉÁÙ¤£°÷§CÀÉ¡A¤£¦p¥h¦~©³ªº§CÀɧC¡AÕÙ¡A¥i¬O¥h¦~©³±zÁÙ¤£ª¾¹D»PFDA¨ó°Ó·|¦³¤°»òµ²ªG°Ú¡A±z¤]¤£ª¾¹D¤jªÑªF·|¦³½è©ãªÑ²¼¡A±a°Ê¥«³õ«H¤ßªº°Ê§@°Ú¡A¨º¼W¥[³o¼Ëªº§Q¦h¡A§AÁÙ·Qµ¥¦b150¤¸ªþªñ±µ¦^¨Ó°Ú¡A¨º°£«D¦V§Ú»¡ªº¡A¸É¸ê®Æµ¹¥¦©µ´Á¤@­Ó¤ë©Î³\´N¦³¥i¯à¤F¡A³ø§i§¹²¦¡C
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G§ë¸ê¬ö«ß10145266  µoªí®É¶¡:2018/6/24 ¤W¤È 01:15:37²Ä 4625 ½g¦^À³
¶È¨Ñ°Ñ¦Ò¤j¡G

¤£¤~«Øij±z§â¥»ª©©Ò¦³°Q½×±qÀY¬Ý¹L¤@¹M

±qP1101¦³¨S¦³¯à¤O©Î¸ê®æ¡A¯à¤£¯à®³¨ì¼Ú¬ü¤@½uÃÄÃÒªº°Q½×¨ì»PAOPªº¶D³^

«Ü¦h¨Æ±¡±z³£¬O¤@¨ý²q´ú

³o¨Ç¨ä¹ê³£¥i¥H¦b°Q½×°Ï¤¤Àò±o¸Ñµª

²Î­p¸Ì¦³¤@­Ó³¹¸`¥s°µ°²³]ÀË©w

¦³¤H´£¥X°²³]¡A´N»Ý­n¥[¥HÀË©w¨ÓÃÒ©ú°²³]¬O§_¬°¯u

¦P²z¡A±z´£¥Xªº³\¦h¥DÆ[°²³]¡Aª©¤W¼ö¤ß¤Î±M·~ªººô¤Í¤]¸ÕµÛ¦^Âбz

¥ç§Y¦bÀ°±zÃÒ©ú¬O§_±zªº¥DÆ[»{ª¾¬°¯u¡A¥HÁקK±¼¤J¿ù»~°²³]¤º

¦p±z¥ý«e©ó°Q½×°Ï´£¨ìªº

®Ú¾ÚÃĵتº»¡ªk¡A©ó¥h¦~12/15¤éªº«e¤@¤ë¡A§Y¤w¹ïaop´£¥X²×¤î±ÂÅv«´¬ùªºÄµ§i¤F

¨º®ÉÀ³¸Ó¬OÃö«Y«D±`®tªº®É­Ô§a

À°±z¬d¤F¤@¤U·í®ÉÃĵØÃĪºªÑ»ù³£¦b©u½uªþªñ(145¥ª¥k½L©³)

1¤ë¤¤¬ð¯}¾ã²z°Ï¶¡¡A³Ì°ª¨ì3/13ªº195¤¸

¦pªG¯u¦³±z©Ò¿×ªº¥ýª¾¡A·Q¥²¨«¶ÕÀ³¸Ó·|¥ý¯}©³¡A¦ý¬O«o­è¦n¬Û¤Ï¡A²{¦b¤S­n¬D¾Ô«e°ª

³o¬q®É¶¡¥~¸ê¤@¸ô¶R¤W¨Ó

¤½¥q­«­n»â¾É¤H¤]¦b³o¬q®É¶¡¤º½è³]ªÑ²¼

»P¨ä»{¬°¦³¥ýª¾¨Ã§ä¥X¥ýª¾

­Ó¤H»{¬°ÁÙ¬OÀR«Ý¤½¥q§´µ½³B²z

¬Û«H·|¬°¤½¥q¤ÎªÑªF°µ¥X³Ì¦n¦Ò¶q

¤£ºÞÃĵØÃÄ©ÎAOP¡A¤°»ò³£¬O°²ªº¡A¥u¦³®³¨ìÃÄÃÒ½æÃÄÁÈ¿ú¤~¬O¯uªº

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GSirius10142542  µoªí®É¶¡:2018/6/23 ¤U¤È 09:08:08²Ä 4624 ½g¦^À³
°ê»Ú¬Fªv¦bµû½×¨â±jÃö«Y®É¡A¦³¤@¥y¸Ü¬O«Ü­«­nªº¡A¥s°µ°«¦Ó¤£¯}¡C

°«¬O¬°¤F·¥¤j¤Æ¤w¤è§Q¯q¡A¤£¯}¬O¦]¬°Âù¤è³£©Ó¨ü¤£¤F¯}¡C

´x´¤¦í³o­Óºë¯«¡A´N¯à²z¸ÑAOP»PÃĵتºµ²ªG¤F¡C

AOP¤£¯à®e³\¸Ñ¬ùµo¥Í¡AÃĵؤ£·|Åý¼Æ¾Ú¨ú±o¤zÂZ¬ü°êÃÄÃÒ¡C

³o¨âºØ±¡ªp³£¤£·|µo¥Í¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡Gª£¦Ì¯»10146792  µoªí®É¶¡:2018/6/23 ¤U¤È 08:15:49²Ä 4623 ½g¦^À³
­n¥XµoÅo¡A¤£»ÝªÈµ²AOPªº°ÝÃD¡A´¼Àºªº¦X§@¹Ù¦ñ¤w¤j¼Q40´X%¸ÜÃD¡A¦A¥[¤W¤C¤ë¥Í§Þ®i¤Î¶T©ö¾Ô¡A¸êª÷µu´Á·|¬y¶i¥Í§ÞªÑ¡A·sÃĪѵu´Á·|¤@°_³s°Ê¡A¾á¤ßªº¤H¥i´î½XÃĵØÃÄ¡A¤£¹L³£µ¥¤T¨¤¦¬ÀĨº»ò¤[¤F¡AÁÙ³vº¥¹Ô°ªªÑ»ù¡A¼Q¥X´N©êºò§a
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GRussell10140734  µoªí®É¶¡:2018/6/23 ¤U¤È 07:12:43²Ä 4622 ½g¦^À³
§Úªº¬Ýªk¸òRookie¤j¤ñ¸û±µªñ¡A

³o¬O¤@³õÁɧ½¹CÀ¸¡AÂù¤è³£¦b°l¨D³Ì¤j§Q¯q¡K

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¶È¨Ñ°Ñ¦Ò10146497  µoªí®É¶¡:2018/6/23 ¤U¤È 06:49:55²Ä 4621 ½g¦^À³
·í¤@¤ÁÁÙ¦sþÓ¤£½T©w©Ê®É¡A½Ð°Ý§A·|À¹þÓ¿û²¯©¹«e½Ä¶Ü¡H¦]¦³¥ýª¾¥ýıªÌ¡]¨º´N§O©ú»¡¬O¨º¨Ç¤H¤F¡^¦­¤w¸gª¾¹D¥L­Ì¤§¶¡ªººò±iÃö«Y¤F¡A©Ò¥H¤~§@½Õ¸`ªº°Ê§@¡A¸U¤@¯u½½L«ç¿ì¡A¦Ü¤ÖÁÙ¯d±o¤@¤ù«C¤s¡A¨º²{®Éªº±¡ªp¤S¸ò·í®É±¡ªp¦³ÂI¤£¦P¡A¦]¬°aop®³¨ì¸ê®Æ¤~´±´£³^¡A¨ì¸É¸ê®Æ´Á­­²×¤îÁÙ¬O°e¥æEMA, ³o´NÃÒ©úaopÁÙ¬O«Ü¦b¥G¼Ú¬wÃÄÃÒªº¡A¨º§A·|±N·í®Éªº¦ì¶¥¸ò²{¦b¤ñ¡A§A¥H¬°ªÑ»ù¬O¦b¤ÏÀ³¤°»ò¡AÃi±o¼o¸Ü¤F

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GRookie10143115  µoªí®É¶¡:2018/6/23 ¤U¤È 06:28:16²Ä 4620 ½g¦^À³
¶È¨Ñ°Ñ¦Ò¤j,·Ó§A©Ò»¡¡AÃĵةó¥æ¨÷´Á­­«e¤i¡AªÑ»ùÅã¥X¯hºA¬O·|¾á¤ßaop¬O§_¿ï¾Ü¥É¥Û­ÑµI

¨º²{¦bªÑ»ù¨Ó¨ìªñ1¦~¨Óªº°ªÂI(1¦~°ªÂI195),¬Oªí¥Ü¼ÖÆ[¨ú±oÃÄÃÒ¶Ü?ÁÙ¬O»PAOPªºª§ºÝ±N¹F¦¨¸Ñ¨M©O?ªÑ»ù·|»¡¸Ü¤£¬O¶Ü?

©Ò¥H§A¯uªºÄ±±o¤§«e¤t´¶¸òª÷¥¿®¦¶æÁn,¤@°Æ¼C©Þ©¸±i,¬O¯uªº­n¥É¥Û­ÑµI¶Ü?

¨º¥u¬O¤@ºØ½Í§Pªºµ¦²¤,Âù¤è¥u¬O­n¨ú±o¤v¤è³Ì¤jªº§Q¯q½}¤F

¤§«e§Ú°Ý¹L¤½¥q,¤½¥qªí¥Ü¦pªG¤Ï¥òµôÃĵØŤF,¼Ú·ùÃÄÃÒ¤U¨Ó¬O§Pµ¹ÃĵØ,Ãĵثh¤ä¥IÁ{§É¸ÕÅç¶O¥Îµ¹AOP

¦ý«áÄò¦b¼Ú¬w½æÃĪº§Q¼í´N¥þÂk©óÃĵØ,¤£¥Î¦A¤À¼íµ¹AOP¤F

¥H¤U­Ó¤HÆ[ÂI

©Ò¥H¤Ï¥òµô¬O¤@°ª©Û,¦pªG¤Ï¥òµôŤF,³o¼ËAOP³o´X¦~ªº¨¯­WªºÁ{§É¸ÕÅç,¤£¬O¥Õ¦£¤@³õ,¬Æ»ò³£¼´¤£¨ì¤F

·íµM¤Ï¥òµô¤£¤@©w¬OÃĵØĹ,¦ýAOP¤@©w·|µû¦ô³o¼Ëµw¤U¥h¬O§_·|¦³§Q,¦pªG¯u§Pµ¹ÃĵØ,¨º«áªG¯u¬O¤£§Q

©Ò¥H§Úı±oÂù¤è«Ü¦³¥i¯à¦b¥òµô«e,¦UÅý¤@¨B¹F¦¨©M¸Ñ,¦ý¾ãÅéÀ³¥HAOP·|§@¸û¤jÅý¨B

¥H¤WÆ[¹îÄÝ­Ó¤HÆ[ÂI,¤Å§@§ë¸ê°Ñ¦Ò,¬ÛÃö°ÝÃD§Ú·Q¬P´Á¤@ªÑªF·|¤½¥q·|§@¸Ô²Óªº»¡©ú

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¶È¨Ñ°Ñ¦Ò10146497  µoªí®É¶¡:2018/6/23 ¤U¤È 05:18:19²Ä 4619 ½g¦^À³
¤§©Ò¥H»¡¥L¦Ñ¦l¥¨·â¡A¬O¦]¬°¥L¤@ª½Áô§Ô¨ì¤µ¦~4¤ë¡A®³¨ì¤F¥L­nªº¸ê®Æ«á¡A¥ß¨è´N¦VICC´£¥X¥òµô»¡ªº
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤pªL10142678  µoªí®É¶¡:2018/6/23 ¤U¤È 04:35:20²Ä 4618 ½g¦^À³
¶È¨Ñ°Ñ¦Ò¤j¡A

§O·Q¤Ó¦h¡A§Ú»¡±z«Ü¦³¡u»¡¬G¨Æ¡vªº¤Ñ¥÷¡A¬O«ü¬Ý±zªºµo¤å´N¹³¦b¬Ý¼@¤@¼Ë¡A¥Í°Ê¤S¦³µe­±(¨Ò¦p´£¨ì¦Ñ¦l¥¨·â)¡AÄÇ´I½ì¨ý¡C

§Ú¥u¬O»{¬°¡A§ë¸ê³o¥ó¨Æ¡A¤£»Ý­n¦³¤Ó¦hªº·Q¹³»P²q´ú¡A©ñ»´ÃPÂI¡A§O§â¦Û¤v·d±o¤Ó²Ö¡C

°Ñ¥[¤@¦~¤@«×ªºªÑªF·|¡A¬O¹ï¦Û¤vªº§ë¸ê­t³d¡A¤£¥u¬O«Øij±z¡A§Ú¤]«Øij©Ò¦³ªÑªF°Ñ¥[¡A´î¤Ö¤ß¸ÌªººÃ°Ý´N¤£¥Î°µ¹L¦hªºÁr´ú¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¶È¨Ñ°Ñ¦Ò10146497  µoªí®É¶¡:2018/6/23 ¤U¤È 03:54:42²Ä 4617 ½g¦^À³
·íµM¦pªG±z¦³§ó¶Kªñ¨Æ¹êªº°ª¨£¡A§Ú­Ì¤]¤£·|§[©ó±µ¨üªº

ªº½T©x¤èªº»¡ªk»Ý­n¦h¦h°Ñ¦Ò¡A¦ý§Ú¤]»á¦n©_±z¤S¬O¦ó®Éµoıaop»PÃĵØÃö«Y¦ü¥G¤£¬O¨º»ò¦nªº¡H

¬Oµo¨¥¤Hª½±µ§i¶D±zªº¶Ü?

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤pªL10142678  µoªí®É¶¡:2018/6/23 ¤U¤È 03:26:49²Ä 4616 ½g¦^À³
¶È¨Ñ°Ñ¦Ò¤j¡A

µoı±z«Ü¦³»¡¬G¨Æªº¤Ñ¥÷¡A«Øij±z¦pªG¬OÃĵتºªÑªF¡A´N¥h°Ñ¥[6/25ªÑªF·|¡A³o¼Ë¬G¨Æ¥i¥H»¡±o§óºë·Ç¡A¤Ö¥´«Ü¦h¦r¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¶È¨Ñ°Ñ¦Ò10146497  µoªí®É¶¡:2018/6/23 ¤U¤È 02:25:34²Ä 4615 ½g¦^À³
ÃĵػPaop¤§¶¡ªºÃö«Y¡A±q¥h¦~©³¥H¨Ó¡A¤@ª½¬O¼vÅTªÑ»ùªº¼ç¦b¦]¯À¡C

±q¥h¦~©³ÃĵسB²z»P¬ü°ê¬ÛÃö¨Æ°È¤§¤º³¡¤H·t½æ«ùªÑ¡A

¨ì¤µ¦~¤G¤ë»PFDAªº¨ó°Ó¶Ç¥X±¶³ø¡AªÑ»ù±q°ªÀɦ^¸¨¡A

¦A¨Ó¸É¸ê®Æ¦^ÂÐEMA¡A©ó¥æ¨÷´Á­­«e¤i¡AªÑ»ùÅã¥X¯hºA(¦]aop»PÃĵØÃö«Y¦­¤w¥ÍÅÜ¡AÁö¤£¤Ó¥i¯à¡AÁÙ¬O·|¾á¤ßaop¬O§_¿ï¾Ü¥É¥Û­ÑµI¡A²¦³ºaop¬O¦³¬Õ¾lªº¤½¥q¡A¦ÓÃĵثoÁÙ¨S¤@ºJ¡A¦ý°£¤F»P¤º³¡¬ÛÃöªº¤H¡A©l²×µL¤Hª¾¹D)¡A§Y¨Ï§Ú²q¿ù¤è¦V¡A¦ý¤j¤j­Ì¤]³£¤ÏÀ³§Q¦h¨£³øªÑ»ù¥²¶^ªº²{¶H¡AÅã¥Ü¨ä¤¤¥²¦³¤º±¡¡]³o¨Ã¤£¬O¦h¥´´X³q¹q¸Ü¡Aµo¨¥¤H·|³zÅSªº¨Æ¡^

¦]¦¹¡A³o¼ËªºÃö«YÁÙ¬O·|«ùÄò¼vÅTªÑ»ù¡A¥u¬O¼vÅT¥Ñ·tÂà©ú¡A

¦n®ø®§¬O¦¹Ãö«Y±N¤£¼vÅT¼Ú¬wÃÄÃÒªº¨ú±o¡]¬Æ¦Ü·|¤ñ·Q¹³¤¤ªº§ó¶¶§Q¡A¦]¬°aop¦ûªº¤À¼í¤ñ§ó¤j¡A¥¦¤ñÃĵاó§Æ±æ¦­ÂI®³¨ìÃÄÃÒ¡^¡A¦ý¬ü°êÃÄÃÒ¶Õ¥²·|¨ü¼vÅT¡A¦]¬°Ãĵؤw´£¥X¤Ï¥òµô¡A°£«D¥L­Ì³£±µ¨ü18%ªº¤À¼í¤ñ¡A¤£µM¥u­naop¤@¤£ªA¡A¨ü¶Ëªº¤@©w¬OÃĵءA¦]¬°³o¹Lµ{¤S¤£ª¾¹D¯Ó¶O¤F¦h¤Ö®É¶¡¦¨¥»¡]aop¥i¥HºCºCªº¸ò§A¿i¡^¡A©óaopµ·²@µL·l¡A­Wªº¬OÃĵءA©Ò¥H¦Ü²×¡A¥u­n¤£¬O­n¥I°ªÃBªºÁ{§É¼Æ¾Ú¶O¥Î³oºØ³àÅv°d°êªº¨Æ¡AÃĵإi¯à·|¿ï¾Ü©}ªA©ó16%¡]¦³¤H´£¥XÃĵإi¥H¥Î¤£´£¨ÑÃÄ«~§@©è¨î¡A§Ú®£©È¥Haop¦p¦¹¦Ñ¦l¥¨·âªÌ¡A¦­´N¦b¦X¬ù¤W­q¥X»@«h¤F¡^¡A¦P®É¡A§Ú¤£«Øij¦]¦¹©Ç¸oÃĵءA¦]¬°¥¦¤wºÉ¤O¤F¡]´£¥X¤Ï¥òµô)¡A¦Ó¥B¥ý«eñ¦X¬ù®Éªº¤£©P©µ¡]¤£µMaop¬°¦ó­n¦p¦¹¤£º¡¡^¡A²{¦bªº§ë¸ê¤H¤]®t¤£¦h¤w¸g­ì½Ì¥¦¤F¡H²¦³º¦p¦¹ªº§@ªk¡A¤~¬O³Ì²Å¦XÃĵتº§Q¯q¡]¦]¬°¤@­Ó¬O4%¡A¤@­Ó¬O50%¥H¤Wªº§Q¯q¡^¦]¦¹¼Ú¬wÃÄÃÒ¹LÃö«á¡]§Ú¤]§Æ±æ¦b¦¹¤§«e´N¥i¥H¶êº¡¸Ñ¨M¡^¡A¤~¬O¯u¥¿¦ÒÅ窺¶}©l¡A´N¬ÝÃĵئp¦ó¦³´¼¼zªº¥h³B²z¤F¡A§Y¨Ïp1101ªº¦n®ø®§¤£Â_¡A¤´»Ý¯d·N

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤p¥¿¥¿10141351  µoªí®É¶¡:2018/6/23 ¤W¤È 11:04:59²Ä 4614 ½g¦^À³
Mesa Discusses the Management of Patients With Polycythemia Vera

Published Online:1:56 PM, Tue April 17, 2018

TARGETED ONCOLOGY: What is the treatment approach for a patient with newly diagnosed PV?

Mesa: With newly diagnosed patients with PV, universally we would use a control of the hematocrit through at least phlebotomy to [get to a] hematocrit of under 45%. That has been shown to be helpful in randomized clinical trials. Next, barring an aspirin allergy, we would use a baby aspirin of 81 mg daily in all individuals in whom there was not a contraindication.

For individuals who have higher-risk disease, prior thrombotic events, higher white count, difficult symptoms, or age over 60, we would consider cytoreductive therapy with either hydroxyurea (Hydrea) or an interferon. This individual would fall under the category of intermediate risk, and there would be a discussion with the patient to decide whether we start that at this point or hold off in case there are any changes.

¥Ø¼Ð¸~½F¾Ç¡G·s¶EÂ_PV±wªÌªºªvÀø¤èªk¬O¤°»ò¡H

Mesa¡G¹ï©ó·s¶EÂ_ªºPV±wªÌ¡A³q±`§Ú­Ì¦Ü¤Ö³q¹LÀR¯ß¤Á¶}³N¨Ó±±¨î¦å²Ó­M¤ñ®e¡A¨Ï¦å²Ó­M¤ñ®e¹F¨ì45¢H¥H¤U¡C ³o¤w³QÃÒ©ú¹ïÀH¾÷Á{§É¸ÕÅ禳À°§U¡C ±µ¤U¨Ó¡A°£«D¥X²{ªü¥q¤ÇªL¹L±Ó¡A§_«h§Ú­Ì·|¦b©Ò¦³¨S¦³¸T§Ò¯gªº¤H¸s¤¤¨C¤Ñ¨Ï¥Î81²@§Jªºªü¥q¤ÇªL¡C

¹ï©ó¦³°ª­·ÀI¯e¯f¡A¬J©¹¦å®ê¨Æ¥ó¡A¥Õ²Ó­M­p¼Æ°ª¡A¯gª¬§xÃø©Î¦~ÄÖ¶W¹L60·³ªº±wªÌ¡A§Ú­Ì·|¦Ò¼{¥Îßm°ò脲¡]Hydrea¡^©Î°®ÂZ¯À¶i¦æ²Ó­M´î·À©ÊªvÀø¡C ³o­Ó¤H±NÄݩ󤤯ŭ·ÀIªº½dÃ¥¡A¨Ã¥B·|»P±wªÌ°Q½×¨M©w§Ú­Ì¬O§_¦b¦¹®É¶}©l©ÎªÌ¦b¦³¥ô¦óÅܤƪº±¡ªp¤U©µ´Á¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤pªL10142678  µoªí®É¶¡:2018/6/23 ¤W¤È 10:07:12²Ä 4613 ½g¦^À³
MPN Advocacy & Education International ¤»¤ë¥÷³q°T¥Z¥Xªº¤@«h¬G¨Æ¡A¤@¦ì¿©±wET¨k«Äªº¥À¿Ë¡A´M¨D¦h¦ìÂå®v±q¶EÂ_¨ìªvÀøªº¹Lµ{¡C

mpnadvocacy.com/2018/06/mothers-story-coping-sick-child/

¤å³¹¦³ÂIªø¡A¦³¿³½ì½Ð¦Û¦æÂI¾\¡A¶ÈºK¿ý¨ä¤¤¤@¥y¸Ü¡C

As a result of Dr. V and Dr. Rytting¡¦s recommendation, we have changed Jedi¡¦s treatment plan from Hydroxyurea (HU) to Interferon.

Dr. V ¬O½Ö§Ú´N¤£¦A¤¶²Ð¤F¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤p¥¿¥¿10141351  µoªí®É¶¡:2018/6/23 ¤W¤È 06:05:27²Ä 4612 ½g¦^À³
2018¦~06¤ë23¤é 04:10 ¤u°Ó®É³ø ³¯¬R¥ú¡þ¥x¥_³ø¾É

¥t¥~¡A§ëÅUªk¤H¬Ý¦nÃĵØÃIJ£«~Ropeg¤W¥«³\¥i¥Ó½Ð¡A¤w¦b¼Ú¬wÃÄ«~ºÞ²z§½¼f¬d¡A¥i±æ©ó¤µ¦~²Ä4©uÀò±o®Ö­ã¡B©ú¦~¤W¥«¡A±À¦ô¾P°â°ª®p±N¶W¹L20»õ¬ü¤¸¡F¥t¦b¬ü°ê³¡¤À¡A¤]¦³¾÷·|¨Ï¥Î¼Ú·ù§¹¦¨ªºÁ{§É¸ÕÅç¸ê®Æ¨ú±o¤W¥«³\¥i¡C¤T¤jªk¤H¬Q¦P¨BºV¶i¡AªÑ»ù©ñ¶q¨«´­¡C

@@ ÃĵØÂåÃĪѥ÷¦³­­¤½¥qªÑªF±`·|

¦aÂI¡G«n´ä®iÄýÀ]504a·|ij«Ç (¥x¥_¥««n´ä°Ï¸g¶T¤G¸ô1¸¹5F)

®É¶¡¡G107¦~6¤ë25¤é¤W¤È10®É¾ã

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GRookie10143115  µoªí®É¶¡:2018/6/22 ¤U¤È 06:27:21²Ä 4611 ½g¦^À³
¤µ¤Ñ¥~¸ê¶R¶WÃĵØ319±i¡A¤T¤jªk¤H¦X­p¶R¶i540±i

·í§Ú­Ì¦b³oÃä§n§n¾x¾x®É¡A¬Ý¬Ý¨º¨Çªk¤H­Ì³£¦b°µ¤°»ò¡H

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¥ý¶i10000164  µoªí®É¶¡:2018/6/22 ¤U¤È 03:57:07²Ä 4610 ½g¦^À³
¦^Âk¥¿ÃD~§ë¸ê¤H­nªº¤£¬O¤f¤ô¾Ô.......¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GAnderson10143089  µoªí®É¶¡:2018/6/22 ¤U¤È 03:14:22²Ä 4609 ½g¦^À³
¦n¤[¨S¦^¨Ó¡A¤@¦^¨Ó´N»D¨ì¿@¿@ªº·Ïµv¨ý¡A§ÚÁÙ¬O¤£­n¥[¤J¾Ô§½¦n¤F¡A«¢«¢«¢¡A¹j¤sÆ[ªê°«¡C
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤p¥øÃZ10142872  µoªí®É¶¡:2018/6/22 ¤U¤È 12:26:46²Ä 4608 ½g¦^À³
´«­Ó¨¤«×·Q

¦pªG¤£¥h¬dÃÒ¡A´N¬Û«H¥ô¦ó¦h,ªÅ°T®§¦Ó¶R¶i©Î½æ¥Xªº¤H

°£¤F¨Ó¶ÃÄw½X(»¡¤£©w¸êª÷ÁÙ¤£°÷¦h,³s¶Ã³£°µ¤£¨ì, ¬Æ¦Ü©ó¦¨¥æ¶q¤]µLªk°^Äm)

¹ê¦b¬Ý¤£¥X¨Ó¹ï¤½¥qªø´Á¸gÀ禳¥ô¦óÀ°§U

³oºØªÑªF¤]µ´«D6446©Ò³ß·R

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¶È¨Ñ°Ñ¦Ò10146497  µoªí®É¶¡:2018/6/22 ¤W¤È 10:52:00²Ä 4607 ½g¦^À³
¬J¬O¦X¬ù¤W©Ò½á¤©Ãĵؤ§Åv¯q¡Aaop¤]¬Oª¾¦W°ê»Ú¯Å¤½¥q¡A¨Ã¥B¬O¦]¾P°âÃB¼W¥[¡A¦Ó½Õ°ª¤À¼í¤ñ¡A§Q¼í¨Ã¤£¦]¦¹¦Ó´î¤Ö¡A¨º¤S¬O¦ó­ì¦]aop­n¤ß¥Í¤£º¡¡A·d©ì©ÔÄ~¦Ó¤W¶Dªº¤p°Ê§@¡A¥H­P¼vÅTÁnÅA¡Haop»PÃĵؤ¤¶¡¨ì©³¬Oµo¥Í¤F¤°»ò¨Æ¡A¦Ó¥¼¦V§ë¸ê¤H»¡©ú¥Õªº¡H

§Ú·Q¦X¬ù¤¤¶¡¥²¬O¦³¼Ò½k¡A¥¼ºÉ©ú½T¦Ó­P¦U¦Û¸ÑŪ¤§³B¡A©Òª§ªº¤]¥²©w¬O¤À¼íª÷¤À°tªº°ÝÃD¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¥ý¶i10000164  µoªí®É¶¡:2018/6/22 ¤W¤È 07:58:44²Ä 4606 ½g¦^À³
ÁÂÁ¬K©M´º©ú¤d¦r«Ø¨¥¡A§Æ±æ¦U¦ì§ë¸ê¤H¦b°Q½×°Ï¸Ì¡AºÉ¶q¤£­n®ö¶O¸ê·½¡A

§Æ±æ³o¦ì°ÎºÙÂyªÌ¦³©Ò¶i°h¡A¤F¸Ñ¤FÃĵطsÃĶ}µo¶i«×¡A¦A¶i¦æ°Q½×....¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GÂyªÌ10142287  µoªí®É¶¡:2018/6/22 ¤W¤È 07:38:46²Ä 4605 ½g¦^À³
Ây¤H¥u¬O±y¹C¤s³¥§ø¤Ò¡A

¤§©Ò¥H㑹¡i¾A¦X¡j¡A¦b¥«Ô·¤@¤ùºq»w

Án¤¤¡A¼å§N¤ô¡A

¥h·Q·QÃĵث᭱ªº¸ô¡AÁÙÆZªø»·ªº¡A

¥B¤£½T©w©Ê¤´µM¦s¦b¡A

现¦b´N¦b¤ñɲ¤j¥ß¥ú¡A

¤£¬O¬P±J¬£ªù®{¡A¤S¬O¤°¤\¡H

°²¦p¤pÂy¤H´X¥y话´N¼v响¥¦ªºÉ²­È¡A

¨º¤£­n¥¦¡A¤]没¤°¤\Ãö«Y¤F

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¬K©M´º©ú10141799  µoªí®É¶¡:2018/6/22 ¤W¤È 05:14:29²Ä 4604 ½g¦^À³
¦X¬ù³£¬O§A±¡§ÚÄ@¡A·í®É³£¦P·N½Í¦nªº

AOP¦P·NÅýÃĵئ³¤À¼í½Õ¾ãªºªÅ¶¡¡A¤]¬O·í®É¦X¬ù¼g¦nªº§a?

¤£¦P·N´N¸Ó·í®É¦A¨ó½Õªº

´N¹³Ä_ÄÖ´IÀA

KeryxÃļt¨Ì¾P°â²bÃBµ¹¥IÄ_ÄÖ¤@©w¤ñ²vÅv§Qª÷¤¤¡A¨ä¤¤ªº50¢H¶·¤ä¥I¤©³\®¶¿³

³o50¢H¤]¬OÄ_ÄÖ´IÀA¤½¥q©x¤è¦Û¤v©M³\®¶¿³³Õ¤hñ­qªº±M§Q±ÂÅv¦X¬ù

50¢H«Ü¸Ø±i¶Ü?

¦X¬ù¤]¬OÄ_ÄÖ´IÀA¤½¥q©M³\®¶¿³³Õ¤h¨ó½Õ½Í§´«á¦P·Nñ­qªº

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¬K©M´º©ú10141799  µoªí®É¶¡:2018/6/22 ¤W¤È 04:36:49²Ä 4603 ½g¦^À³
§Ú»{¬°¦b2009¦~¨S¦³²Ä¤@½u¡B²Ä¤G½u¥¿¦¡®Ö­ã¥ÎÃĨϥΤU¡A¤£¯à©Ç¤½¥q¨S¦³¦ô¨ì¥«³õ¾P°âÃB¥i¯à¹F¨ì¤Q»õ¬üª÷

¤¤¸Î·sÃÄÅý¬ü°êÂåÀøÅé¨tª½±µ°ª»ù¶R³æ¡I

magazine.chinatimes.com/financier/20130328006562-300221

³o½g2013¦~·í®É¬O¤¤¸Î°õ¦æªøªº±i©À­ì±µ¨ü³X°Ý

³X½Í¸Ì»¡

¡uTMB-355¡v¦b¨¾ªv·R´þ¯f¬rªº¦X¦¨¤W¡A¬O¤@·s«¬ÃÄ¡]First-in-Class¡^¡A¯f¬rªº§ÜÃĩʸû§C¡AÂå¥Í¤ñ¸û³ßÅw¥Î¡A¦]¦¹ÃÄ»ù´Á±æ¸û°ª¡A¹w­pÀøµ{­q»ù¬ù¦b¨C¦~3¸U¬üª÷¥ª¥k¡C

¤~¹L¤­¦~¡AÅܤƳo»ò¤j¡A®³¨ìÃÄÃÒ«áÃÄ»ùÅܦ¨¨C¤H¤@¦~¥ÎÃÄ»ù®æ¬°11.8¸U¬ü¤¸

2013¦~¨ì2018¦~¡A®t´X¦~?

2009¦~¨ì2018¦~¡A®t´X¦~?

¥h¦~¤À¼í¯à¼W¥[¡AÀ³¸Ó¬O¦X¬ù¸Ì¦³¼g¥i¥H¦A­×§ïªº±ø¥ó¡A±ø¥ó²Å¦X¡A´N¯à¦A½Í¤À¼í¡C

­n¤£µM§Ú·Q¤@¤Á´N³£·Ó¦X¬ù¨«¡A¤£¬O¤½¥q¤Ï®¬­n­«½Í¡A¦Ó¬O¦X¬ù¸Ì©ú©w¡A¤½¥q¦³³o­ÓÅv§Q¡A±ø¥ó²Å¦X´N¯à¦A¨ó½Õ¤À¼í¡C

¦b2009¦~·í®Éªº®ÉªÅ¸Ì¡A¤Q»õ¬üª÷¯u¬O¨S¯à¹w¦ô¨ìªº

¦p¯u¦Ò¼{¦³¤í©P©µ¡A¦X¬ù¸Ì³s¦A½Í¤À¼íªºªÅ¶¡³£¤£·|¦³§a

¤£¹L³o¦¸ªº©x¥q¹ï©ó¦¨¥»³o³¡¤À¡A¤½¥q¥i¯à¯uªº¨S¼g¶i¦X¬ù¸Ì¡A¦³ª§Ä³¤F¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¬K©M´º©ú10141799  µoªí®É¶¡:2018/6/22 ¤W¤È 01:58:52²Ä 4602 ½g¦^À³
¥ý¶i¤j¡A

±z¬O¶}ª©¤H¡A¦³Åv­n¨Dª©¥D¸T¤î¬Y¨Ç±b¸¹¦b³o­Óª©µo¨¥

ÂyªÌ³o­Ó±b¸¹ªø¤[¨Óµo¨¥³£¬O¦ü¬O¦Ó«D¡BªÅ¤f»¡¥Õ¸Ü¡A

²@µLFDA¸ê®Æ¡B¨ä¥L·sÃÄ©ÎÃļt¨Ò¤l¡BÁ{§É¼Æ¦r¡B°ò¥»­±¡B§Þ³N­±ªº®Ú¾Ú©M´£¨Ñ

§Ú¤£¬O©Úµ´ªÅ¤èµo¨¥©Î£¸¨¥°ó

¥u¬O»{¬°£¸¨Ç´c·Nªºµo¨¥¹ê¦bµLªk¼W¶i¥»ª©°Q½×©Ê

¥t¤@¦ìª©¤ÍÁöµM©Mª©¤W¨ä¥L³¡¤Àª©¤Í¤£¦X

¦ý¨º¦ìª©¤Í¬Ý±o¥X¨Ó¥XµoÂI¬O¦n·N

¦Ó³o£¸¦ìÂyªÌª©¤Íªºµo¨¥´N¤£¬O³o¼Ë¡A¦Ñ¬O´£¥X»~¾É©Ê½èªºµo¨¥

¨Ò¦pÃÄÃҥӽСB±µ¨ü©Î©Úµ´¡BÃÄÃÒ®Ö­ã¡B¦UºØ·|ij¡A³£¦³£¸©wªº®É­­¡A¥H¤Î¬yµ{¡AFDA·|¦b£¸©wªº®É¶¡¤ºµ¹¤©¦^ÂÐ

¤£¬O¥b¦~¡B¨â¦~¡B¤T¦~³oºØ§t½kªº¼Æ¦r

¥L¤£¬O²Ä¤@¦¸¶Ã»¡³oºØµL®Ú¾Úªº¸Ü

¥L¤§«eªºµo¨¥

·|­û¡GÂyªÌ10142287 µoªí®É¶¡:2018/3/23 ¤U¤È 09:24:49

Ây¤H¦b¦¹¡A¦³¨Æ¶Ü¡H

¬Ý¨Ó¤S±o»¡説¤@¨Ç¤H¤£³ßÅwªº¡u¨Æ¹ê¡v¡A

­º¥ý¡A¤£ºÞ­n¤£­n¦b¬ü°ê¸É§@¤T´ÁÁ{§É¡A

¥ú¦¬¶°¸ê®Æ¡A¦b¤U¥b¦~°e¬ü°êFDAªº®É¶¡¡A

´N¥i¯à¨ì²Ä¥|¤F¡A

¦b¬ü°êFDA¼fij¸ê®Æ¡A´N¥b¦~§a¡]§O¥H¬°¤H®a³£¬O

ÄåÄå¬ü¥N¤l¡^¡A

¥i¯à©ú¦~²Ä¤@©u¤~ª¾¾å­n¤£­n¸É§@¤T´Á¤F¡A

­Y»Ý¸É§@¡u¤p¤T´Á¡v¡A¨º´N¦A¨Ó¤T¡B¤­¦~Åo¡A

¦p¥iª½±µ¦b¬ü¥Ó½Ð¡A¨º®¥³ß¡A

¨S¦³¬ü°ê¡uBTD¡v¤Î¡u©t¨àÃÄ¡v¸ê®æÅ@¨­¡A´N¡u¨Ì³W©w¡v

«ö³W¯x¨Ó¡A´N±q»¼¥ó¥Ó½Ð¡BFDA©ó¤T­Ó¤ë«á¨M©w¬O§_±µ¨ü

¥Ó½Ð¸ê®Æ¡A

µM«á©Î³\¦Aµ¥¤@¦~¥b¦Ü¤G¦~§a¡I

----

¤W­±¬O¥L»~¾É©Êªºµo¨¥

§Ú¦³§ä¨ì¥¿½Tªº¡A¤j®a³£¬Ý¹L¤F¡A¦A¶K£¸¦¸

www.yaozui.com/p/171110

Á{§É»Ý­n©MFDA¶}ªº¦U¶µ·|ij¬yµ{©M®É¶¡

³o­Óºô¯¸¦³«Ü¸Ô²Óªº¾ã¸Ì

¬Ý¤F¤§«á´Nª¾¹D

¬ü°êFDA¼fij¸ê®Æ¡A¤£·|¨ì¥b¦~³o»ò¤[

¯Ê¤°»ò¸ê®Æ¼Æ¾Ú»Ý­n¸Éªº¦bPre-BLA meetings¶¥¬q´N·|ª¾¹D¤F

¤£·|¬O©ú¦~²Ä¤@©u¤~ª¾¾å­n¤£­n¸É§@¤T´Á

Ãĵز{¦b³o­ÓPre-BLA meetingsÁÙ¨S¶}§a? (¨S¦³¬Ý¨ì¤½§i»¡¤w¸g¶}·|)

©Ò¥HÁÙ¨S¦³°eNDA/BLA

±q¦VFDA¥Ó½Ð¶}Pre-BLA meetings·|ij

¨ìPre-BLA meetingsµ²ªG¥X¨Ó¡A«Ü§Öªº

´N¤T­Ó¤ë¥ª¥k

Pre-BLA meetings·|ij¨S°ÝÃD«á´N¬O°eNDA/BLA

NDA/BLA¥Ó³ø­º¥ý·|¶i¦æ60¤Ñªºªì¼f(¨ä¤¤¥]¬A§Î¦¡¼f¬d)¡C

¹ï©ó¨º¨Ç§Î¦¡¼f¬d¤£¦X®æ©Î§Þ³N¤º®e¦s¦b©úÅã¯Ê³´ªº¥Ó³ø¸ê®Æ¡A¤@«ß¤£¨ü²z¦Ó°h¼f¡C

Pre-BLA meetingsµ²ªG¸ê®Æ¤£°÷­n¨D¤]¥i¥Hµw°e

µw°eªºµ²ªG´N¬OBLAªì¼f°h¼f

³q¹Lªì¼f«áªºBLA¡A¥i¥Hª½±µ¶i¤H½Æ¼f(¨ä¤¤¥]¬A§Þ³N¼f¬d)

³o¦ìÂyªÌ©Úµ´§ä´M¥¿½T¸ê®Æ¡B´£¨Ñ¥¿½T¸ê°T¨Ó¥æ¬y©M°Q½×¡A±Ð¾Ç¬Ûªø

µo¨¥Á`¬O»~¾É§ë¸ê¤H

ªÅ¤f»¡¥Õ¸Ü¡A¹ïÃĵةúÅ㪺´c·N

¥ý¶i¤j

«Øij±z¸T¤î³o¦ìÂyªÌª©¤Í¦b³o­Óª©µo¨¥

ÁÂÁ¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡Gonly10135877  µoªí®É¶¡:2018/6/21 ¤U¤È 11:12:37²Ä 4601 ½g¦^À³
www.gbimonthly.com/2018/04/21819/

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡Gavandia10146474  µoªí®É¶¡:2018/6/21 ¤U¤È 09:57:44²Ä 4600 ½g¦^À³
¦pªG¬O¤@¯ë¤H¥Í¤p«Ä ´Á«Ý«Ä¤lªø¨ì200¤½¤À¬O¦b§@¹Ú

¦ý­Y¬O «À©ú¸ò¸­²ú ¥Íªº¤p«Ä ªø¨ì200¤½¤À¬O¦X²z´Á«Ý§a?

ropeg ¦³­Ó¥¨¤H¿Ë±­ jakafi ¤µ¦~MPN¥«³õ¹w¦ô23»õ¬üª÷= 500»õ¥x¹ô

jakafiÁÙ¥u¬O­Ó¤k«Ä (¤G½u) ¦Óropeg ¬O¨k«Ä (¤@½u)

´Á«Ýropeg ªø±o¤ñjakafi °ª¤]¬O¦X²z´Á«Ý§a?

¦³¹Ú«Ü¬ü¨S¿ù ¦ý¿v¹Ú­n½ñ¹ê ¤@¤Áªº¹w¦ô³£¬O¦³©Ò¥» ¦Ó«D¤Ñªá¶Ã¼Yªº³Û

ropeg³o«Ä¤lÃh­L¨ì²{¦b³£¤w¸g§Ö¤Q¦~¤F

²{¦b¶ZÂ÷¹w²£´Á¤]¤£¨ì¥b¦~¤F

¦b³oª©¤W«ù¦³ÃĵØÃĶW¹L¨â¤T¦~¬Æ¦Ü§ó¦hªº¥ý¶iÀ³¸Ó¤]¤£¦b¤Ö¼Æ

¹ï©óÃĵØÃĪº¤F¸Ñ ·d¤£¦n¤ñ³Í°ò¤ÀªR®v§ó¼F®`

¬y©ó¤f¤ô¤§ª§²@µL·N¸q

³Ì«á·|¤£·|Åܤj¥ß¥úÁÙ¬O¹Ú¤@³õ

¤@¤Á´NÅý®É¶¡¥hÃÒ©ú§a

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¥ý¶i10000164  µoªí®É¶¡:2018/6/21 ¤U¤È 09:57:17²Ä 4599 ½g¦^À³
ªÑ¥«¸Ì¿é®a¦û¦h¼Æ¡A¿é®a³£¬O²´¥úµu²Lªº.....·íµMµLªk¬Ý¥XÃĵػX¹Ðªº¬Ã¯]....¡C
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GLibad10145748  µoªí®É¶¡:2018/6/21 ¤U¤È 09:09:34²Ä 4598 ½g¦^À³
Ãĵئ³¤H¬Ý¦n,´N¦³¤H¬ÝÃa«Ü¥¿±`.

¥~¸ê«ùªÑ¤w¹F10%¥ª¥k,¤£·|¬Ý¦oÃa§a!

¥Í§Þ¬D¾Ô»P¤£½T©w©Ê¤ñ¹q¤l·~¤j

ÃĵØRopeg(P1101)Á{§É,¤w§¹³ÓHU¤F

¥¼®³ÃÄÃÒ«e,¬Ý¦n©Î¬ÝÃa«Ü¥¿±`,¨S¦³¹ï©Î¿ù.

®³ÂI¤p¿ú½ä¦o¹³¤j¥ß¥ú¤@¼Ë,°µ­Óµo°]¹Ú¦³¦ó¤£¥i?

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GRussell10140734  µoªí®É¶¡:2018/6/21 ¤U¤È 09:08:07²Ä 4597 ½g¦^À³
¤£­n¬ÝÃĵغ¦²´¬õ¡A

¥Í§ÞªÑ¤j®a³£°_¨Ó¤£¬O«Ü¦n¶Ü¡H

¦ó­W©O~

ÂyªÌªºÀt³À¤G¥P¬O³o¼Ë¶}¥Ü¤j²³ªº¶Ü¡H

­ü~

»Õ¤UÀt³À¤G¥P´J¨¥¬Ý¯E¹©³£Ý¢Àt¤F

¬ÝÃĵءKÁÙ¬Oºâ¤F§a¡I

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GÂyªÌ10142287  µoªí®É¶¡:2018/6/21 ¤U¤È 07:57:19²Ä 4596 ½g¦^À³
Ô£¦Ì¡ã

¤°»ò®É­Ô¡A¤¤¸Î¦¨¬°¸ò­·ªº¤p§Ì¤F¡A

¬Ý°_¨Ó¡A¥i¯à¦³¤H¡u»~§âªF­··í±¡­¦¤F¡v¡A

¤µ¤Ñ¶R¤JÃĵتº¡A¤â¸}¤£°÷§Q¸¨ªº¡A

¡u©ú¤Ñ¹L«á¡v¡A¥i¯à±o¡u®¬¤£·íªì±o¤º¶Ë¡v¤F¡A

¸q©M¹Î¦¡ªº®¥ºû¡A¥u¬O»s³y´d¼@ªº¶}©l¡A¥¦¼Ú¬wÃĵý¡A

¦Aµ¥¥b¦~§a¡A¹L¤£¹L©|¥¼ª¾¡A¬ü°êÃÄÃÒ¡A¦ü§Ï¦ò¤ÑÃä±m­i¡A

¦Aµ¥2¡B3¦~§a⋯,¯à¹L¶Ü¡H

²ö®_¦Ï¡A

¤@½g³ø§i¡A´N³Q§j±·ªº¤W¤Ñ°ó¡A¤×¦p¤p»¡𥚃¤ÑÀs¤K³¡ªº¬P±J¬£¡A

¤B¬K¬î¥X¨µ⋯,¡u¬P±J¦Ñ¥P¡BªZ¥\»\¥@¡B¤Ñ¤UµL¼Ä¡v⋯,

现¦b´N¦b¨v·Q¡i¤ñ»ù¤j¥ß¥ú»ù®æ¡j¡A³£§Ñ¤F¤£¤p¤ß¦³­Ó¸U¤@¡A

¨ì¨º®É¡A¤Û·Q¯}㓕¡A¡i¤j¥ß¥ú¤ñ¤£¦¨¡A¤Ï¬°ÂûÀn¤§»ù¡j¡A

«u¡BÃø©Ç¡AªÑ¥«¥Ã»·¿éªº¤H¦û¦h¼Æ⋯!

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GDarren10146466  µoªí®É¶¡:2018/6/21 ¤U¤È 05:39:12²Ä 4595 ½g¦^À³
ÁÙ¨S¹L ´N³Û¨ì280¶ô ³Í°ò ....¨º¹L¤F¤£´N¤T¦Ê°_¸õ... «¢

Ä~Äòªø´Á«ù¦³ ÀR«Ý¦n®ø®§

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GLibad10145748  µoªí®É¶¡:2018/6/21 ¤U¤È 05:31:46²Ä 4594 ½g¦^À³
¨º¤@¶ô¦a­ì¨Ó¬OÁp¥ÍÃį²ªº,«á¨ÓÁp¥ÍÃÄ¥h¤F´­¦{»\¼t.

Ãĵؤ~±o¯²³o¶ô­·¤ôÄ_¦a

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤p´²¤á10028616  µoªí®É¶¡:2018/6/21 ¤U¤È 05:16:58²Ä 4593 ½g¦^À³
¤½¥q¦b·s¦Ë¥ÍÂå¶é°Ï¡A¦­´N¯²¦a¤F¡A­±¿n1.3¤½³¼¡A¦ì©ó¦è¥_°¼©P¬É¡A¾Fªñ°ªÅK·s¦Ë¯¸¡A¬O¶i¾n¶é°Ï·sÃĤ½¥q¤¤­±¿n³Ì¤jªº¡A¸Ô·s¦Ë¬ì¾Ç¶é°ÏºÞ²z§½ºô¯¸¡C

¥¼¨Ó¥D­n¬O¨ÑB¨x©ÎC¨x¥ÎÃĤ§¥Î¡C

www.sipa.gov.tw/home.jsp?serno=201601210001&mserno=201001210037&menudata=ChineseMenu&contlink=content/introduction_7_2.jsp&serno3=201601210003

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GRussell10140734  µoªí®É¶¡:2018/6/21 ¤U¤È 05:07:59²Ä 4592 ½g¦^À³
www.cpmda.org.tw/news_show_n1.php?news_id=1414
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GRussell10140734  µoªí®É¶¡:2018/6/21 ¤U¤È 04:04:06²Ä 4591 ½g¦^À³
money-link.com.tw/RealtimeNews/NewsContent.aspx?SN=903266002&PU=0010

²£¯à¤£¬O°ÝÃD¡K

¥»ª©¦­¦­«e¤w¦³°Q½×

·s¼W·s¦Ë¼t¥Øªº°£¤F¼W¥[²£¯à¥~

À³¸Ó¬O­n¤À´²­·ÀI¡K

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡Gavandia10146474  µoªí®É¶¡:2018/6/21 ¤U¤È 03:15:48²Ä 4590 ½g¦^À³
¥t¥~¤U©P¤@ªÑªF·|

¬Û«H¤j®a³£«Ü·Qª¾¹D

AOPª§Ä³ ¸ò FDAÃÄÃҥثe¥Ó½Ð¶i«×

¦ýÁÙ¦³¤@­Ó°ÝÃD ·Q½Ð¯à¨ìªÑªF·|²{³õªº¥ý¶i­ÌÀ°¦£´£°Ý

´N¬O¥x¤¤¼t¥Ø«e²£¯à°ÝÃD

¥Ø«e¹B§@ªº²£¯à¯à§_¨¬¶q¨Ñµ¹¥¼¨Ó¼Ú¬w¬Æ¦Ü¬ü°êªº¥«³õ

¥¼¨Ó¦³¨S¦³¶i¤@¨B¸ê¥»¤ä¥X ÂX«Ø·s¼tªº­pµe

­Y²£¯à¤£¨¬ ¦³µL¶i¤@¨B´M¨D¥N¤u¹Ù¦ñªº¥i¯à??

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡Gavandia10146474  µoªí®É¶¡:2018/6/21 ¤U¤È 01:28:40²Ä 4589 ½g¦^À³
fda¸òema¨úÃҫ᪺ÃĵØÃĵ´¹ï¦³¹ê¤O¸ò¤j¥ß¥úª§ªÑ¤ý ³oÂI§Ú¦Ü¤µ³£²@µLÃhºÃ

MPN¥ÎÃĦ~½Æ¦X¦¨ªø©ú©ú¥Õ¥ÕÂ\¦b¨ºÃä ¤S¤£¹³¹q¤l·~¦³²£·~´º®ð´`Àô¸ò²H©ô©u

·íµM³o¤]­n·PÁÂincyte jakafi ªñ´X¦~¨Ó¿n·¥À°¦£promote ¨Ã¥´¶}¾ã­ÓMPN¥«³õ

¦ý¤j®a¤]³£ª¾¹D ¦]¬°¨S¦³¯u¥¿¤@½u¥ÎÃÄ ¨ä¹ê PV ET MF ÁÙ¦³¤Ó¦h¯f¤H±Ú¸s©|¥¼¶}µo

¬Û«H¤@½uÃÄ·|¹ý©³§ïÅܦ¹ÂåÀø¥ÍºA

­nª¾¹D ¤@½uÃĤ@¥¹¥Î¤W NCCN guideline ¬O·|½Õ¾ãªº

¦å²G¸~½F¬ìÂå®vªº¨M©w¤£¹³¬O¬Ý·P«_©Î¬O»óÄuª¢¦³¤@°ïªvÀø¿ï¶µ

¦å²G¸~½F¬O¤j¯f ©Ò¦³³B¸m°ò¥»¤W³£¬O¨Ì·Ó guideline °µ¨Æ

´Nºâ¦æ¾P¦AÄê ²Å¦Xguideline »P criteria ªº¯f¤H

Âå®v¬O¤£¤Ó¥i¯à¤£¶}ÃĪº

³Ñ¤U¥u¬O«OÀI¤½¥q«ç»ò½Íªº°ÝÃD¤F

·íµM²{¶¥¬q¸òaopªºª§Ä³¯àºÉ¦­¸Ñ¨M³Ì¦n ´N¹³¤¤¬ü¶T©ö¾Ô¤@¼Ë

¨â®a¤½¥q³£¥u¬O¦bª§¨ú§ó¦hÄw½X ¨S¦³¤H·|²Â¨ì®³¥ÛÀY¯{¦Û¤vªº¸}

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¶È¨Ñ°Ñ¦Ò10146497  µoªí®É¶¡:2018/6/21 ¤U¤È 12:33:41²Ä 4588 ½g¦^À³
«¢«¢¡A§Ú¤]¬O³o¼Ë»{¬°
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GLibad10145748  µoªí®É¶¡:2018/6/21 ¤U¤È 12:32:23²Ä 4587 ½g¦^À³
¶È¨Ñ°Ñ¦Ò¤j,

ÃĵحY¦³18%¯u¦n,¤µ¦~7¤ë°_­x¤½±Ð´N¨S¦³18%¤F

¦Ü¤ÖÃĵØÁÙ¦³18%

Ãĵإ[ªo!

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¶È¨Ñ°Ñ¦Ò10146497  µoªí®É¶¡:2018/6/21 ¤U¤È 12:22:08²Ä 4586 ½g¦^À³
¤À¼í¤ñªº½Õ°ª¡A½Ð°Ý¦b·íªì2009¦~®Éªº¦X¬ù¡A¦³µL¦X·N·í¾P°âÃB¹F¨ì¤Q»õ¬üª÷®É¡A´N¥i¦Û°Ê½Õ¦Ü20%¡A­Y¦³¦¹¦X·N¡A«h¸ò¥»´NµL»Ý2017¦~7¤ëªº¦A¨óij¤F¡A¨º»ò¡A¨ì©³¤S¬O½Ö¦bij©w¤À¼í¤ñ®É¡A¦Ò¼{¦³¤í©P©µ¡A¬J¬OÃĵطíªì¦³¤í©P©µ¦b¥ý¡A¬O¦]µo²{«á¨Ó¦³¸û¤j°Ó¾÷¡A¤~­n¨D­n´£°ª¤À¼í¤ñ¡A½Ð°Ýaop§Y¨Ï¬O«á¨Ó³Ì¤j¨ü¯qªÌ¡A¬O¤£¬O´N¥²¶·À³¸Ó·ÓÃĵةҴ£Ä³ªº¨Ó°µ¡H¦A»¡¥Õ¤@ÂI¡A­Y§A¤µ¤Ñ©Ò§ë¸êªº¬OaopªºªÑ²¼¡A¦Ó«DÃĵتºªÑ²¼¡A·íÃĵذµ¥X³oºØ´£Ä³®É¡A§A¬O§_´N·|¦]¦¹ªYµM±µ¨ü¡H¬JµM¤j®a³£¬O¦b°Ó¨¥°Ó¡A·íªì¦bñ¦X¬ù®ÉÃĵإu·QÂÇaop¤§¤O§áÂà¦H§½¡A¦Ó¦X·N³o¼Ëªº¤À¼í¤ñ¡A·íµo²{´«aopÁȤӦh®É¡A¤~»¡­n½Õ°ª¤À¼í¤ñ¡A­Y¬O³oºØ±¡§Î¡A¨º²{¤µ¤S¬O½Ö¸û¦³¹L¥¢¦b¥ý¡H¦ÓÃĵØÃø¹D¨Æ«e¤£ª¾§@¦p¦¹ªº½Õ¾ã¡A¶Õ¥²³y¦¨©¼¦¹Ãö«Yªººò±i¡H­Y¤§«e¦X¬ù¦­¦³¦¹³W©w¡A¤]¤£¦ÜºtÅܦ¨¤µ¤Ñ³oºØ§½­±

¤£¹L³o¤@¤Á¦p¤µ¤]¤£¬O­«ÂI¡A´N¦pLibad¤j©Ò»¡ªº¡A¬Û«H¨ì®É·|§@¥X¹ï©¼¦¹³£¦³§Qªºµ²ªG¡]¨º´N¬O²{¦b¤j®a³£¦b½Íªº18%°Õ¡^

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GLibad10145748  µoªí®É¶¡:2018/6/21 ¤U¤È 12:06:26²Ä 4585 ½g¦^À³

¤j¥ß¥úEPS 100¤¸,ªÑ»ù4500-5000

ÃĵØ,Ropeg(P1101)¾P°âÃB°ª¹F10»õ¬üª÷¥H¤W

EPS ·|¤ñ¤j¥ß¥ú¤Ö ? ¥Í§Þ¿ú³£ªá¦b¨úªºÃÄÃÒ«eªº¬ãµo¤ÎÁ{§É

»s³y¦¨¥»¤ñ,¹q¤l·~¤Ö«Ü¦h«Ü¦h,¦Ó¥BRopeg(P1101)¤S¬O¿W¦û¥«³õ¤@½u¥ÎÃĤ§¿W¨¤Ã~

ÃĵØEPS ·|¤ñ¤j¥ß¥ú¤Ö ?

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GLibad10145748  µoªí®É¶¡:2018/6/21 ¤W¤È 11:37:22²Ä 4584 ½g¦^À³
Ropeg(P1101)¾P°âÃB°ª¹F10»õ¬üª÷¥H¤W

AOP,Ãĵإòµô®×¥u¬O¤â¬q:¦U¦Ûª§¨ú³Ì¤jÀò§Q

³Ì²×EMA,FDAÃÄÃÒ¤´¥i¨ì¤â,¤£¥²¾á¤ß.

¥²³º AOP,Ãĵس£¬O¨ô¶V¤½¥q,¸gÀçªÌ¤]¬OÁo©ú¤H

¤£·|¥É¥Û­ÑµI,¨â±Ñ­Ñ¶Ë

¦X«h¨â§Q,¥¼®³¨ìÃÄÃÒ«e»PAOPªºÃö«Y¤£©y¼¹¯}Áy

Ãĵإ[ªo!

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤p´²¤á10028616  µoªí®É¶¡:2018/6/21 ¤W¤È 11:29:27²Ä 4583 ½g¦^À³
³ogºô¨C¦¸³£·d¤£²M·¡¡AÃĵØ2018/04/19¤½§i¬O«ü¨Ï¥ÎP1101ÃÄ«~ªº¶O¥Î¡A³o·íªì2009¦~½Íªº´N¬O¡¨­ì®Æ¦¨¥»»ù+©T©w¤ñ¨Ò??%¡¨(³oÂI¤½¥q¥¼¤½§i¡A±À´úÀ³¦³20%¥H¤W)¨Ó­pºâ¡A¦Ó¤£¬O«üÀ禬¤§Åv§Qª÷(³Ì°ª¥i¹F20%¡A2017/07/03­«°T¤½§i¡A³oÂIÂù¤è¤w¹F¦@ÃÑ)¡C

¨º¬°¦ó¤½¥q­n½Õ°ªÃÄ«~ªº¨Ï¥Î¶O?¨º¬O¤½¥q¥¼¨Ó¥x¤¤¼t±N¾É¤J¥Í²£·s»sµ{(¤½¥q107¦~³ø¦³´£¨ì)¡A¥i±N¥Í²£¦¨¥»¤j´T­°§C¡A©¡®ÉAOP¨Ì¦X¬ù³W©w¥i¥H¥Î§C»ù¨ú±oP1101¡AÃĵطíµM¤£Ä@·N³o¦¨¥»­°§C¤§¦¨ªGAOP¥i¤À¨É(¦]¬°­n§ë¤J¤H¤Oª«¤O¤§µ²ªG)¡A©Ò¥H¦VAOP¨ó°ÓÃÄ«~¤À¼í¤ñ´£°ª¤§¥i¯à©Ê¡AAOP¤£Ä@·N¡A´N§Q¥Î107.04¤¤¤½¥q´£¨Ñ§¹¾ãCMC¸ê®Æµ¹AOP«á¡A§Q¥ÎÃÄ«~¤À¼í¤ñ´£°ª¬°Ä³ÃD¡A´£¥X¥òµô¡A¥H±»Å@¥i¤£´£¨ÑCONTI-PVªº¸ê®Æ¡C

©Ò¥H¤j®a³£¬O¦b°Ó¨¥°Ó¡Aª§¨ú³Ì¤j§Q¯q§a¤F¡A¥u¤£¹LAOP¥ý¤£¨Ì¦X¬ù¿ì²z¡A¯u¤£À³¸Ó¡C

¦ý§Ú¬Û«H¡A³Ì«á·|¹F¦¨¦@ÃÑ¡AAOP¦~©³®³¨ìEMAÃÄÃÒ«á¡A¨S¦³ÃĽæ¸Ó«ç»ò¿ì?

«Øij¦U¦ì¤j¤j¦³ªÅÀ³¸Ó°Ñ¥[ªÑªF·|¡A°Ý­Ó²M·¡¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡Gellelin10138869  µoªí®É¶¡:2018/6/21 ¤W¤È 10:51:42²Ä 4582 ½g¦^À³
Gºô°w¹ïÃĵعïAop´£¥X¤Ï¥òµô¦³º¡¸Ô²Óªº»¡©ú

¥ß³õÁٺ⤤¥ß~

µØ¤Í­Ì¥i¥H¬Ý¬Ý!

¤£ª¾¹D¦³¨S¦³¤j¤j­Ìª¾¹D¡A¤@¯ëICC°w¹ï¦¹Ãþ®×¤l¤j·§¦h¤[ªº®É¶¡·|µ²®×©O?

www.genetinfo.com/investment/featured/item/17439.html?limitstart=0

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GLibad10145748  µoªí®É¶¡:2018/6/21 ¤W¤È 10:14:39²Ä 4581 ½g¦^À³
¡m¥ÍÂåªÑ¡n¥Í§Þ¤ë¨ÓÁ{¡A³Í°ò³Û¶RÃĵØÃÄ

2018/06/21 08:23 ®É³ø¸ê°T

¡i®É³ø-¥x¥_¹q¡j¥Í§Þ¤ë²±¨Æ7¤ëµn³õ¡Aªk¤H¾÷ºc¦b¤¤¬ü¶T©ö¾Ô°T®§¯É¶Ã¤§»Ú¡A»â¥ý±N¥Ø¥ú©ñ¨ì¡u¤£¥eÅv­È¡B¸û¤£¨ü°ªÃöµ|¼vÅT¡vªº·sÃıڸs¡A³Í°ò§ëÅUªì¦¸µûµ¥ÃĵØÃÄ (6446) ¡Aµ¹¤©¡u¶R¶i¡v»P280¤¸±À´ú¦X²zªÑ»ù¡AÄâ¤âªáºXÀô²y¡B·ç«HÃÒ¨é¡A¹w¥ýª£¼ö¥Í§Þ¤ë§ë¸ê®ðª^¡C

¡@¥xÆW¥Í§Þ¤ë¸g¹L³s¦~¯Ñ¯Ð¡A¤w¦¨¬°°ê»Ú­«­n¥Í§Þ²£·~±M·~¬¡°Ê¡A¥»¦¸¤º®e¦³¡G¨È¬w¥Í§Þ°Ó¾÷°ª®p½×¾Â¡BµØ¤H·s¿³¥«³õ°Ó¾÷¦X§@¬ã°Q·|¡B°ê»Ú¬ã°Q·|¡B¥Íª«¬ì§Þ¤j®i»P¥Í§Þ°Ó¾÷´C¦X·|¡C¬¡°Ê±N¦b7¤ë¤¤µn³õ¡A¥B¥ú¬O¤½¥q®i±æ»¡©ú·|¡A«K¶°µ²43®a°ê¤º¥~¥ÍÂå¥ø·~¦@Á¸²±Á|¡A¦V§ë¸ê¤H¶i¦æ·~°È²³ø¡C

¡@³Í°ò§ëÅU¥Í§Þ²£·~¤ÀªR®v·¨¤S¿o«ü¥X¡A³J¥Õ½èÃĪ«¨ã³Æ¦w¥þ©Ê»PÃÄ®ÄÀu¶Õ¡AÂå¬É§ï±Ä³J¥Õ½èÃĪ«§@¬°¦hºØ¯e¯fªº¥D­nªvÀø¤è¦¡¡A®Ú¾Ú¬ã¨s¾÷ºcBusiness Wire¹w¦ô¡A¥þ²y³J¥Õ½èÃĪ«¥«³õ³W¼Ò¦Ü2020¦~±N¹F2,487»õ¬ü¤¸¡]¬ù·s¥x¹ô7.46¥ü¤¸¡^¡A2015¡ã2020¦~½Æ¦X¦¨ªø²v¬°7.3¢H¡C

¡@ÃĵØÃĬO¥x¼t±Mª`³J¥Õ½èÃĪ«Àç¹Bµ¦²¤ªº¥Nªí¡A¾ú¸g¦h¦~¬ãµo§ë¤J¡A¶i¤J¦¬³Î¶¥¬q¡A¨äRopeg¥¿¥Ñ¼Ú¬wÃÄ«~ºÞ²z§½¶i¦æ¤W¥«³\¥i¥Ó½Ð³Ì«á¼f¬d¡A³Í°ò¹w´Á¡ARopeg±N¨ú¥N¶Ç²Î¤zÂZ¯À»P¨ä¥LÃĪ«¡A¦¨¬°¯u©Ê¬õ¦å²y¼W¥Í¯g¡]PV¡^ªvÀø¤èªk¡A²£«~¤W¥««á¤T¦~¡AÀ禬¦ô¥i¹F10»õ¬ü¤¸¡C

¡@ªáºXÀô²y»P·ç«HÃÒ¨é¡A¬O¥~¸ê°é¤¤¹ï¥xªÑ·sÃıڸs§ëª`³Ì¦hÃöª`ªÌ¡CªáºXÀô²y¥Ñ¥xÆW°Ï¬ã¨s³¡¥DºÞ¨¦¤ë²[¡]Peter Kurz¡^±¾«Ó¡A¤Á¤J¬ã¨s¥Í§Þ»â°ì¡F·ç«HÃÒ¨é¥Ñª¾¦W¬ì§Þ²£·~¤ÀªR®vĬ«p¦X¬D°_­«¾á¡A¬°ªº³£¬O¦V°ê»Ú«È¤á¤¶²Ð¥xÆW¬°·sÃĬãµo¤j°ê¡A¥H´Á¶i¤@¨B±N¸êª÷¾É¤J¹q¤lÃþªÑ¥H¥~¼Ðªº¡C

¡@¨é°Ó¥xªÑ¬ã¨s³¡¥DºÞ¤]¤£¿Ð¨¥¡A¥xªÑ·sÃıڸs¦V¨ÓÅý¬ã¨s¾÷ºc¡u¤S·R¤S«ë¡v¡C·sÃĤ½¥q­YÀò±oÃÄÃÒµ¥Âà¾÷¡AÀò§Q¤jÃzµoªº´Á±æ±`·|±a°ÊªÑ»ù¼Æ­¿Â½´­¡A¤£¹L¡A¦U¤½¥q©Ò¬ãµo·sÃÄ´X¥G¥þ¤£¬Û¦P¡A¹w´ú«e´ºÃø«×·¥°ª¡A¤]µ¹¬ã¨s¾÷ºc±a¨Ó¤£¤p¬D¾Ô¡C¡]·s»D¨Ó·½¡G¤u°Ó®É³ø¢w²«Â·æ¡þ¥x¥_³ø¾É¡^

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GSirius10142542  µoªí®É¶¡:2018/6/20 ¤W¤È 08:43:57²Ä 4580 ½g¦^À³
To avandia

¦Û±q4174¤j¶^«á¡AÃÒ¨é·~¤j­P¤£¤ÓÄ@·N±À·sÃĪѡA´Nºâ­n¥X³ø§i¡A¥Ø¼Ð»ù¤]·|ºÉ¶q«O¦uªººâ¡A¤£­n°¾Â÷¥«»ù¤Ó»·¡C

¦pªG¶TµMµo¤@­Ó¥Ø¼Ð»ù¤­¦Ê¡B¤@¤dªº³ø§i¡A¥i¯àÁÙ·|³Q¥DºÞ¾÷Ãö¨n¤W¡A©Ò¥H¡A¤£­n¤Ó¬°Ãø§O¤H¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡Gavandia10146474  µoªí®É¶¡:2018/6/19 ¤U¤È 11:43:39²Ä 4579 ½g¦^À³
³Í°ò³o¥÷³ø§iªº¦ôºâ·Pı«D±`«O¦u ¦Ó¥B¥þ½g³£¨S¦³´£¨ì¤@­Ó­«ÂI

´N¬OEMA ¸ò FDA ³£¬O¥HPV¤@½u¥ÎÃĨӮֵoÃÄÃÒ

¤@½u¥ÎÃÄ ³o¤~¬O­«ÂI¤¤ªº­«ÂIªü

¤@¥÷15­¶ªº§ë¸ê³ø§i©~µM°¦¦r¥¼´£¤]º¡©_©Ç...

¦pªGjakafi ¤G½uªvÀøªº ²Ä¤@¦~¾P°â¥i¹F 166M

¦ó¥Hropeg ¤@½u¥ÎÃÄ©~µM¬ü°ê²Ä¤@¦~¥u¦³ 117M ¼Ú¬w¥u¦³70M ???

¦óªp³oÁÙ¬OMPN¥ÎÃÄ¥«³õ¦h¦~¨Ó½Æ¦X¦¨ªø«áªº¾P°âµ²ªG

¤£½×¬O pv¥«³õº¯³z²v ©Î¬O ¹F¨ì peak sale ©Ò»Ý­nªº®É¶¡ ¦ôºâ³£¤Ó«O¦u

ropeg ¥«³õ¼ç¤OÀ³¤£¶È¤î©ó¦¹

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡Gmengs10146592  µoªí®É¶¡:2018/6/19 ¤U¤È 11:13:04²Ä 4578 ½g¦^À³
Elle ÁÂÁ©pªº¤À¨É

¯¬ ¾Þ§@¶¶§Q

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡Gellelin10138869  µoªí®É¶¡:2018/6/19 ¤U¤È 11:04:30²Ä 4577 ½g¦^À³
¨Ó¤F!½Ð¨É¥Î!

drive.google.com/file/d/1NbdkQjbSTx9RIGV0zO-qRV7dlGtiH4vp/view?usp=sharing

º¡¤â¥Í§ÞªÑªº§Ú¡AÃĵجO®Ö¤ß«ùªÑ(©`¦Ì¤p¤á)

¥u­n¦³¬ÛÃö®ø®§³£·|Ãöª`

©ê¤F¥|¦~¦³¤F

´Á«Ý¦­¤é¶}ªáµ²ªG

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡Gmengs10146592  µoªí®É¶¡:2018/6/19 ¤U¤È 10:37:53²Ä 4576 ½g¦^À³
«¢«¢§Ú¬O«üElle¤j©Ô ¦pªG¦³¬Ý¨ìªº¸Ü¦A³Â·Ð.. ¤£µM¶}­Ó¤á¤F:)
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¶È¨Ñ°Ñ¦Ò10146497  µoªí®É¶¡:2018/6/19 ¤U¤È 10:35:06²Ä 4575 ½g¦^À³
«¢«¢¡A§Ú¨S¦b³Í°ò¶}¤á¡A§Ú¤]¤£¬O·|­û
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡Gmengs10146592  µoªí®É¶¡:2018/6/19 ¤U¤È 10:29:35²Ä 4574 ½g¦^À³
¤W­±ªº¤j¤j·PÁ¤À¨É³ø§i¡A¥i§_¤]Âà¶K¤@¤U³Í°ò¸Ì­±¦³½gÁ¿¥Í§Þªº¡A6/15¸¹¥Í§Þ²£·~: ¥xÆW³J¥Õ½èÃĪ«¶}µoÃļt·§ªp³o½g

ÁÂÁÂ

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¶È¨Ñ°Ñ¦Ò10146497  µoªí®É¶¡:2018/6/19 ¤U¤È 10:13:33²Ä 4573 ½g¦^À³
www.genetinfo.com/investment/featured/item/17412.html
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡Gwu701610136601  µoªí®É¶¡:2018/6/19 ¤U¤È 10:11:13²Ä 4572 ½g¦^À³
·PÁÂRookie¤jª½µó¦V¤½¥q¨DÃҨäÀ¨Éµ¹ª©¤W¦P¦n¡A

¦P·NRookie¤j©Ò­z¡Aª½±µ¦V¤½¥q¨D¥¿¬O³Ìª½±µ»P²M·¡ªºÂç²M¤èªk¡C

Ãĵإ[ªo

6/19 ¥~¸ê¤j¶R180±i¡B¦ÛÀç°Ó½æ¶W30±i¡A¤T¤jªk¤H¦X­p¶R¶W150±i

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¶È¨Ñ°Ñ¦Ò10146497  µoªí®É¶¡:2018/6/19 ¤U¤È 10:07:58²Ä 4571 ½g¦^À³
§Ú·QRookie¤j³o¼Ëªº¦^µª¡A¨Ã¤£·|¦]¦¹´î¤Ö¥«³õ¹ï¦¹¨Æ¥óªº¼~¼{¡A§Y¨ÏÃĵجO¯¸±o¦í¸}ªº¡A§A¤]¤£ª¾³o¶D³^¬O§_·|«Ü§Öµ²§ô¡A¦Óaop¬O§_¦A¤W¶D¡H¤j®a³£²M·¡ª¾¹Daop­nªº¬O¤°»ò¡A¤j®a¤]³£¦³¦@ÃѬü°êÃÄÃÒ¤~¬OÃĵتº¥D¾Ô³õ¡Aaop¤]¬O¬Ý·Ç¤F³o¤@ÂI¡A¤~¤£Â_¥Î¥dÃö¨Ó¹F¨ì¥¦ªº¥Øªº(»{¬°ÃĵØÁȤӤj¤F¡^¡AªÑ¥«³Ì¤jªº§QªÅ´N¬O¥¦ªº¤£½T©w©Ê¡A­Y½T©w¤F¡A³ÌÃaªºµ²ªG¤£´N¬O³o¼Ë¦Ó¤w¡A¨ºµ²ªG¤Ï¦Ó¬O¦nªº¡F­YÁ{§É¼Æ¾Úaop´N¬OÅK¤F¤ß¤£µ¹¡A¦pªGÃĵئb¬ü°êÁٻݭ«§@¤T´ÁÁ{§É¡Aµ¥µ¥¤¾ªøªº¤âÄò¡A¨º¤]´Nºâ¤F¡A­Yµ²ªG¯u¦p¤j®a©Ò¼Ö¨£ªº¡A§K§@¤T´ÁÁ{§É¡A§AÁÙ·|§Æ±æ¦³¦¹ÅܼƵo¥Í¡HÃĵاY¨Ï¯u¦h¤F4%ªº¤À¼íª÷¡A«o¤]®I¤U¨ú±o¬ü°êÃÄÃÒªº¥t¤@ÅܼơA»P¦X§@¹Ù¦ñªººò±iÃö«Y¡A¨ì©³­È¤]¤£­È¡H¤d¸U§O¦]¤p§Q(§Y¨Ï¬O¤£¤pªº§Q¯q¡^¡A¦ÓÃa¤F¤j§½¡A®Ú¾ÚÃĵتº»¡ªk¡A©ó¥h¦~12/15¤éªº«e¤@¤ë¡A§Y¤w¹ïaop´£¥X²×¤î±ÂÅv«´¬ùªºÄµ§i¤F¡A¦Ó·s¼t·s»sµ{ªº´£¥X¬O¤µ¦~¥|¤ëªº¨Æ¡A¬Gaop¹ïÃĵؤ§¤£º¡¡A©ó¥h¦~§Y¤w¬Ý¥X¸ñ¶H¤F(¤]´N¬O2017¦~7¤ë´£°ª¤À¼í¤ñ¦Ü20%¥H«áªº¨Æ¡^¡A¦Ó·s»sµ{¦¨¥»­°§C¤]¥u¤£¹L¬Oaop­n­°§C¤À¼í¤ñªºÂǤf¦Ó¤w¡AÃĵب«¨ì³o¤@¨B¡A¨ä¹ê¨Ã«D¤j¦h¼ÆªÑªF©Ò¼Ö¨£ªº

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡Gellelin10138869  µoªí®É¶¡:2018/6/19 ¤U¤È 10:07:32²Ä 4570 ½g¦^À³
¬ã¨s³ø§i¨Ó¤F!

»Ý­nªº§Ö¤U¸ü³á!

drive.google.com/file/d/1iEyR_MOL9EAo_vev17rv7-S2kc6s8M5u/view?usp=sharing

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡Gªü¤¤10143502  µoªí®É¶¡:2018/6/19 ¤U¤È 09:47:34²Ä 4569 ½g¦^À³
³Í°òÀɮצ³15­¶

¥i¯à­n¥h³Í°ò¶}¤á,´N¥i¥H¬Ý¨ì³ø§i

¬Ý¦n®³¨ì¼Ú¬üÃÄÃÒ5¦~¤º¦³20»õ¬üª÷¥«³õ

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡Gavandia10146474  µoªí®É¶¡:2018/6/19 ¤U¤È 09:26:45²Ä 4568 ½g¦^À³
¨S¦³³Í°ò±b¸¹¡A¦³¨S¦³¤j¤j¯à´£¨Ñ ³Í°ò§ëÅU ¹ïÃĵØÃĪº³Ì·s§ë¸ê³ø§i ÁÂÁÂ!
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GRookie10143115  µoªí®É¶¡:2018/6/19 ¤U¤È 08:36:57²Ä 4567 ½g¦^À³
§Æ±æ¦b³o­Óª©¯d¨¥,³£¯à¸g¹L¤@©w¬dÃÒ,¤£­nÁ¿¤@¨Ç¬O¬O¦Ó«DªºÁÁ¨¥,¨Æ«áÅçÃÒ¤]³£¤£¬O¯uªº

¤µ¤Ñ¸ß°Ý¹L¤½¥q,¤½¥qªºÁ¿ªk±µªñ¤p´²¤á¤j²Ä2ÂIªº»¡ªk

¥D­nÄpµ²ÂI¦bÃĪº¦¨¥»­pºâ,¦b·sªº»sµ{¤U,P1101ªº¦¨¥»¥i¯à¤j´T­°§C,AOP»{¬°·s»sµ{³q¹L«áÀ³¥H·s¦¨¥»»ù+¤@©w%¼Æ§@¬°ÃĪº

¦¨¥»¤~¦X²z,Âù¤è¹ï³oÂI¨S¦@ÃÑ,©Ò¥HAOP¤£´£¨Ñ§¹¾ã¼Æ¾Ú¨Ó¥dFDAÃÄÃÒªº¥Ó½Ð,¦ý°ò¥»¤W¤£¼vÅTEMAÃÄÃÒ¥Ó½Ð

­Ó¤Hı±o

¥Ø«eAOP¬O¯¸¤£¦í¸}ªº,²¦³º·s»sµ{¬O¥¼¨Ó¦¡,¥BÁٻݳq¹LEMA¼f®Ö,¤]¤£¬O´N¤@©w¹L,®³¤@­Ó¥¼¨Ó¦¡¬°²z¥Ñ,À³¸Ó¬O¯¸¤£¦í¸}ªº

¥H¤WÆ[¹î¶È¨Ñ°Ñ¦Ò,¤Å°µ§ë¸ê¨Ì¾Ú

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¶È¨Ñ°Ñ¦Ò10146497  µoªí®É¶¡:2018/6/19 ¤U¤È 07:15:32²Ä 4566 ½g¦^À³
¦³±À´úICC¤w¹ïÃĵا@¥X¤£§Q§P¨M¡A¬G´£¥X¤Ï¶D³^¡F¦pªG¤£§Qªº§P¨M¡A¬Oºû«ù­ì¥ýªº16%¤À¼í¤ñ¡A¦Ó«DÁٻݤä¥I°ªÃBªºÁ{§É¼Æ¾Ú¶O¥Î¡AÀ³¸Ó´N¤£¥Î¨«¨ì¨â±Ñ­Ñ¶Ëªº¦a¨B¡A¥i¨£aop¹ïÃĵث᭱´£¥X½Õ°ª¤À¼í¤ñ¦Ü20%ªº§@ªk¡A¤º¤ß¬O·¥«×ªº¤Ï·P¡A»PÃĵةҺٹF¦¨¨óijªº»¡ªk¡A¦³«Ü¤jªº¸¨®t¡F§Ú»{¬°´£¥X¤Ï¶D³^«á¡A­Y³Ì²×ªºµ²ªG¡A¬O¦U°h¤@¨B¡A±N¤À¼í¤ñ­°¦Ü18%¡A¨º»ò¹ïÃĵئӨ¥¡A´N¬O·¥¤jªº¦¨¥\¡C
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤p´²¤á10028616  µoªí®É¶¡:2018/6/19 ¤U¤È 05:11:17²Ä 4565 ½g¦^À³
§Ú¬Û«HÂù¤è³£¦³¤j´¼¼z¥h³B²z¡A·|©M¸Ñ¨Ì¬ù¿ì²zªº¡C

1. AOP­nªº¬OÃĵإI¿ú¶RÁ{§É¼Æ¾Ú¡A³o³¡¤ÀÀ³¸Ó¬OCONTI-PVªº¼Æ¾Ú¡C(³o³¡¤À«D¦X¬ù¤º®e)

2. Ãĵحnªº¬OÃÄ«~»ù®æ¤§´£°ª¡A·íªì¦X¬ù½Íªº¥i¯à¦¨¥»»ù+XX%(³oÂI­n¤½¥q»¡©ú)¡A¦]¬°¥¼¨Ó±N¾É¤J·s»sµ{¡AÃÄ«~¦¨¥»»ù·|­°§C³\¦h¡C(³o³¡¤À¤]«D¦X¬ù¤º®e)

¦]¬°EMAÃÄÃÒ¥i¯à©óQ4®Ö©w¡A¦pªGAOP¤£´£¨ÑÃöÁäÁ{§É¼Æ¾ÚÅýÃĵإӽÐFDAÃÄÃÒ¡AÃĵشN¤£´£¨ÑÃÄ«~µ¹AOP¡A¦pÂù¤è§¡¤£¨Ì¬ù¿ì²z¡A«h¤G±Ñ­Ñ¶Ë¡AÃĵإi¯à­n­«·s¿ìÁ{§É©Î¶RAOP¤§©Ò¦³Á{§É¼Æ¾Ú¡AAOP«h¨S¦³ÃÄ¥i¥H½æ¡A³o¹ï¥ô¦ó¤@¤è³£¨S¦n³B¡A³Ì­«­nªº¬O¯f¤H¤§·l¥¢«Ü¤j¡C

¥H¤W¬O¤p§Ìªº©å¨£¡A½Ð°Ñ¦Ò¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤p¥øÃZ10142872  µoªí®É¶¡:2018/6/19 ¤U¤È 04:40:17²Ä 4564 ½g¦^À³
¤j®a³£©¿²¤¤@ÂI

±M§QÅv¦b6446

²Ä¤@¦¸¬Ý¨ì¦³±M§Qªº, ³Q¦æ¾P²oµÛ»ó¤l¨«

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G°e³øªº10135990  µoªí®É¶¡:2018/6/19 ¤U¤È 02:18:39²Ä 4563 ½g¦^À³
¤@ÂI¤p¬Ýªk

1 ¥HµL±ÂÅvª÷´«¹êÅç¼Æ¾Ú¨Ï¥ÎÅv.µL¤£¤½¥­--AOP ¤½¥qÀ³µLÀv´£¨ÑÁ{§É¼Æ¾Ú¨ÑÃĵضi¦æ¨ä±ÂÅv¼Ú¬w¥H¥~°Ï°ì¥]§t¬ü°êFDAµ¥ÃÄÃҥӽШϥÎ...³o±ø³Q±À½¾÷·|¤£¤j.

2. ´£°_·l®`¥òµô¬O¥H¤À¼í¬°¥D¶b--ÃÒ©ú«e¶µ.¦Ó¥Bñ¬ù®ÉÀ³¸Ó¤]¨S¨¬¥H±À½ªº·å²«..

3.AOP¤½¥q«o©ó¤µ¦~4¤ë¤¤«Ý¤½¥q§¹¾ã¥æ¥I©Ò¦³ÃĪ«¤Æ¾Ç»s³yºÞ¨î¬yµ{¤å¥ó¡]CMC) «á³w¦V°ê»Ú°Ó·|¡]ICC¡^¥¿¦¡´£°_·l®`¥òµô--AOP¤]¤£·Q¥òµô®×¼vÅTRopeg(P1101)¤§¼Ú¬wÃÄÃҥӽФ§¶i¦æ

4.¼vÅTRopeg(P1101)¤§¬ü°êÃÄÃҥӽФ§¶i¦æ--­n¬ÝÃöÁä¼Æ¾Ú¬O§_³£¤w¨ú±o.³Ñ¤U¥¼¸É»ô¬O§_¼vÅT...³o­n½Ð¤½¥q»¡©ú¤F

5.³ÌÃaªº±¡ªp¤pªº²q..¦^¨ì¤À¼í12%-16% ³Ì¨Îªºµ²ªG??...½Ð¤½¥q»¡©ú¤F

³o³õ¥òµô®×¬OAOPµo°Êªº.´£°_¤Ï¥òµô..

ÃÙ¦PRussell¤j ¥H¾Ô¹G©M¡K§Ú¤ä«ù¤½¥q +1

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡Gªü¤¤10143502  µoªí®É¶¡:2018/6/19 ¤U¤È 02:16:01²Ä 4562 ½g¦^À³
³Í°ò§ëÅU¦³³Ì·s6446¬ã¨s³ø§i
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G§ë¸ê¬ö«ß10145266  µoªí®É¶¡:2018/6/19 ¤U¤È 02:05:21²Ä 4561 ½g¦^À³
¦pªG¤½¥q·s»D½Z¬°¯u

¬Ý¨Ó¤]¤w¸gµ¹AOP¦h¦¸¾÷·|¤F

¦ýAOPÁÙ¬O¦b­A¤@¨Ç¤p¤â¬q

¥Õ¯È¶Â¦r

AOP¨Ä¨Ä·Ó«´¬ù¨«¡A¤£­n·d¨ì¼Ú¬w¥«³õ¤]¨S¤F

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GRussell10140734  µoªí®É¶¡:2018/6/19 ¤U¤È 12:51:48²Ä 4560 ½g¦^À³
¥H¾Ô¹G©M¡K

§Ú¤ä«ù¤½¥q

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤ý£«¬Â10136621  µoªí®É¶¡:2018/6/19 ¤U¤È 12:24:53²Ä 4559 ½g¦^À³
°_¦]ÁÙ¬O¬Ý¨ìÃĵئb¼Ú¬w¥«³õ¥H¥~ªºÃe¤j°Ó¾÷¦b²´¬õ¡A·Q¤ÀªMü¡A¦Ó³B³B¤NÃø¡C
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GLibad10145748  µoªí®É¶¡:2018/6/19 ¤W¤È 10:21:21²Ä 4558 ½g¦^À³
¥òµô®×±N¤£¼vÅTRopeg(P1101)¤§¼Ú¬wÃÄÃҤάü°êÃÄÃҥӽФ§¶i¦æ ?? ?

1.AOP¤½¥q¤è³°Äò´£¨Ñ¡A±©¦Ü¤µ§¹¾ãªºÁ{§É¼Æ¾Ú¤]©|¦³³¡¤À¥¼¸É»ô

¥¼§¹¾ãªºÁ{§É¼Æ¾Ú¤£¼vÅTRopeg(P1101)¬ü°êÃÄÃҥӽФ§¶i¦æ ?? ?

2.²×¤î±ÂÅv«´¬ù¦³®Ä¤§¤Ï¥òµô

¦pªGÃĵزפî±ÂÅv«´¬ù¦³®Ä¤§¤Ï¥òµô¦¨¥\¤F.

­ì¥ý¬OAOP¥Ó½Ð¼Ú¬wÃÄÃÒ,­YAOP³Q²×¤î±ÂÅv«´¬ù,¤£¼vÅTRopeg(P1101)¼Ú¬wÃÄÃҥӽФ§¶i¦æ ?? ?

3.AOP·l®`¥òµô¡]¤À¼í¬°¥D¶b¡^

¦pªGAOPĹ·l®`¥òµô¡]¤À¼í¬°¥D¶b¡^,¹ï°]°È·~°ÈÀç¹B¤£·|²£¥Í­«¤j¼vÅT?

¦X«h¨â§Q,¥¼®³¨ìÃÄÃÒ«e»PAOPªºÃö«Y¤£©y¼¹¯}Áy

Ãĵإ[ªo!

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡Gª£¦Ì¯»10146792  µoªí®É¶¡:2018/6/19 ¤W¤È 09:31:51²Ä 4557 ½g¦^À³
¥H¤Uªº·s»D½Z¡A¬Ý°_¨ÓµuªÅ¡A¦ý¤]¬Oªñ´Á·Q¥[½Xªº¦n¾÷·|

ÃĵØÂåÃÄ»¡©ú¡A2009¦~»PAOP¤½¥q©Ò­qªº±ÂÅv«´¬ù¦³¬ù©w¡AAOP ¤½¥qÀ³µLÀv´£¨ÑÁ{§É¼Æ¾Ú¨ÑÃĵضi¦æ¨ä±ÂÅv¼Ú¬w¥H¥~°Ï°ì¥]§t¬ü°ê FDA µ¥ÃÄÃҥӽШϥΡA±©AOP¤½¥q¥¼¨Ì¬ù´£¥X§¹¾ãªºÁ{§É¼Æ¾Ú¡A¬Æ©Î­n¨D¤½¥q¤ä¥I°ªÃB¹ï»ù¥H¨ú±oÁ{§É¼Æ¾Ú¡A¦b¸g¿Ô¸ß¼w°ê«ß®v·N¨£«á¦VAOP¤½¥q´£¥Xĵ§i«ß®v¨ç¡A¿×¨ä¦æ¬°¨Ì±ÂÅv«´¬ù¤w¹FÄY­«¹H¬ù¡A¦pAOP¤½¥q¥¼©ó30¤é®É­­¤º¸É»ôÁ{§É¼Æ¾Ú¡AÃĵإi³w¦æ²×¤î±ÂÅv«´¬ù¡AAOP¤½¥q¹E©ó«e­z®É­­¡]2017¦~12¤ë15¤é¡^ ®É´£¨Ñ¼Æ¾Ú¨Ã«ÅºÙ¸Ó¦X¬ù¤w¦æ¸É¥¿¡A¬G­ì±ÂÅv«´¬ù¤´µM¦³®Ä¡C¨Æ¹ê¤W¸gÃĵؽLÂI¨ä©Ò´£¨Ñ¼Æ¾Úµo²{©|¦³¤£¥þ¡A¸g¤½¥q«ß®v¦A¥h«ß®v¨ç­n¨D¡AAOP¤½¥q¤è³°Äò´£¨Ñ¡A±©¦Ü¤µ¤]©|¦³³¡¤À¥¼¸É»ô¡F°Zª¾AOP¤½¥q«o©ó¤µ¦~4¤ë¤¤«Ý¤½¥q§¹¾ã¥æ¥I©Ò¦³ÃĪ«¤Æ¾Ç»s³yºÞ¨î¬yµ{¤å¥ó¡]CMC) «á³w¦V°ê»Ú°Ó·|¡]ICC¡^¥¿¦¡´£°_·l®`¥òµô¡]¤À¼í¬°¥D¶b¡^¡A¤½¥q¦b»P¼w°ê«ß®v¥þ½L³W¹ºÀ³¹ïµ¦²¤«á¡A¸³¨Æ·|¹E©ó6¤ë15¤é¶i¦æ²`¤J°Q½×¨Ã¨Mij°£°w¹ïAOP¤½¥q©Ò´£¥òµô®×¶i¦æµªÅG¥~¡A¥ç©ó¦P¤@¥òµôµ{§Ç¤¤´£°_²×¤î±ÂÅv«´¬ù¦³®Ä¤§¤Ï¥òµô¡A¥Hª§¨ú¤½¥q¤ÎªÑªF¤§³Ì¤jÅv¯q¡C

Ãĵئb¼Ú¬w¤¤³¡®É¶¡6¤ë18¤é¤w¥Ñ©e½Ð¼w°ê«ß®v©ó¦P¤@¥òµôµ{§Ç¤¤´£¥XµªÅG¤Î´£°_¤Ï¥òµô¡A¥òµô®×±N¤£¼vÅTRopeg(P1101)¤§¼Ú¬wÃÄÃҤάü°êÃÄÃҥӽФ§¶i¦æ¡A¨Ã¥¼¹ï°]°È·~°È²£¥Í­«¤j¼vÅT¡A¨äÀç¹B¤Î°]°È·~°È¤@¤Á¥¿±`¡C¡]½s¿è¾ã²z¡G±i¹Å­Ê¡^

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤p¥øÃZ10142872  µoªí®É¶¡:2018/6/18 ¤W¤È 10:12:26²Ä 4556 ½g¦^À³
¤º¦æ¬Ýªù¹D(¤½¥q¤½§iªº­I«á²z¥Ñ)

¥~¦æ¬Ý¼ö¾x(ªÑ»ù)

ªÑ»ùº¦,´CÅé´N·|¶¶¶Õ¬Ý¦h¡A¤Ï¤§¥çµM

©Ò¥H¬O¦h¬OªÅ, ¨ä¹ê³£¬Oµu½u®ÄÀ³

¥Ø«eªºªÑ»ù¥u¬O¤Ï¬M¼Ú¬wÃÄÃÒ¨ú±oªº§Q¦h

¨Ã¥¼¤Ï¬M¯u¥¿±a¨ÓÀ禬«áªºre-rating(¤¤¸ÎÀ禬ÁÙ¨S¦³°_¨Ó)

§ó¥¼¤Ï¬MFDAªºÃÄÃÒ(¨S¤Hª¾¹D)

¥i¯à¦³¤H»{¬°6446ªº·s»D½Z¹L¦h¡A ¨C¦¸µo¥¬³£¶^,¤£ºÞ¦h©Î¬OªÅ

¨ä¹êÂk©S­ì¦]¡A´N¬O¤½¥q§Æ±æ¤½¶}«Ü¦hµ²½×,©M¨C¤@­Ó¨½µ{¸O©Î¬O¶¥¬q¶i®i

¦ý¨S¦³Á¿¨ì«e¦]«áªG,Åý¤j®a³y¦¨»~·|

¦ý¦pªG¦³¤H¦³ºÃ°Ý¥´¹q¸Ü¥h¤½¥q¡A¤½¥q¤]·|¸ÑÄÀ«e¦]«áªG

³oºØª¬ªp, ¨ä¹ê´N¬Ý¤j®a«ç»òµûÂ_

¦U¦ì§Æ±æ¤@®a¤½¥q³£¦b¹Lµ{¤¤³£¤£¤½§i,³Ì«áª½±µÅuµP©O?

ÁÙ¬O§Æ±æÀH®É¤½§i¨C­Ó¶¥¬q,Åý§ë¸ê¤H¥i¥H¦Û¦æ§PÂ_©Ò»Ý©M­·ÀI?

ÁÙ¬O«Øij¤j®a¡A¯uªº­«µø´N¥h°Ñ¥[ªÑªF·|,«HªÌ«í«H¡A¤£«HªÌ«í¤£«H

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G·s¶i10143606  µoªí®É¶¡:2018/6/17 ¤U¤È 11:26:50²Ä 4555 ½g¦^À³
1) ­Ó¤H¤Ñ¯uªº·Qªk¬O¡K¦³§Q¥i¹Ï¤~·|­p¸û©¼¦¹ªº§Q¯q¡AµM¦ÓÁ{§Éµ²ªG»PEMA¼f®ÖÃÄÃÒªººA«×¡AAOP»PÃĵؤ@©w¤ñ©Ò¦³ªÑªF²M·¡¡C

2) AOP¤w¸g§ë¸ê¤F«Ü¦hª÷¿ú°µÁ{§É¹êÅç¡AAOP¤@©w¤]­nÃÄÃÒ³q¹L¥L¤~¦³¦^¦¬§ë¸ê¦¨¥»ªº¾÷·|§a

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GLibad10145748  µoªí®É¶¡:2018/6/17 ¤W¤È 10:35:59²Ä 4554 ½g¦^À³
©Ò¥H¯u¬Û¤´¥¼¤j¥Õ.

1.¥òµô®×¬O½Ö´£¥Xªº,AOP ? ©Î¬OÃĵØ?

2.¬O¥òµôAOP¤£º¡ÃĵØÃĪº¥x¤¤¼t»sµ{Àu¤Æ·|±a¨Ó®Ä¯q

©Î¬OÃĵØÃÄÅv§Qª÷¥Ñ16%½Õ¤É¨ì20%.

Ãĵؤ½§i¥[ªo!

¤½§i«Ü²M·¡,©ú¥Õ,«e«á¤@­P,¦³¨º»òÃø¶Ü?

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GLibad10145748  µoªí®É¶¡:2018/6/17 ¤W¤È 10:16:40²Ä 4553 ½g¦^À³
Ãĵت§¨ú¤½¥q¤ÎªÑªF¤§³Ì¤jÅv¯q,µ¹¥L¤@­ÓÆg.

³Ì­«­nªº¦n®ø®§¬O,¥òµô®×±N¤£¼vÅT Ropeg (P1101) ¤§¼Ú¬wÃÄÃҤάü°êÃÄ

ÃҥӽФ§¶i¦æ¡C

¤£¹L¬O§_¼vÅT¥H«á»PAOPªº¦X§@? ¨s³ºÃĵئ³¤µ¤Ñ,AOP¥\¤£¥i¨S.

¥ë¦ñ¶¡¨«¤W¥òµôÁ`¬O¶Ë·P±¡,ºÉ¶q¨ó°Ó¤ñ§L¦¥¬Û¨£¦n.

ªB¤Í­n¦h¼Ä¤H­n¤Ö,¤£­n¥u·ÓÅU¦Û®a¤H.

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡Gucss10142657  µoªí®É¶¡:2018/6/17 ¤W¤È 10:11:05²Ä 4552 ½g¦^À³
¦U¦ì¤j¤j¡A¹ï©ó³o¤½§i¡A¨ä¤¤¤@¬q¸Ü§ÚÁÙ¬Oı±o«Ü¯Ç´e>¡i¥»¤½¥q¬°ª§¨úªÑªF³Ì¤j§Q¯q¡A­n¨D­«·sÍù­q¤À¼í¤ñ¡A¦ýÂù¤è¥¼¹F¦¨¦@ÃÑ¡j¬OÃĵش£¥X¡A¦Ó¤£¬OAOP´£¥X

1.¨Æ¹êµo¥Í¤é:107/04/19

2.¤½¥q¦WºÙ:ÃĵØÂåÃĪѥ÷¦³­­¤½¥q

3.»P¤½¥qÃö«Y(½Ð¿é¤J¥»¤½¥q©Î¤l¤½¥q):¥»¤½¥q

4.¬Û¤¬«ùªÑ¤ñ¨Ò:¤£¾A¥Î

5.µo¥Í½t¥Ñ:

¥»¤½¥q±µÀò ICC (°ê»Ú°Ó·|) ¤§°ê»Ú¥òµô°|³qª¾¦³Ãö¥òµô¤@®×

6.¦]À³±¹¬I:

¥»¤½¥q»P AOP ¤½¥q¦X§@¹Lµ{¤¤¡A¦³Å²©óÃÄ«~¬ãµo»s³y¤w§ë¤J¤j¶q¸ê·½¥B¼Ú¬wMPN ÃÄ«~¾P°â¥«³õ¥¨¤j¦¨ªø¡A¡i¥»¤½¥q¬°ª§¨úªÑªF³Ì¤j§Q¯q¡A­n¨D­«·sÍù­q¤À¼í¤ñ¡A¦ýÂù¤è¥¼¹F¦¨¦@ÃÑ¡j¡AAOP ¤½¥q¹E¦V ICC Án½Ð¥òµô¡C¥»¤½¶É±µÀòICC ¥òµô³qª¾¡A¥»¤½¥q©Ò©e°U¼w°ê«ß®v±NÀÀ­q¦]À³¤è®×¡A¥H¸P«O¤½¥q¤ÎªÑªF³Ì¤jÅv§Q¡C±© AOP ¤½¥q¤Î¥»¤½¥q¹ï¥Ó½ÐÃÄÃÒªº¥Ø¼Ð§¹¥þ¤@­P¡A¥»¥òµô®×±N¤£¼vÅT Ropeg (P1101) ¤§¼Ú¬wÃÄÃҤάü°êÃÄÃҥӽФ§¶i¦æ¡C

7.¨ä¥LÀ³±Ô©ú¨Æ¶µ:

·sÃĶ}µo®Éµ{ªø¡B§ë¤J¸g¶O°ª¥B¨Ã¥¼«OÃÒ¤@©w¯à¦¨¥\¡A ¦¹µ¥¥i¯à¨Ï§ë¸ê­±Á{­·ÀI¡A§ë¸ê¤HÀ³¼f·V§PÂ_ÂÔ·V§ë¸ê¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G§ë¸ê¬ö«ß10145266  µoªí®É¶¡:2018/6/17 ¤W¤È 02:15:09²Ä 4551 ½g¦^À³
©Ò¥H¯u¬Û¤j¥Õ....

·d¤F¥b¤Ñ­ì¨Ó¬OAOP¤£º¡ÃĵØÃĪº¥x¤¤¼t»sµ{Àu¤Æ·|±a¨Ó®Ä¯q

»{¬°ÃĵØÃĨì®É·|ÁȤӤj~~~~

®Ú¥»´N¤£¬O·í®Éª©¤W°Q½×ªºÅv§Qª÷¥Ñ16%½Õ¤É¨ì20%³o¤@¥ó¨Æ

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GAlan Liu10136094  µoªí®É¶¡:2018/6/16 ¤U¤È 10:05:39²Ä 4550 ½g¦^À³
°w¹ïÃĵØÃÄ´£¥X¹ïAOP¥òµô®×¦V°ê»Ú°Ó·|(ICC)¤Ï¥òµô¤@®×¡A«YÃĵØÂåÃÄ°w¹ï¥¼¨Ó P1101 ¥Í²£¬yµ{¦A¶i¦æÀu¤Æ¥H­°§C»s³y¦¨¥»¡A¦bAOP±oª¾«á±ýª§¨ú¥¼¨ÓÃĵØÃÄÃÄ»ù­°»ù¥¼ªG¡AÂù¤è¥¼¹F¦¨¦@ÃѤU¡AAOP ¤½¥q¹E¦V ICC Án½Ð¥òµô¡C

ÃĵØÃĦ³Å²©óÃÄ«~¬ãµo»s³y¤w§ë¤J¤j¶q¸ê·½¡A¬°ª§¨úªÑªF³Ì¤j§Q¯q¡A¨Mij¹ïAOP¥òµô®×¦V°ê»Ú°Ó·|(ICC)´£¥X¤Ï¥òµô¡A¬G¥»¦¸¥òµô¤@®×¡A¬°°w¹ï¥x¤¤³J¥Õ½èÃļt¥Í²£ªºÃÄ»ù³¡¤À¡A¨Ã«D¾P°âÅv§Qª÷¡AÂù¤è¨óij½Õ¤ÉÅv§Qª÷¤ñ²v¥i°ª¹F20%¤@®×¡A©ó2017¦~7¤ë3¤éÃĵØÃĤ½§i·s»D½Z¤w©w®×¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GKid10147031  µoªí®É¶¡:2018/6/15 ¤U¤È 11:02:32²Ä 4549 ½g¦^À³
À³¸Óºâ¦n¨Æ§a
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤p¥¿¥¿10141351  µoªí®É¶¡:2018/6/15 ¤U¤È 07:38:44²Ä 4548 ½g¦^À³
¸³¨Æ·|¨Mij¹ïAOP¥òµô®×¦V°ê»Ú°Ó·|(ICC)´£¥X¤Ï¥òµô

1.¨Æ¹êµo¥Í¤é:107/06/15

2.¤½¥q¦WºÙ:ÃĵØÂåÃĪѥ÷¦³­­¤½¥q

3.»P¤½¥qÃö«Y(½Ð¿é¤J¥»¤½¥q©Î¤l¤½¥q):¥»¤½¥q

4.¬Û¤¬«ùªÑ¤ñ¨Ò:¤£¾A¥Î

5.µo¥Í½t¥Ñ:

¥»¤½¥q©ó¤µ¦~4¤ë¥÷±µÀò ICC (°ê»Ú°Ó·|) ¤§°ê»Ú¥òµô°|³qª¾¦³ÃöAOP´£¥X¥òµô

¤@®×¡A¸³¨Æ·|¨Mij¹ïAOP¥òµô®×¦V°ê»Ú°Ó·|(ICC)´£¥X¤Ï¥òµô

6.¦]À³±¹¬I:

ų©óAOP¤½¥q·~¤w¦V°ê»Ú°Ó·|( ICC ) ´£°_¥òµô¡A¥»¥òµô®×¼w°ê©e¥ô«ß®v«Øij

¥»¤½¥q°£¤F¶i¦æµªÅG¥~¡A¬°¦Ò¶q¤½¥q³Ì¤j§Q¯q¡A¥çÀ³©ó¦P¤@¥òµôµ{§Ç¤¤´£°_¤Ï

¥òµô¡C¥»¤½¥q¸g¸³¨Æ·|¨Mij³q¹L¡A±Ä¨ú¼w°ê©e¥ô«ß®v¤§«e­z«Øij¡A¥»¥òµô®×°£

¶i¦æµªÅG¥~¡A¥ç©ó¦P¤@¥òµôµ{§Ç¤¤´£°_¤Ï¥òµô¥Hª§¨ú¥»¤½¥q¤ÎªÑªF¤§³Ì¤jÅv¯q¡C

±©¥»¤½¥q»PAOP¤½¥q¶¡¤§¥òµô®×±N¤£¼vÅT Ropeg (P1101) ¤§¼Ú¬wÃÄÃҤάü°êÃÄ

ÃҥӽФ§¶i¦æ¡C

7.¨ä¥LÀ³±Ô©ú¨Æ¶µ:

·sÃĶ}µo®Éµ{ªø¡B§ë¤J¸g¶O°ª¥B¨Ã¥¼«OÃÒ¤@©w¯à¦¨¥\¡A ¦¹µ¥¥i¯à¨Ï§ë¸ê

­±Á{­·ÀI¡A§ë¸ê¤HÀ³¼f·V§PÂ_ÂÔ·V§ë¸ê¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤p¥¿¥¿10141351  µoªí®É¶¡:2018/6/14 ¤U¤È 10:12:32²Ä 4547 ½g¦^À³

twitter.com/jjkiladjian

J.J. Kiladjian

I¡¦m sure you want to know more about interferon therapy for #mpnsm! Don¡¦t miss this communication on Friday at 12:15 room A7! #EHA23 - presentation S132 ⁦@PVReporter⁩ ⁦@VJHemOnc⁩

PV Reporter

¦^Âе¹ @jjkiladjian

Absolutely, I¡¦m very interested in updates on interferon therapy and other new research that is presented. Would like to touch base with you after the conference. Thanks for the heads up!

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GRussell10140734  µoªí®É¶¡:2018/6/14 ¤U¤È 01:57:09²Ä 4546 ½g¦^À³
¬d¤F¤@¤U¡K

107¦~²Ä¤@©u²{ª÷¸ò¬ù·í²{ª÷¦³29»õ¦h¡A

¤T¦~¤º¤£¯Ê¤l¼uÅo

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤p¥øÃZ10142872  µoªí®É¶¡:2018/6/14 ¤W¤È 08:36:00²Ä 4545 ½g¦^À³
1. ªü¤¤¤j:§Ú¦³½T©w¹L, ¤u¼t¥Í²£§Q¼í+¤½¥q®Ú¾Ú(AOPªºÀç·~ÃB¤À¼í, ¤£¬OÀò§Q¤À¼í)

2. ¦w¼w´Ë¤j:¼W¸êªº³¡¤À, ¤½¥q¦³³W¹º, ¦ý¤£«æ, ²¦³ºªÑ»ù¤£¦p¹w´Á

³Ì«á«Øij¦U¦ì¤j¤j

¦pªG¦³ªÅ´N¨Ó°Ñ¥[ªÑªF·|

²¦³º½Ð°²¤@¤Ñªº¦¨¥»»·§C©ó6446¤@¤Ñªºº¦¶^

¦pªG¦b¤¤«n³¡µLªk°Ñ¥[ªÑªF·|ªº

¦³¥ô¦ó°ÝÃD¤]¥i¥Hª½±µ¥´µ¹¤½¥qµo¨¥¤H©Î¬O¥N²zµo¨¥¤H

¤½¥q¨Ã¤£µ½©ó´CÅé¤å¦r¡A¦ý¦³Ô£´NÁ¿Ô£

¦pªG¸I¨ì´CÅ馳°¾¨£

¨º´N·|§á¦±­ì·N

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GRussell10140734  µoªí®É¶¡:2018/6/14 ¤W¤È 08:23:55²Ä 4544 ½g¦^À³
¦pªG¨S°O¿ùªº¸Ü¡K

·Ó¨C¦~¬ù¤K»õªº¤ä¥X¨Óºâ¡A

¤½¥q¤â¤W²{ª÷³¡¦ì¬ù¥i¨Ñ¤äÀ³3¦~¡C

¤T¦~¤º¥u­n·d©w¼Ú¬w¸ò¬ü°êPVÃÄÃÒ¡A¨ä¹ê¨S¦³¥²­n¦A¼W¸ê¡C

¼Ú¬w¥«³õ¥u¬O«eµæ¡K

¬ü°ê¥«³õ¸ò¥¼¨ÓET»PB¨x¥«³õ¡A

¤~¬O­«ÂI¡K

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GAnderson10143089  µoªí®É¶¡:2018/6/14 ¤W¤È 08:16:49²Ä 4543 ½g¦^À³
¥h¦~Àç·~¶O8.94»õ¡A«e¦~8.53»õ¡C

«áÄò¦pªGÁÙ¦³¨ä¥LÁ{§É¸ÕÅç¶i¦æ¡A³oµ§¶O¥Î¤j·§«ÜÃø­°¤U¨Ó¡A¦pªG¼Ú¬w¤W¥«´Áµ{¨üªý¡A

ª÷¬yµLªk«ö¹w´Á¶i¨Ó¡A·d¤£¦n«Ü§Ö±o¼W¸ê¡A¤£µM¨ä¥L¹êÅç¤]·|¨ü©µÌX¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡Gªüºµ10136469  µoªí®É¶¡:2018/6/14 ¤W¤È 07:10:33²Ä 4542 ½g¦^À³
½æÃĵ¹AOP·íµM¦³§Q¼í¡A¥t¥~AOPÁÙ·|«ö·Ó¾P°âÃBµ¹ÃĵØÅv§Qª÷¡A¥u¬O¦b2019¥ú¾a³o¨âµ§¦¬¤J­ncover¤@¦~8»õ¦hªº¬ã¾PºÞ¶O¥Î¬O¤£¥i¯àªº
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡Gªü¤¤10143502  µoªí®É¶¡:2018/6/14 ¤W¤È 06:06:00²Ä 4541 ½g¦^À³
¤¤¸Î¬O§äÃÄ©ú±d¼w¥Í²£

²{¦bp1101¬OÃĵئۤv¥Í²£

p1101»s³y§¹¦¨,¬O«ö¦¨¥»µ¹aop½æ,ÁÙ¬O¤@©w¥Í²£§Q¼í,¥Í²£§Q¼í«ç»òºâ

³o±N¼vÅT¨ì¦pªG¦~©³¨úÃÒ,¬O§_2019¦~¦³¾÷·|Âà¬Õ

¥¼¨Ó¦³°Ñ¥[ªÑªF·|ªº¤j¤j,Ác½Ð°Ý¤@¤UªL°õ¦æªø

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GDarren10146466  µoªí®É¶¡:2018/6/14 ¤W¤È 12:34:15²Ä 4540 ½g¦^À³
½Ð°Ý ¦U¦ì ¤j¤j ²{¦b °e¥ó¤F ´N³æ¯Â¥u¬O¦Aµ¥ÃÄÃÒ¶Ü? ¤¤¶¡ÁÙ·|¦³Ô£®ø®§¥X²{¶Ü?
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¶È¨Ñ°Ñ¦Ò10146497  µoªí®É¶¡:2018/6/13 ¤U¤È 08:11:19²Ä 4539 ½g¦^À³
«¢«¢¡AÁÂÁ¡A§Æ±æ¨ì®É¤£­nÝ¢Àt¡C
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GLibad10145748  µoªí®É¶¡:2018/6/13 ¤U¤È 08:08:44²Ä 4538 ½g¦^À³
¶È¨Ñ°Ñ¦Ò¤j,

³o¦¸µ¹±z«ö­ÓÆg!

¤ÀªR©ú¥Õ²M´·,­@¤ßµ¥«ÝÃĵتѻù¤@­¸½Ä¤Ñ.

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¶È¨Ñ°Ñ¦Ò10146497  µoªí®É¶¡:2018/6/13 ¤U¤È 07:52:55²Ä 4537 ½g¦^À³
ÃĵؤT­Ó¤ë¨Ó¤w¨ì¤T¨¤§Î¾ã²z¥½ºÝ¡A¬O¸Ó¨ìªíºAªº®É­Ô¡A¸É¸ê®Æ°e¥ó¬JµL©µ´Á¡A¥[¤W²³¤H¤]¼ÖÆ[´Á«Ý¨â­Ó¤ë¤º±N¦³EMAªº¦n®ø®§¡A¤Îªñ¤é¤j¤j­Ì´£¥X³\¦h¥¿­±®ø®§¡A³£¦³§U©óÃĵة¹¤W¶i¤J¥t¤@¾ã²z°Ï¶¡¡A³o¤]¬O¥ý«e´£¹Lªº­Y¦³¯u¹ê§Q¦h¡A¸Ó¦³ªº¥ý¨M±ø¥ó¡A¥u¬O¨ì®É¬O°²¬ð¯}¡AÁÙ¬O¥D¤É¬q¦æ±¡ªº¶}©l¡AºÝ¬ÝEMAªº¦^À³¡A§ÚÁÙ¬O¶É¦V©ó¼f·V¼ÖÆ[«eªº¨â­Ó¦r¡F§Ú»{¬°¥L­Ì½T¬O­n§@µu½u¨S¿ù¡A¦ý¤]»¡©ú¤FªÑ»ùªñ´ÁÀ³·|½Ä°ª¡A¬OÁo©úªº¨Mµ¦¡C
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GDarren10146466  µoªí®É¶¡:2018/6/13 ¤U¤È 05:39:51²Ä 4536 ½g¦^À³
¹L¥h1¤Ñ¡A ¡y¼w«H ¡z¶R¶i235±iÃĵØÃÄ ¡AÁÙ¦n¦³Äw½XK½u¡A¤~§ä±o¨ìÃöÁä¨é°Ó¡ã
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤p¥øÃZ10142872  µoªí®É¶¡:2018/6/13 ¤U¤È 05:36:33²Ä 4535 ½g¦^À³
©ú¤Ñ­n¦³¤ß²z·Ç³ÆÅo

³o®a¼w«H¦ÛÀç

§Ú¬Ý¤F³o¤@­Ó¤ëªº¥æ©ö¬ö¿ý

³Ìªø«ùªÑ5¤Ñ

90% ³£¬O¹j¤Ñ½æ¥X

¥u¬O6446³oºØ¦¨¥æ¶q

¥LÀ³¸Ó·|¬å¨ì¦Û¤vªº¤â¸}

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GDarren10146466  µoªí®É¶¡:2018/6/13 ¤U¤È 05:29:39²Ä 4534 ½g¦^À³
°£«D¥L¤Ñ¤Ñ¶R ¤£µM ¥H¥L³o¨â¤Ñ¶Rªº±i¼Æ.... ®Ú¥» ¸ò¥~¸êµLªk¤ñÀÀ ¤]µLªk¼vÅTªÑ»ù¤Ó¦h °£«D¥L¥u¬O¶R¨Ó¥e¦ì¤l ¸Õ¸Õ¤ô·Å
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡Gªüºµ10136469  µoªí®É¶¡:2018/6/13 ¤U¤È 05:17:28²Ä 4533 ½g¦^À³
¤@¦¸¶R¤F235±i¦pªG¬OµÛ²´©óª£µu½u¤]¬O«Ü©_©Ç¡I

¤µ¤Ñ¦Û¤v©Ô°ª¡Aµu½u¦A±þ§C¶Ü¡H

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GAnderson10143089  µoªí®É¶¡:2018/6/13 ¤U¤È 04:23:56²Ä 4532 ½g¦^À³
¬Ý¤F¤@¤UÄw½X¡A¥H¬°¬O¥~¸ê©M§ë«H¡Aµ²ªG¬O·Rª£µuªº¦ÛÀç°Óªñ¨ÓÅͧ½¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GDarren10146466  µoªí®É¶¡:2018/6/13 ¤U¤È 02:37:40²Ä 4531 ½g¦^À³
ªk¤H ªñ´Á ¶R¶i»ù ¤]³£¦A (ªñ´Á§CÂI167) ~ (185ªºªñ´Á°ªÂI) ³o°Ï¶¡§y³f

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GDarren10146466  µoªí®É¶¡:2018/6/13 ¤U¤È 02:32:08²Ä 4530 ½g¦^À³
ªñ´Á°Ï¶¡³£¦A 167 ~ 185¥ª¥k ¨Ó¦^ ¬OÆZ¾A¦X¥[½Xªº¤@­Ó°Ï¶¡

½Ð°Ý¤@¤U ¦U¦ì¤j¤j ¦pªG¼Ú¬wÃÄÃÒ¹L ¬ü°ê¤@¼Ë´N®e©ö¹L¶Ü@@?

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G·s¶i10143606  µoªí®É¶¡:2018/6/13 ¤U¤È 12:45:01²Ä 4529 ½g¦^À³
wu7016¤j¡GGOOD!

¦n¥D·N...¦ýÁÙ¬O­n¤Þ¥H¬°Å²¡AÂÔ¨¥·V¦æ...§K±o¦p§Ú¾Ç²ßµÛµeªê¤£¦¨¤ÏÃþ¤ü...

³Ì«á¤@¨½¸ô¤F¡I¤½¥q»PªÑªF¤j®a³£¡m¨¯­W¡n¡A¡m¤ß­W¡n¤F¡I

§Ú­Ó¤H¬O»{¬°¼Ú¡A¬üªº½Ñ¦ìÅv«ÂÂå¥Í¡A¦b¹ïP1101ªº½×­z¨¥½×¤WÀ³¸Ó¤]¬O·|¬Ã±¤¦Û¤vªø¦~¸gÀ窺±M·~¦a¦ì¡A¦Ó¤£·|»D­·°_»R¡C

¯¬½Ñ¦ì¤j¤jªø´Á§ë¸êÃĵذ·±d¡A¤S§Ö¼Ö¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡Gwu701610136601  µoªí®É¶¡:2018/6/13 ¤W¤È 11:38:36²Ä 4528 ½g¦^À³
Dear ·s¶i¤j¡A

·PÁ±zªº¤À¨É¡A³z¹L±zªº§V¤O¬ã¨s¤Î»P¤½¥qIRªºª½±µ·¾³q¡A¨ä¹ê¤@¤è­±Åýª©¤Wªº¦P¦n¹ï©ó¤½¥qÀç¹B¶i«×¦³§ó¶i¤@¨Bªº¤F¸Ñ¡F¥t¤@¤è­±¤]À°¦£¤½¥qIR§K°£­«½Æ»¡©ú»P¦^ÂЧë¸ê¤H¬Û¦PijÃD¡C¬Û«Hª©¤W¦³³\¦h¤j¤j«D±`·PÁ·s¤jªº°^Äm¡A³Ì«áÁÙ¬O­n«ô°Uª©¤W¦U¦ì¤j¤j¦p¦³»P¤½¥qª½±µ±µÄ²ªº²Ä¤@¤â¸ê°T¡AÁÙ¬O§Æ±æ¯à¤£§[«ü±Ð¨Ã¤À¨Éµ¹ª©¤W¦P¦n¡C¦A¦¸·PÁ¡ã¡ã

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡Gavandia10146474  µoªí®É¶¡:2018/6/13 ¤W¤È 11:07:16²Ä 4527 ½g¦^À³
¬Ý¨Ó³o¨â¤Ñ¼ö¯Pªº°Q½× ¤µ¤ÑªÑ»ù¤ÏÀ³¤F¥«³õ¤Wº¥º¥¦³¨Ç¤Hµo²{ÃĵØÃĪº»ù­È

±qªÑ»ù¸ò¥«­Èªº°ò¦¤W¨Ó»¡ incyte ¬O¤@¶¡´X¥G¥D¥´¥u¦³ jakafi (2nd PV + 1st MF) ªº¤@¶¡Ãļt

¤§«e¦³¨ÖÁÊÃD§÷¸ò·sÃĬãµo¥¢±Ñ¾É­PªÑ»ù±q°ªÂI¸y±Ù

¦ýincyte ¥Ø«eÁÙ¦³±µªñ5000»õªº¥«­È (ªÑ»ù³Ì°ª150®É ¥«­È¤W¥ü¥x¹ô)

³o¬O«D±`Åå¤Hªº ¦ý¤]¤£·|¤Ó·N¥~

¦]¬°°ê»Ú¤W½Ñ¦p J&J pfizer roche ³o¨Ç¤½¥q³W¼Ò³£¬O¶W¹L¥x¿n¹qªº

¥Nªí¯à¥´¤J°ê»Ú¥«³õªºÃļt ´N¬OÀ³¸Ó¨É¦³³o¼Ëªº¥«­È³W¼Ò

¬Û¸û¦P¼Ë¥D¥´ MPN ªºÃĵØÃÄ

±q¹êÅç¼Æ¾Ú¤W¨Ó¬Ý ropeg ¬O§¹¥þ¤£¿é jakafi

¬Æ¦Üpv¦³§ó¤jªº¼ç¦b¥«³õªÅ¶¡ ­Ó¤H»{¬°fdaÃÄÃÒ¤U¨Ó¤T¦~¤º·|¶W¹Ljakafi ªº peak sale 500»õ¥«³õ

§ó¦óªp ¤zÂZ¯À´N¬OÂå®v¥­±`«Ü²ßºD¦b¨Ï¥ÎªºÃĪ« ¤£½×¬O¨xª¢ÁÙ¬O¦å²G¯e¯f

¹ï©óÂå¬Éªº±µ¨ü«× ¤W¤â«×¬O«D±`°ªªº

Á¿³o»ò¦h ¦^¹LÀY¨Ó¬Ý ¥Ø«eÃĵØÃÄ©~µM¥u¬O¤@¶¡¥u¦³¥«­È400»õªº¤½¥q...

¬Ý°_¨Ó¤w¸g³W¼Ò¤£¤p ¦ý¸ò°ê»ÚÃļt¤ñÁÙ¦³¦n¤jªº¤ñ»ùªÅ¶¡

©Ò¥H ¯uªº­n¬Ý»·¬Ý¤j¤@ÂI

ÃĵØÃĶZÂ÷¥´¥@¬É¬×¥u®t³Ì«á¤@­ù¸ô¤F...

¦pªG¯uªº¶¶§Q¨ú±oema ¸ò fda ÃÄÃÒ ½Ð§O»´©ö¤U¨®

¦]¬°³o¶¡¤½¥qªº¥Ø¼Ð¥«­È¶Õ¥²­n¶W¶V incyte

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G·s¶i10143606  µoªí®É¶¡:2018/6/13 ¤W¤È 11:04:25²Ä 4526 ½g¦^À³
Russell¤j...ÁÂÁ±zªº¹ªÀy...

¤]·PÁ¤ѩR¤j¦A¦¸«ü¾É¡C

¦½ÃC¡A¦½ÃC...

¨Æ¹ê¬O¦]¬°¤p§Ì°w¹ï4/24¤½¥qªº·s»D½Z§¹¥þ¬Ý¤£À´...©Ò¥H§Q¥Î¥ð°²®É¡A³v¥y¡A³v±øªº½Ð±Ð¤½¥q¨ä±M·~³N»y¬O¦ó·N»P·N¸q......

¦]±`«ôŪºô¤W§ë¸ê¥ý¶iªº«ü¾É¡A©Ò¥H®Äªk¾Ç²ß...

¸U¸U¨S«ä¦Ò¨ì­ì¨Ó­Ó¤H¸ò¤½¥qªº½Ð¯q¬O¤£¯à¤½¶}ªº¡A¤S·|¯A¶û¤º½u¥æ©ö...¡H

ÁÙ¦n§Ú¨S¦]½Ð¯q¤½¥q«á´N¦³¶R¡A½æ¥æ©öÃĵتѲ¼...§_«hÁÙ¯uªº®`¨ì¤F­@¤ß«ü¾Éªº±M·~¤H¤h¡C

¯u¤S¾Ç²ß¨ì­ì¨Ó«ü¾É¥L¤H¤]¬O¦³¯A¶û¤º½u¥æ©ö¤§¶û...

³o¯u¤S¼Wªøª¾ÃѤF¡I

³oºô¯u¥¿¬O³\¦hª¾ÃѪº¾Ç²ß¨Ó·½¡C

Æg¡AÆg¡AÆg¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GRussell10140734  µoªí®É¶¡:2018/6/13 ¤W¤È 07:11:53²Ä 4525 ½g¦^À³
·s¶i¤j¡K

ª©¤W³\¦h¤j¤j¤]³£ÁÙ¦b¾Ç²ß¡A

±q§A´£¨Ñªº¸ê°T¤]¤S¾Ç¤F¤@½Ò¡C

ÁÂÁ¡K

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GRussell10140734  µoªí®É¶¡:2018/6/13 ¤W¤È 12:07:57²Ä 4524 ½g¦^À³
¨ä¹ê¤½¥qªk»¡·|¦³»¡©ú¹L¡A§Æ±æ¯à¦bPV¤W¥«¦³²{ª÷¬y¤J«á¡A¦A°µ¨ä¥L¤T´ÁÁ{§É¡C

¦]¬°¦b¼Ú¬ü°µÁ{§É¬O«Ü¿N¿úªº¡A¤½¥qÀ³¸Ó¤£·Q¦A¸òªÑªF®³¿ú¡A

¦óªp¼W¸ê³y¦¨ªÑ¥»¿±µÈ¡A±Nµ}ÄÀEPS¡A¹ïªÑªF¤£¨£±o¦³§Q¡K

³o¤@ÂI¡A§Ú¬O¤ä«ù¤½¥q¡C

¥u¬O³o­ÓPVÃÄÃÒ¨ú±o¹ê¦b¤£®e©ö¡K

À³¸Ó¬OEMA¸òFDA³£·Q¬Ý§¹¾ã¤G¦~ªºÁ{§É§a¡I

§Ú·Q¤µ¦~À³¸Ó³£·|¦³µ²ªG¥X¨Ó¤F¡K

¥[ªo¤F!!

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G·s¶i10143606  µoªí®É¶¡:2018/6/12 ¤U¤È 11:32:48²Ä 4523 ½g¦^À³
2018/04/24

________________________________________

ÃĵØÂåÃÄ ET ¤T´ÁÁ{§É­pµe¡AFDA ¶R³æ

¯u©Ê¦å¤pªO¼W¥Í¯g¡]ET¡^»P¯u©Ê¬õ¦å²y¼W¥Í¯g¡]PV¡^¦PÄÝ©ó°©Åè¼W¥Í©Ê¸~½F¡]MPNs¡^¡A¦³Ãþ¦üªº­P¯f¾÷Âà¡A¥«­±¤Wªº¶Ç²Î¤zÂZ¯À©Îªø®Ä PEG ªø®Ä«¬¤zÂZ¯À¹ï©ó¨âªÌ¤]¦P¦³Àø®Ä¡A¦]¦¹¤zÂZ¯À³Q off-label ¨Ï¥Î©óªvÀøET ªº¾ú¥v¤w¦³´X¤Q¦~¤§¤[¡C

µM¦Ó¡AET²Ä¤@½uÁ{§É¥ÎÃĬ° HU¡A¦ý¦¹ÃĨèS¦³³Q FDA ®Ö­ã¹L¡A¦Ó²Ä¤G½u¥ÎÃÄ Anagrelide (Agrylin)¡A¨âªÌ¬ÒÁ{§É¤W¨Ï¥Î¦h¦~¤§ÃĪ«¡C¨Æ¹ê¤W¦Û Anagrelide °Ý¥@¨´¤µ¤G¤Q¦h¦~¥H¨Ó¡A¥¼´¿¦³¥ô¦ó ET ·sÃijQ®Ö­ã¤W¥«¡A¥i¨£¹ï³oÃþ¨u¯fªº­¯¥Í¥H¤Î·sÃĶ}µo¤§§xÃø¡BÅ㨣ÂåÃĬɹï ET ¨u¨£¯e¯f»Ý¨D¥¼¦³­«µø¡C

¤µ¦~ 4 ¤ë 17 ¤é¡AÃĵØÃÄ»P FDA ¶i¦æ­±¹ï­±·|ij¡A·|ij¤¤ÃĵØÃĦV FDA ©x­û»¡©ú¦³Ãö Ropeg¡]P1101¡^¦b¬ü°ê¶i¦æ¯u©Ê¦å¤pªO¼W¥Í¯g¡]ET¡^²Ä¤G½u¥ÎÃÄÁ{§É¸ÕÅ礧¬ÛÃö¨Æ¶µ¡C

·|ij¤¤¡AÃĵØÃĦb¨â¦ì·í¥N¬ü°êªº°ê»Ú³Ìª¾¦WªºÅv«Â·N¨£»â³S (KOL) ¥þ¤è¦ì¤ä«ù¤U¦V FDA ¦b®y©x­û°µ¥X«Ü²`¤Jªº»¡©ú¡GÃĵØÃÄ¥H PROUD/CONTI-PV ¬°¤@­Ó§¹¾ã©Êªº¡]integrated¡^Á{§É¸ÕÅç¡A°w¹ï¨ä¤¤¯f±w¤§¦å¤pªO¼W¥Í (thromobocythemia) ©M¥Õ¦å²y¼W¥Í¡]leukocytosis) ¶i¦æ¤ÀªR¡C¨ä¤¤¡A3¦Ü12­Ó¤ëªº´Á¶¡ªºÁ{§É¼Æ¾ÚÅã¥Ü Ropeg ¥i¦³®Ä´î¤Ö¦å¤pªO©M¥Õ¦å²y¼Æ¥Ø¡C¬Û¸û¤§¤U¡AAnagrelide ¶È¯à­°§C¦å¤pªO¼Æ¥Ø¡C¾Ú¦¹¡AFDA ¹ï©óÃĵØÃÄ´£¥Xªº ET Á{§É­pµe®×¡AÂù¤è²`¤J°Q½×¤T¤jijÃD¡A¤w¸g¨ú±o FDA »{¦P¤]¤À§O±o¨ì©ú½T¦^À³¡C

ijÃD¤@¡G¦³Ãö¨ü¸ÕªÌªº¯Ç¤J¡þ±Æ°£±ø¥ó¡]inclusion/exclusion criteria¡^¬O§_¥i¥H±µ¨ü°µ¬°µù¥U¥Îªº²Ä¤T´ÁÁ{§É¸ÕÅç³]­p¡H

¸g°Q½× FDA ¦P·NÃĵØÃÄ´£¥Xªº ET ¯Ç¤J/±Æ°£±ø¥ó¡A§Y HU µL®Ä©Î¹ï©ó HU °Æ§@¥Î¤£­@¨üªº¯f¤H¡A¤Î°ª¦MÀI¸s ET ¯f¤H(¦~ÄÖ>60·³¡A´¿¦³¦å®ê©ÎET¬ÛÃö¥X¦å¯f¥vªÌ)¡C

ijÃD¤G¡G¦³Ãö¹ï·ÓÃĤΠRopeg ¾¯¶q¡A¦¹¸ÕÅç³]­p¬O§_¥i³Q±µ¨ü¡A¨Ã°µ¬°µù¥U¥Îªº²Ä¤T´ÁÁ{§É¸ÕÅç¡]Pivotal Study¡^¡H

FDA ªí¥Ü¥i±µ¨ü Anagrelide ¬°¥D¹ï·ÓÃÄ¡CFDA ¨Ã«Øij¥HPROUD/CONTI-PVÁ{§É¸ÕÅç¡A¶i¦æ Ropeg ªºÃĪ«°Ê¤O¾Ç¤ÎÃÄ®Ä¾Ç ¡]PK/PD) ¤ÀªR¡CÃĵØÃÄ¿í·Ó FDA «ü¥Ü¡A¥Ø«e¥¿©e°U±M·~¤½¥qºòÆr±K¹ª¶i¦æ PK/PD ªº¬ã¨s¤ÀªR¡B¥Î¥H±À´ú§Ú­Ì´£¥Xªºº¥¼W¾¯¶qªº¦X²z©Ê¡C

ijÃD¤T¡G¦¹¸ÕÅç³]­p¥D­nÀø®Ä«ü¼Ð¬O§_¥i³Q±µ¨ü°µ¬°µù¥U¥Îªº²Ä¤T´ÁÁ{§É¸ÕÅç³]­p¡H

¸g°Q½× FDA ªí¥Ü©Î¥i¦P·NÃĵØÃÄ´£¥X¥H(¦å²G¤ÏÀ³²v¡B¯gª¬§ïµ½¡B¤ÎµL¦å®ê©Î ET ¬ÛÃö¥X¦å) §@¬°ºî¦X¥D­nÀø®Ä«ü¼Ð¡A¨Ã¥HÁͶդÀªR (trend analysis) ¶i¦æ¦¹¸ÕÅçµ²ªG¤ÀªR¡CFDA §Æ±æÃĵØÃĦb´£¥X§¹¾ãÁ{§É¸ÕÅç³]­p­n¥]¬A²Î­p¤ÀªR­pµe ¡]SAP) «á¦VFDA¶i¦æ»¡©ú¡A¤@¨Ö°Q½×¡A³o¬O«D±`¤jªº¬ð¯}¡C

°Ñ»P¦¹¦¸·|ijªº°ê»Ú³Ìª¾¦WªºÅv«Â·N¨£»â³S¡]KOL¡^­Ì¤À¨É¥L­Ì©M³o¸s©x­û¤¬°Êªí¥Ü¡A¹L¥h¤G¤Q´X¦~¨Ó¡AET ¨S¦³¥ô¦ó·sÃÄ°Ý¥@¡A¦ÑÃÄ HU ©MAnagrelide ªº°Æ§@¥Î·¥¤j¡A©x¤è»{¦PÃĵØÃÄ­P¤O¶}µo ETªvÀø·sÃĪº§V¤O¡A«w§Æ±æ¯à°÷¦hµ¹¤©¥»¤½¥q§ó¦h¤ä«ù¡C

¥»¦¸·|ij¥Ñ¸Ó³¡ªù³Ì°ªªø©x¿ËÁ{·¾³q¨Ã¨â«×´£¤Î±N¨Ó¹ï Ropeg ­q©w¥é³æ¤§¨Æ¡A»P·| KOLs §¡¦³¦P·P¡A«wªí¥Ü¹ï¯f±w¤ÎÂå¬É²×©ó¦³¤F·sªº¿ï¶µ¤F¡I

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G·s¶i10143606  µoªí®É¶¡:2018/6/12 ¤U¤È 11:28:51²Ä 4522 ½g¦^À³
½Ñ¦ì¤j¤j¡K©êºp©êºp¡I¤Þ°_¤j®aªº§xÂZ¡I

¤p§Ì¶i¤@¨B¸Ô²Ó»¡©ú¡K

1 ¤p§Ì¬O°w¹ï¥H¤U2018/4/24³o½g·s»D½Z¤£¸Ñ¤§³B¤~¥h¹q¨D±Ð¥j¸g²z.

www.pharmaessentia.com/chinese/news_2018042401.html

2 ¨D±Ð¤º®e¬Æ¦h¡A¥j¸g²z¤]¤£¹½¨ä·Ðªº«ü¾É¡A©Ò¥H¤p§Ì«e¤å¥u¬OºK­n­«ÂI¡A¬O¤p§Ìªº¿ù¡AÀ³¸Ó»¡¤£¬O¤°»ò¤º½u®ø®§¡A¤j®a¥i§O»~·|¤F¡I

°w¹ïET±wªÌªº±¡§Î¸Ô²Óªº«ü¾É¡Aµo¨¥¤H¬O«ü¾É»¡©ú¥H¤U¡K.

PVªº¯f¤H¨ä¹ê¤j³¡¤À¤]³£¦³ETªº°ÝÃD¡APV¯f¤H¬O¬õ¦å²yªº°ÝÃD¡AET¬O¦å¤pªOªº°ÝÃD¡A§Ú­Ì¦bPVªº¯f¤HÁ{§É¤W¬Ý¨ì°w¹ïETªºÀø®Ä¤ñPVªºÀø®Ä§ó§Ö§ó¦n¡AET¤T´Á¦¬®×¤H¼Æ¬O¨â¦Ê¦h¦ì¡AÁ{§É®É¶¡¥Ø«e¤]¬O­q¦b¤@¦~¡C

¦b¦¹¦A¬°¤p§Ìªº°½Ãi¸ò½Ñ¦ì¤j¤j¸ÛÀµ­Pºp¡I

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡Gªüºµ10136469  µoªí®É¶¡:2018/6/12 ¤U¤È 10:53:53²Ä 4521 ½g¦^À³
¤½¥q¦bÁ{§Éªº¶i¦æ¤W¹ê¦b¤£¤Ó¦æ¡A

¹³¬O¨â¦~«e¤WÂd¤½¶}»¡©ú®Ñ´N»¡­n¦VFDA¥Ó½ÐETªº¤T´ÁÁ{§É¡A

¨ì²{¦b¨â¦~¹L¥h¤FÁÙ¬O¨S°e¥ó¡F

C¨x¤T´Á¬Ý¨Ó¤]¤w¸gµL¯e¦Ó²×¡C

¦ý¬O¬Û¹ï¨Ó»¡¡A

AOP°õ¦æÁ{§É¹êÅç´N«Ü¦³¸`«µ¡A

´X¥G³£·ÓµÛ¶i«×¦b¨«¡C

¬Q¤éAOP©xºô¤W¤½¥¬¤w¦^ÂÐEMAªº°ÝÃD²M³æ¡A

¥HAOP°T®§µo§GªºÄYÂÔ¡A

¬Û«HAOP¹ï¦~©³¨ú±oÃÄÃÒÀ³¸Ó¬O¦³¤Q¨¬ªº§â´¤¡C

Ãĵطí®É­n¤£¬O¹J¨ìAOP³o­Ó¶Q¤H¡B±NP1101±a©¹MPN»â°ìµo®i¡A

Ãĵز{¦b¥i¯àÁÙ¦b¨x¯f»â°ì­W¾Ô....

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GRussell10140734  µoªí®É¶¡:2018/6/12 ¤U¤È 09:56:32²Ä 4520 ½g¦^À³
­«ÂI§Ñ¤F»¡¤F....

¬d¤F¤@¤U

ºµ¤j....±z¬O¹ïªº

www.cpmda.org.tw/news_show_n1.php?news_id=4696

©Ò¥H¤@¶}©l§Ú¬O»¡...¦pªG....

Á`¤§....´N¬O¥ý®³¨ì²Ä¤@±iÃÄÃÒ´N¹ï¤F.....

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GLibad10145748  µoªí®É¶¡:2018/6/12 ¤U¤È 09:51:30²Ä 4519 ½g¦^À³
¥j³Õ¤hªº°w¹ï­Ó§O¨p¤HºÃ°Ý¦^ÂÐ,­Ó¤Hı±o¤£§´,¦³¤º½u®ø®§¤§¸·.

¥j³Õ¤h¹q¸Ü¦^ÂФ£¬O¤½¶}®ø®§,Ãĵئ¹§@ªk¶··V­«.

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GRussell10140734  µoªí®É¶¡:2018/6/12 ¤U¤È 09:50:05²Ä 4518 ½g¦^À³
¥HÃĵتk»¡Â²³øÀɨӬݡAET¸òPV¯f±w¤H¼Æ¨ä¹ê¨Ã¨S¦³®t«Ü¦h¡A©Ò¥H¥«³õ³W¼ÒÀ³¸Ó¤]¤£¤p¡C

mops.twse.com.tw/nas/STR/644620171219M001.pdf

¦Ü©ó¤G½u¥ÎÃÄ....

Åý§Ú·Q¨ìGºô«ç»ò®³Jakafi¨Ó»ÄP1101....

Jakafi¤@¶}©l´N³]©w¦b¤G½u¥ÎÃÄ¡AÁöµM¤£¬O¤@½u¥ÎÃÄ¡A¦ý¯f±w¨S¦³¿ï¾Ü¡A©Ò¥H¨S¦³Ä³»ùªÅ¶¡...

µ²½×¬O¡A¤G½u¥ÎÃĪºµ¦²¤¦b¥«³õ­q»ù¤è­±¤j³Ó!!!

«¢~­ì¨ÓGºô¬O¤Í­x......§Ú»~·|¥¦¤Ó¤[¤F.....

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡Gªüºµ10136469  µoªí®É¶¡:2018/6/12 ¤U¤È 09:45:33²Ä 4517 ½g¦^À³
Russel¤j

P1101¥Î¦bETªº¾AÀ³¯g¤W®Ú¥»¨S°µ¹LÁ{§É¡A

¤½¥qªº·N¹Ï¬Oª½±µ°µ¤T´Á¡A

¤~·|¦³©xºô¤W¤w¸g·Ç³Æ¶i¤J¤T´Áªº¹Ïªí¡C

¦pªG¦³°µ¹L¤@¤G´Á¡A

¦­´N·|¦³¤@¤G´ÁÁ{§É¼Æ¾Úªº¤½¥¬¤F.....

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡Gªüºµ10136469  µoªí®É¶¡:2018/6/12 ¤U¤È 09:34:26²Ä 4516 ½g¦^À³
¦Ó¥BP1101¥Î¦bETªº¾AÀ³¯g³W¹º¬O¤G½u¥ÎÃÄ¡A

¼ç¦b¯f±w¼Æ¤ñPV¤Ö«Ü¦h¡A

¦]¦¹¨S¦³©Ò¿×»ù­È­¿¼Wªº¥i¯à¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GRussell10140734  µoªí®É¶¡:2018/6/12 ¤U¤È 09:32:55²Ä 4515 ½g¦^À³
À³¸Ó¬O«ü¤@¡B¤G´ÁÁ{§Éµ²ªG!!

¹w­p¤µ¦~¶}©l¤T´ÁÁ{§É....

©xºô¦³¶i«×ªí

www.pharmaessentia.com/chinese/product_1.html

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡Gªüºµ10136469  µoªí®É¶¡:2018/6/12 ¤U¤È 09:22:03²Ä 4514 ½g¦^À³

ÃĵتºÃĮڥ»³£ÁÙ¨S¥Î¦bETÁ{§É¡A

­þ¨Óªº®ÄªG¤ñPV¦n?

¥j³Õ¤h¦pªG¯u±o³o¼Ë»¡¡A

¨º¯u¬O«Ü©_©Ç¡I

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GRussell10140734  µoªí®É¶¡:2018/6/12 ¤U¤È 09:03:43²Ä 4513 ½g¦^À³
·s¶i¤j¡K

¦pªG¤j¤jªº®ø®§¬O¯uªº¡A¯u¬O®¶¾Ä¤H¤ß¡C

RopegÁ{§ÉÀø®Ä¦bET©~µM¤ñPV¦n¡K

¨ºÃĵػù­È°Z¤£¬O­n­¿¼W¡K

´Á«ÝCSR»°§Ö¥XÄl°eFDA¡K

´N¹³¥ý«e»¡ªº¡A®³¨ì²Ä¤@±iÃÄÃÒ¬O³Ì­«­nªº!!

©¹«áÂX¤j¾AÀ³¯g´N®e©ö¦h¤F¡K

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G·s¶i10143606  µoªí®É¶¡:2018/6/12 ¤W¤È 10:13:54²Ä 4512 ½g¦^À³
·PÁ½Ѧì¤j¤jªº«ü¾É...

ªñ¤é¦³½Ð±Ð¤½¥qµo¨¥¤H¥j¸g²z

¡m1¡n:¬ü°ê¶i«×¦p¦ó...¡H

µª¡G«D±`¶¶§Q¡AÀ³¸Ó¦³¾÷·|¤ñ¹w´Áªº¦n¡C

¡m2¡n:ETªº¶i«×...¡H

µª¡G¨Ì¾ÚÁ{®É§ÉªºÀø®ÄP1101ªvÀøETªº®ÄªG¤ñªvÀøPVÁÙ­n¦n¡C

¥H¤W´£¨Ñ¤j®a¤À¨É¡C

ªÑªF·|®ÉÀ³¸Ó¤]¥i¥H¦A¨DÃÒ©óªL°õ¦æªø¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤p´²¤á10028616  µoªí®É¶¡:2018/6/12 ¤W¤È 08:55:29²Ä 4511 ½g¦^À³
¦U¦ì¤j¤j

106¦~«×¦~³ø¥XÄl¤F

doc.twse.com.tw/pdf/2017_6446_20180625F04_20180612_084931.pdf

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GSirius10142542  µoªí®É¶¡:2018/6/12 ¤W¤È 06:47:07²Ä 4510 ½g¦^À³
¦^µª·s¶i¤jªº²Ä¤@­Ó°ÝÃD¡A§Ú°O±o¥h¦~°e¥ó®É¡A¤½¥q¯S§O¦³´£¨ì¡A«e¤@¦~(2016)¦b¼Ú¬w¡A¯à°e¥óªº¥þ³¡¨ú±oÃÄÃÒ¡C

¦]¬°EMA¤£·|»´©öÅýÃļt°e¥ó¡A¯à°e¶i¥h´N¬OªÖ©w¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤p¥¿¥¿10141351  µoªí®É¶¡:2018/6/12 ¤W¤È 06:28:20²Ä 4509 ½g¦^À³
¥xÆW¥Í§Þ¤ë - ¥Íª«¬ì§Þ¤j®i

2018/7/19(¥|)¦Ü7/22(¤é)

¥x¥_¥@¬É¶T©ö¤¤¤ß«n´ä®iÄýÀ] (¥x¥_¥««n´ä°Ï¸g¶T¤G¸ô1¸¹)

ÃĵØÂåÃĪѥ÷¦³­­¤½¥q

¼t°Ó¤ÀÃþ¡GÂåÃÄ»PÂåÀø°Ï

Åu¦ì¸¹½X¡GM720A

ÃĵØÂåÃÄ(6446)¥D­n¶}µo¨u¨£¦å²G¯e¯f¡BºC©Ê¨xª¢¥H¤Î¨ä¥L¯e¯fªºªvÀø¡CÃĵØÂåÃÄ¥x¤¤¼t¤w³q¹L¥xÆWTFDA»{ÃÒ¡A¦P®É¤]²Å¦XcGMP³W½d¡F¼t¤º³W®æ¤Î¾Þ§@¥ç¿í´`¬ü°êFDA¤Î¼Ú·ùEMA³W½d¡C

¥D­n¬ãµo¶µ¥Ø/¾AÀ³¯g

− P1101: ªvÀø¯u©Ê¬õ¦å²y¼W¥Í¯g, ºC©Ê°©Åè²Ó­M©Ê¥Õ¦å¯f, °©ÅèÅÖºû¤Æ, ¦å¤pªO¼W¥Í¯g, C«¬¨xª¢(°ò¦]«¬²Ä1«¬/²Ä2«¬), B«¬¨xª¢

− Oraxol: ªvÀø¨ÅÀù

− PD-1/PD-L1+P1101: ªvÀø¨xÀù

− KX01: ªvÀø¤û¥ÖÅ~

¥xÆW¤Î¼Ú·ù¦å²G¾Ç·|ÂùÃä¬ã°Q·|²`¨sMPN ÃĵØÂåÃÄRopeg·s«¬ªø®Ä¤zÂZ¯ÀÅD¬°¥D¬y

·s»D½Z

²Ä¥|©¡¥xÆW¤Î¼Ú·ù¦å²G¾Ç·|ÂùÃä¬ã°Q·|¡]HST-EHA Joint Symposium¡^4¤ë14¤é©ó¥x¤jÂå°|°ê»Ú·|ij¤¤¤ßÁ|¦æ¡A¥DÃD¬°°©Åè¼W¥Í©Ê¸~½F¡]MPN¡^¡C¬ã°Q·|¥Ñ°ê¤º°©Åè²¾´Ó©M¦å²G¸~½F¯e¯fÅv«ÂÂå®v­ð©u¸S¤Î­^°ê¼C¾ô¤j¾ÇÂå¾Ç¬ã¨s°|Anthony R. Green³Õ¤h¶}³õ¡A±qMPN¯e¯fªº¹w´ú¨ìªñ´ÁªvÀøµ¥¡A¥Ñ¥|¦ì°ê»ÚÅv«Â¶i¦æºtÁ¿¡C

¨ä¤¤¡Aªk°êMPNÅv«ÂJean-Jacques Kiladjian³Õ¤h¡A¥H¡uMPNºÞ²z¤è­±ªº³Ì·s¶i®i¡v¬°ÃD¡A¤¶²Ð¦X¨ÖJakafi»P¤zÂZ¯ÀªvÀøMF¡]°©ÅèÅÖºû¤Æ¡^ªºÁ{§É¸ÕÅç¡A¦A¦¸ªí©ú¤zÂZ¯À¬OMPNªvÀøªº§ó¦n¿ï¾Ü¡CÃĵØÂåÃÄ¡]¥xÆWÂd¶R¤¤¤ßªÑ²¼¥N½X¡G6446¡^¦Û¥D¶}µoªºRopeg¬O¤@ºØ¥þ·sªºalfa-2bªø®Ä«¬¤zÂZ¯À¡A¼Ú¬w¹Ù¦ñAOP¤½¥q¤w¦VEMA»¼¥ó¥Ó½ÐªvÀøPV²Ä¤@½u¥ÎÃĤ§Ropeg¡]°Ó«~¦WBESREMI¡^¤W¥«³\¥i¥B¤w¶i¤J¼f®Ö¶¥¬q¡F¤µ¦~2¤ë¤¤¡AÃĵØÂåÃĹ椦b°ê»Úª¾¦WªºÅv«Â·N¨£»â³S¡]KOL¡^¤Îªk³W±M®aªº³­¦P¤U¡A»PFDA©x­û­±¹ï­±·|ij¡Aµ²ªG¶i®i¶¶§Q¡A¦³§U©óRopeg¥Ó½Ð¬ü°êÃÄÃÒ¡CÃĵØÂåÃĦb¦å²G¯e¯f·sÃĪº¬ãµo¤W¡A¤£¶È¨«¦b°ê»Ú«eºÝ¡A§ó´£¤ÉÆW·sÃĬãµoªº°ê»Ú¯à¨£«×¡C

Jean-Jacques Kiladjian³Õ¤h¥Ø«e¬Oªk°ê¸t¸ô©ö´µÂå°|©M¤Ú¾¤¨f¼wù¤j¾Ç±Ð±Â¡Aªø´Á­P¤O©ó°©Åè¼W¥Í©Ê¯e¯f¡B°©Åè¤Æ¥Í¤£¨}¯g­Ô¸sªºÁ{§É¬ã¨s»PªvÀø¡A¤]´¿°Ñ»P¹LIncyteºX¤UPV·sÃÄJakafiªºÁ{§É¬ã¨s¡A¦bMPN¯e¯f»â°ì¨ã¦³°ê»ÚÅv«Â¦a¦ì¡CJean-Jacques Kiladjia«ü¥X¡A¬ã¨sµo²{MPNªº²Ó­M¤j¦h±a¦³JAK2V617Fªº°ò¦]¬ðÅܤ§«á¡A¤Þµo¤Fªñ¦~¦bMPN»â°ìªº°ò¦©MÁ{§É¬ã¨s¦³¤F·N¥~ªº·s°T®§¡C

Kiladjian³Õ¤h«ü¥X²{¦b¦³¶V¨Ó¶V¦hªºÃÒ¾ÚÅã¥Ü¤zÂZ¯À¡]IFN£\¡^¥i¥H»¤¾É­«­nªº¤À¤l¤ÏÀ³²v¡C¦¹¥~¡A¤zÂZ¯À°±Ãī᪺Á{§É¡A¤À¤l©M§ÎºA¾Ç¤Wªº¤ÏÀ³²v¤Î«ùÄò©Ê¡AÅã¥Ü¤zÂZ¯À¦³ªv¡MPNªº§Æ±æ¡C¦b¤ñ¸ûRopeg»PHUªº3´Á¸ÕÁ{§ÉÅ礤¡]PROUD-PV¬ã¨s¡^¡AÅã¥Üµo²{¨âºØÃĪ«¹ï³y¦å²Ó­Mªº¤£¦P¼vÅT¡CRopeg¥i¥H§í¨îJAK2¬ðÅܪº³y¦å²Ó­M²§±`¼W¥Íªº²{¶H¡A³o¬OHU¥¼¨£ªº§@¥Î¡CRopegªº¼Ð¹v©ÊÅã¥Üªø´Áªº«ùÄò¤À¤l¤ÏÀ³²v¥u¯à³z¹L¤zÂZ¯ÀªvÀø¨Ó¹ê²{¡CµM¦Ó¡A³o¨Ç¯e¯fªº¤À¤l½ÆÂø©Ê¥i¯à·|§«Ãª¤zÂZ¯Àªº®Ä¥Î¡C¦]¦¹¡A©M¨ä¥L¼Ð¹vÃĪ«Áp¦XªvÀø¥i¯à¥i¦³®Ä®Ú°£MPN¡A¦ý¨ä¥i¥Î©óÁp¦X¤zÂZ¯Àªº¼Ð¹vÃĪ«¤´¦³«Ý¬ã¨s½T»{¡C

¥Ø«e¥¿¦b¶i¦æI/II´ÁÁ{§É¸ÕÅ窺RUXOPEG¬ã¨s¡]NCT02742324¡^¥ÑKiladjian©Ò¶i¦æ¡CRUXOPEG¬O¶}©ñ¦¡¡B¦h¤¤¤ßªºBayesian 1/2´Á¾AÀ³©Ê¸ÕÅç¡A§Y¬O¥Hruxolitinib (Jakafi)»PPEG-INFa-2aªº²Õ¦X¨ÓªvÀøMF¡C¹w­p±N¦¬42¦W¯f±w¡A¤w©ó¤µ¦~1¤ë§¹¦¨12¦W¯f±w¡A±N©ó¤µ¦~©³§¹¦¨¡C¨ä¤¤²Ä1¶¥¬q¥]¬A9²Õ¾¯¶q¼W¥[¡A²Ä2¶¥¬q±N¦b²Ä1¶¥¬qªº¿ï©w¾¯¶q¤§¶¡¶i¦æÀH¾÷¤Æ¡C¥D­n¥Ø¼Ð«h¬O§ä¥Xruxolitinib©M¤zÂZ¯Àªº³Ì¦³®Ä¾¯¶q²Õ¦X¡A¦P®É²Å¦X¦w¥þ©Ê¡C¥D­n®e§Ô¼Ð·Ç¬°¦b45¤Ñ¤ºµo¥Í¾¯¶q­­¨î©Ê¬r©Ê¡C¥D­nÀø®Ä¼Ð·Ç¬°6­Ó¤ë¤ºµÊŦªø«×ÁYµu> 50¢H¡C¦¸­n¥Ø¼Ð¬°¤À¤l¤ÏÀ³²v¡]¶q¤ÆJAK2¡ACALR©ÎMPL¬ðÅܵ¥¦ì°ò¦]­t¾á¡^¡BBMÅÖºû¤Æ´î¤Ö¡B¥Í¬¡½è¶q©M¯gª¬ºtÅÜ¡B¤ÎÁ`Åé¦s¬¡²v¡C¥D­n¯Ç¤J¼Ð·Ç¡G¶EÂ_¦³MF¡]WHO 2008¼Ð·Ç¡^¡AIPSSªº¤¤µ¥©Î°ª­·ÀI¡A¦³JAK2¡ACALR©ÎMPL¬ðÅÜ¡C¥D­n±Æ°£¼Ð·Ç¡G´¿±µ¨üruxolitinib©Î¤zÂZ¯ÀªvÀø¡]©Î¸T§Ò«ü¼x¡^¡A¨ã·F²Ó­M²¾´Óªº¸ê®æ¡A¨xŦ¡B¤ßŦ©ÎµÇŦ¥\¯à¤£¨¬¡A¦Û¨­§K¬Ì©Ê¯e¯f¡A¦³¼~Æ{¯g¯f¥v¡C¦b4­Ó¦¬®×¸s²Õ¤¤¡A¦³12¦W±wªÌ¤w©ó2018¦~1¤ë§¹¦¨¤J²Õ¡A³Ì«á¤@¦¸¾¯¶q¬°ruxolitinib 20 mg BID + peg-IFN£\135 mcg / week¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G·s¶i10143606  µoªí®É¶¡:2018/6/12 ¤W¤È 12:36:33²Ä 4508 ½g¦^À³
ÁÂÁ¤ѩR¤jªº¸ê®Æ¡A¦ý¤£ª¾EMAÀò­ãªº¤ñ¨Ò¤]¬O¤j­P¦p¦¹¶Ü¡H

ÃĵجOÄÝ©ó¥Íª«©ÊÃÄ«~ÁÙ¬O³æ®è§ÜÅéÃÄ¡H

·PÁ«ü¾É¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤p¥¿¥¿10141351  µoªí®É¶¡:2018/6/11 ¤U¤È 11:00:45²Ä 4507 ½g¦^À³
AOP Orphan´£¥æªºRopeginterferon alfa-2b¦b¼Ú·ù¡]EU¡^ªvÀø¬õ¦å²y¼W¦h¯g¡]PV¡^ªº¤W¥«³\¥i¤w¸g¦b®ÉÄÁ°±¤î«á«ì´_¡C³o­Ó¶°¤¤µ{§Çªºµ²½×¹w­p±N©ó2018¦~²Ä¥|©u«×§¹¦¨¡C
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤p¥¿¥¿10141351  µoªí®É¶¡:2018/6/11 ¤U¤È 10:56:53²Ä 4506 ½g¦^À³
AOP©t¨à«Å¥¬¨äRopeginterferon alfa-2b¼Ú¬wÀç¾P±ÂÅvµ{§Çªº¶i®i

AOP Orphan´£¥æªºRopeginterferon alfa-2b¦b¼Ú·ù¡]EU¡^ªvÀø¬õ¦å²y¼W¦h¯g¡]PV¡^ªº¤W¥«³\¥i¤w¸g¦b®ÉÄÁ°±¤î«á«ì´_¡C³o­Ó¶°¤¤µ{§Çªºµ²½×¹w­p±N©ó2014¦~²Ä¥|©u«×§¹¦¨¡C

¤zÂZ¯À¡]IFN¡^¤w¦¨¥\À³¥Î©ó¥]¬APV¡AºC©Ê²É²Ó­M¥Õ¦å¯f¡]CML¡^©M¨ä¥L°©Åè¼W´Þ©Ê¸~½F¡]MPNs¡^¦b¤ºªº¦UÏú¦å²G´c©Ê¸~½F¬ù¤T¤Q¦~¡AµM¦Ó©|µLIFN¤wÀò±o³o¨Ç¾AÀ³ÃÒªººÊºÞ§å­ã¡C

Ropeginterferon alfa-2b¬O²Ä¤@­Ó³æPEG¤ÆªºIFN¡A¨C¨â¶gÀ³¥Î¤@¦¸¡]¨C­Ó¤ë¥u¶i¦æ¤@¦¸ªø´Áºû«ùªvÀø¡^¡C³Ð·sªº»E¤A¤G¾J§Þ³N©M¤À¤l¬O¥ÑAOP©t¨à¤½¥qªºªø´Á¦X§@¹Ù¦ñPharmaEssentia Corporation¡]¥xÆWÃÒ¨é¥æ©ö©Ò¡G6446¡^µo©úªº¡C

2009¦~¡AAOP©t¨à¨ú±o¤FPharmaEssentia¤½¥qªº¿W®a³\¥i¡A¶}µo©M°Ó·~¤Æ¼Ú¬w¡A¿W¥ß°ê®aÁp¦XÅé¡]CIS¡^©M¤¤ªF¥«³õªºPV¡ACML©M¨ä¥LMPNs¤¤ªºRopeginterferon alfa-2b¡C

¦Û2009¦~¥H¨Ó¡AAOP​​©t¨àPVµo®i­p¹º¡]¥]¬AI´Á/ II´ÁÁ{§É¸ÕÅçPEGINVERA¡^©MIII´ÁÁ{§É¸ÕÅçPROUD-PV¡APEN-PV©MCONTINUATION-PV¤w¸g«Ø¥ß¤F°ª®Ä¡A¦w¥þ©Ê©M­@¨ü©Ê¨}¦nªºRopeginterferon alfa-2b¦bPV¤¤¡C PharmaEssentia¤½¥q¤w¸g§ë¸ê¤FÃĪ«¦b¨ä»â¤g°Ó·~¤Æªº·Ç³Æ¤u§@¥H¤Î¸ÓÃĪ«ªº°Ó·~¥Í²£¯à¤O¡C¸Ó¤½¥q¦b¥x¤¤ªº¥@¬É¯ÅcGMP¥Íª«»s¾¯¤u¼tÀò±o¥xÆW­¹«~©MÃĪ«ºÞ²z§½¡]TFDA¡^ªº»{ÃÒ¡A¨Ã¥B¦Û2018¦~¥H¨Ó¤]³q¹LEMA»{ÃÒ¡A¨ä³]­p©M¸gÀç²Å¦X¬ü°êFDAªº©Ò¦³­n¨D¡C

¹w­pRopeginterferon alfa-2bªº°Ó·~¥i¥Î©Ê±Nº¡¨¬±wªÌ©MÂå¥Í¹ïªø´ÁªvÀø©|¤£¥iªv¡ªº¯e¯fÃþ«¬ªº¤é¯q¼Wªøªº»Ý¨D¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤p¥¿¥¿10141351  µoªí®É¶¡:2018/6/11 ¤U¤È 10:50:12²Ä 4505 ½g¦^À³
AOP Orphan announces progress of its European Marketing Authorization Procedure of Ropeginterferon alfa-2b

AOP Orphan´s submission for marketing authorization of Ropeginterferon alfa-2b for treatment of Polycythemia Vera (PV) in the European Union (EU) has resumed after clock-stop. The conclusion of this centralized procedure is expected for Q4/2018.

Interferons (IFNs) have been successfully applied in various hematological malignancies including PV, Chronic Myeloid Leukemia (CML) and other myeloproliferative neoplasms (MPNs) for about three decades, however no IFN has obtained regulatory approval in these indications yet.

Ropeginterferon alfa-2b is the first monopegylated IFN with an improved application of only once every two weeks (and only once per month in long-term maintenance treatment). The innovative pegylation technology and the molecule have been invented by PharmaEssentia Corporation (Taiwan Stock Exchange: 6446), a long-term partner of AOP Orphan.

In 2009, AOP Orphan has in-licensed from PharmaEssentia Corporation the exclusive rights to develop and commercialize Ropeginterferon alfa-2b in PV, CML and other MPNs for European, Commonwealth of Independent States (CIS), and Middle Eastern markets.

Since 2009, AOP Orphan´s Development Program in PV including the phase I/II trial PEGINVERA and the phase III trials PROUD-PV, PEN-PV and CONTINUATION-PV, have established high efficacy and favorable safety and tolerability of Ropeginterferon alfa-2b in PV. PharmaEssentia Corporation has invested in preparations for commercialization of the drug in its territory and in the capability for commercial manufacturing of the drug. The company´s world-class cGMP biologics facility in Taichung is certified by the Taiwan Food and Drug Administration (TFDA) and since 2018 also by EMA , and it is designed and operated to be compliant with all U.S. FDA requirements.

Commercial availability of Ropeginterferon alfa-2b is expected to fulfill an increasing need of patients and physicians for the long-term management of a yet incurable class of diseases.

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G·s¶i10143606  µoªí®É¶¡:2018/6/11 ¤U¤È 10:12:28²Ä 4504 ½g¦^À³
·PÁ¤ѩR¤j»P½Ñ¦ì¤j¤j

¸g±`©Êªº´£¨ÑÃĵئU¤è­±ªº¸ê®Æ¤À¨É¤j®a

¤p§Ì¦³¤@­Ó°ÝÃD¡A¬O§_¥iÀµ°U­þ¦ì¤j¤j´£¨Ñ¥H¤U¸ê®Æ

1 ªñ´X¦~EMA¼f¬dÃÄÃÒ³q¹L»P¤£³q¹Lªº¤ñ¨Ò¬O¦h¤Ö¡H

2 ¤SEMAÃļt¼f¬d³q¹L«á¦ý¸ÓÃÄ«o¨S³q¹Lªº¦Ê¤À¤ñ¬O¦h¤Ö¡H

³Ò¾r¤F ÁÂÁ¤j®a

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤ý£«¬Â10136621  µoªí®É¶¡:2018/6/11 ¤U¤È 07:27:21²Ä 4503 ½g¦^À³
ÁÂÁ¤p´²¤á¤jªº¤À¨É¡A¦pªGp1101³Q®Ö­ã¬°pv¤@½u¥ÎÃÄ¡A¦]¬°¬O±©¤@®Ö­ãªº¡A©Ò¥HÂå¥Í·|¤£¶}¶Ü¡H¯f±w·|¤£­n¶Ü¡H²{¦b³Ì­«­n¬O®³¨ìÃÄÃÒ¡A©Ò¥H¥u¦³³Ñµ¥«Ý¤F¡C
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GRussell10140734  µoªí®É¶¡:2018/6/11 ¤W¤È 08:52:21²Ä 4502 ½g¦^À³
»{¦P¤j¤j­ÌªºÆ[ÂI!

§Ú¤]»{¬°®³¨ì²Ä¤@±iÃÄÃÒ¬O³Ì­«­nªº¡K

(µL½×²Ä´X½u)

®³¨ì«áµL½×ÂX¤j¨Ï¥Î½d³ò¡A

©Îoff-label use¡A

ªÅ¶¡³£¤j¦h¤F¡K

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤p´²¤á10028616  µoªí®É¶¡:2018/6/11 ¤W¤È 08:45:08²Ä 4501 ½g¦^À³
£«¬Â¤j¤j

¥H¤U³o½gºK¦Û¤½¥qºô¯¸¤§·s»D²Ä¤­¬qÀ³¥i´£¨Ñ°Ñ¦Ò¡C

¦Ü©óavandia¤jªº°ÝÃD¡A´N½Ð°ª¤â­Ìµoªí§a~~~

www.pharmaessentia.com/chinese/news_2018041702.html

2018/04/17

________________________________________

ÃĵØÃÄRopegÀò¡u»sÃIJ£·~Â૬¤É¯Å­p¹º¡v®Ö­ã¸É§U

ÃĵØÃÄ(6446)ªí¥Ü¡A¬°ÅTÀ³¬F©²¹ªÀy¥»¤g»sÃÄ·~ªÌ©Ý®i°ê»Ú¥«³õ¡B±À¤É¥~¾P²£­È¡A¦P®É¦]À³ºX¤UªvÀø¯u©Ê¬õ¦å²y¼W¥Í¯g¡]PV¡^·sÃÄRopeg¥¼¨Ó¤W¥««á¤§¯f±w»Ý¨D¡A±N±Ò°ÊRopeginterferon alfa-2b²Ä¤G¥N»sµ{§Þ³N¤É¯Å¡AÂX«Ø²Å¦XPIC/S GMP³W½dªº·s»sµ{¥Í²£½u¡C¥Ø«e¸Ó­pµe¤wÀò¸gÀÙ³¡¡u»sÃIJ£·~Â૬¤É¯Å­pµe¡vªº®Ö­ã¸É§U¡A¤½¥q¹w­p¤µ¦~¨ú±o¼Ú·ù(EMA)ÃÄÃÒ«á¡A¦b2020¦~±N¦VEMA©x¤è³æ¦ì´£¥X²Ä¤G¥N»sµ{®Ö­ã«áÅܧó¥Ó½Ð¡A¥H´£°ª³J¥Õ½è²£²v¡BÀu¤Æ»sµ{¨BÆJ¨Ã©ñ¤j²£¯à¡C¦¹Á|±N¦³§U¤½¥q¤j´T­°§C¥Í²£¦¨¥»¡B´£°ªÃÄ»ùªºÄvª§Àu¶Õ¡B´£¨ÑPV¤Î¦å¤pªO¼W¦h¯gµ¥¨u¨£¦å²G¯e¯f»â°ìªº¥ÎÃĻݨD¡A±a°Ê¤½¥qÀ禬ªº¦P¨BÂX¼W¡C

¤½¥qªí¥Ü¡A¥x¤¤³J¥Õ½è¤u¼t©ó2012¦~¿³«Ø¡Bµo®i²Ä¤@¥N¥Íª«»sµ{¡A¨Ã©ó2017¦~9¤ë¤@¦¸³q¹LEMA¬d®Ö¨Ã¨ú±oEMA GMP»{ÃÒ¡A¬O¥xÆW²Ä¤@®a³q¹LEMA»{ÃÒªº³J¥Õ½èÃļt¡A±µ¤U¨Ó¥u­n¶¶§Q¨ú±o¼Ú·ùPVÃÄÃÒ¡A§Y¥i¨Ì¥þ²y¦æ¾P³W¹º»P¾P°â»Ý¨D¶i¦æ¨ÑÀ³¡CµM¦Ò¶qRopeginterferon alfa-2b²Ä¤@¥N»sµ{¸û¬°Ác½Æ¥B¥Í²£¬yµ{¶O®É¡A¥[¤W­Y¨Ì¤½¥q³W¹º¥¼¨Ó¤T¦~±N¦A¥Ó½Ð¨ú±o¬ü°ê¡B¤é¥»¡B¤¤°ê¤§PVÃÄÃÒ¡A¨Ã¦P®É±Ò°Ê¦h°ê¦h¤¤¤ßªºET¤T´ÁÁ{§É¸ÕÅç«á¡A¥x¤¤¼t²£¯à±N¤£¼Å©Ò»Ý¡A¶i¦Ó¼vÅT¥þ²y¨ÑÀ³¡A¦]¦¹ÅTÀ³¬F©²´£­Òªº¡u»sÃIJ£·~Â૬¤É¯Å­pµe¡v¡A¨M©w±Ò°ÊRopeg²Ä¤G¥N»sµ{§Þ³N¤É¯Å¥Hº¡¨¬¥¼¨Ó¯f±w»Ý¨D¡C

ÃĵØÃÄ«ü¥X¡ARopeginterferon alfa-2b²Ä¤G¥N»sµ{§Þ³N¶}µo­«ÂI¡A¥]¬A¥Íª«»sµ{§å¶q©ñ¤j¡A¶i¦æ»sµ{½T®ÄÃÒ©ú²£«~«~½èªºÃ­©w©Ê»P¤@­P©Ê¡F¥Íª«»sµ{§ï¨}»PÀu¤Æ¡A¥H´£°ª³J¥Õ½è²£¶q¡B¯Â«×»P¦^¦¬²v¡F¦¹¥~¡A¤]±N¾É¤J¦Û°Ê¤Æ³]³Æ¡A´£¤É¥Í²£®Ä¯à»P­°§C¦¨¥»¡C¤½¥q«ü¥X¡A²Ä¤G¥N»sµ{»P§Þ³NÀu¤Æ±N¥ý±q¹êÅç¤p³W¼Ò¸ÕÅç¨ú±o»sµ{ÃöÁä¨BÆJ¡B­«­n°Ñ¼Æ»P±±¨î½d³òµ¥¡A¦A±N¶}µo§Þ³N²¾Âà¦Ü¥x¤¤GMP¼t¶i¦æ¸Õ¶q²£»P»sµ{½T®Ä¡C¦Ó¬°°t¦X¤G¥N»sµ{¤É¯Å¡AºX¤U¥x¤¤¼t±N¦P¨BÂX«Ø²Å¦XPIC/S GMP³W½dªº·s»sµ{¥Í²£½u¡C

ÃĵØÃĶi¤@¨B«ü¥X¡ARopeg¤G¥N»sµ{ªº¤É¯Å¤£¦ýÃÒ©ú¥xÆW¨ã¦³¶}µo³J¥Õ½è·sÃÄ»sµ{ªº¬ãµo¯à¤O¡A¸Ó»sµ{¶}µoªº»ù­ÈÃì¡A§ó¯àÀ³¥Î©ó¤£¦P³J¥Õ½è·sÃĪº¶}µo¡A¥i¥[³t²£·~¬É³J¥Õ½è·sÃÄ»sµ{§Þ³N¤§¾ã¦X¡A¨ú±oÃöÁä»â¥ý¦a¦ì¡A¹ï©ó¥Ø«e°ê¤º¥Íª«ÂåÃIJ£·~ªº¶i¨B»P´£¤É³£¦³·¥¤j§U¯q¥B¨ã«ü¼Ð©Ê·N¸q¡C

ÃĵØÃĪí¥Ü¡A¤½¥q³Ð·sµo©úªºªø®Ä«¬¤zÂZ¯ÀRopeg¡A¥iÀ³¥Î¦b³\¦h¾AÀ³¯g¡A¦pPV¡BET¡BºC©Ê°©Åè©Ê¥Õ¦å¯f¡]CML¡^¡B°©ÅèÅÖºû¤Æ¡]MF¡^µ¥¡A¥Ø«e°w¹ïPVªvÀø¤£¦ýÀòFDA¡BEMA»{©w¬°©t¨àÃÄ¡A§ó¤w§¹¦¨¼Ú¬w¤T´ÁÁ{§É¸ÕÅç¨Ã¶i¦æÃÄÃҥӽСA¨ÌEMA¼f®Ö¬yµ{±À¦ô¡A³Ì§Ö±N©ó¤µ¦~©³¨ú±oÃÄÃÒ¡A©¡®É±N¬O¥þ²y²Ä¤@­Ó³Q®Ö­ãªvÀøPV¯f±w°ß¤@²Ä¤@½u¥ÎÃĪº³Ì¦n¿ï¶µ¡AÂå®vªº¥ÎÃĤ覡¤]·|¥X²{¤j´T«×ªº§ïÅÜ¡C¥Ñ©óRopeg¤W¥««á¨Ã«D¦b¤@¯ëÃħ½ÂdÂi¾P°â¡A¥²¶·ÂǥѥDªvÂå¥Í¤§¶EÂ_¶}ÃÄ¡AÃĵØÃıN¿n·¥»P¼Ú¡B¬ü¡B¤é¡B¤¤°ê¡B¥xÆWµ¥¦å²G¯e¯f»â°ìÅv«Â¤Î¦U¦å²G¯e¯fÂå¥Í¦X§@¶i¦æ¸ÕÅç¡AÂǥѥD¿ì©Î°Ñ¥[¦å²G¯e¯fÂå¾Ç¬ã°Q·|¤Î¯f±wÃöÃh¬¡°Ê¨Ó¶i¦æ²£«~±À¼s¡A¹F¨ì¥þ²yÃÄ«~¨ÑÀ³¡B³yºÖMPN¯f±w¬°¥Ø¼Ð¡C

¸ê®Æ¨Ó·½ www.moneydj.com/KMDJ/News/NewsViewer.aspx?a=3b0d43c7-ea73-4d13-ad04-ebfc654f2027

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡Gavandia10146474  µoªí®É¶¡:2018/6/10 ¤U¤È 01:00:46²Ä 4500 ½g¦^À³
¦n©_¤@°Ý

°²³]ÃĵØÃĶ¶§Q¨ú±o¼Ú¬w¬ü°êªº PV ÃÄÃÒ

¨º¬O§_ET¤T´Á©Î¬Æ¦Ü¬O BC¨xª¢ ¹êÅçµ²ªG¥X¨Óµ²ªG«D±`¦n

¦b¥¿¦¡ÃÄÃҥӽЫe

¬O§_´N¥i¥HÅýÂå®v¥HOff-label use¶}¥ß?

¦pªG¬O³o¼Ë¨ú±oÃÄÃÒ ¨ä¹ê´Nµ¥¦P©ó®³¨ì¤J³õ¨é

ÁöµM¬O¥Hpvªº¦W¸q®³¨ìÃÄÃÒ ¦ý«áÄò¥«³õªº®Ä¯qÀ³¸Ó·|»·¶W¹L¥Ø«e·Q¹³

²¦³º¤zÂZ¯À¥»¨Ó´N¬Oªø¤[¥H¨ÓÂå®vªvÀø¨xª¢¸ò¦å²G¯e¯fªººD¥ÎÃÄ

²{¦b¦³¤F¥[±jª©ªº¤zÂZ¯À À³¸Ó§ó¯à»¡ªAÂå®v¤jÁx¨Ï¥Î

°ß¤@¦³ºÃ¼{ªº³¡¤À¬O »P«OÀI¤½¥q³¡¤Àµ¹¥Iªº³¡¤À¦bÃÄÃҥӽЫe¸Ó¦p¦ó½Í? «OÀI¤½¥q·|µ¹¥I¶Ü??

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤ý£«¬Â10136621  µoªí®É¶¡:2018/6/8 ¤U¤È 09:08:24²Ä 4499 ½g¦^À³
½Ð°Ý¦U¦ì¤j¤j¡AHU¦b¼Ú¦{¬O®Ö­ãªºPV¤@½u¥ÎÃĶܡHÁÙ¬O¸ò¬ü°ê¤@¼Ë¡AÁÂÁ¤j®a¡C
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GLibad10145748  µoªí®É¶¡:2018/6/8 ¤U¤È 05:57:50²Ä 4498 ½g¦^À³
¨S¿ù ,2018 HU²{¦b¬Othe gold standard¡C¦]P1101¥¿¦b°e¥ó¥Ó½ÐEMA,FDAÃÄÃÒ

2018¦~©³ ÃÄÃÒ¤U¨Ó, P11O1 ´N¬O PV ªº 2019 the gold standard.

P1101 ¬° PV ªº¤@½u¥ÎÃÄ.

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GAnderson10143089  µoªí®É¶¡:2018/6/8 ¤U¤È 01:30:49²Ä 4497 ½g¦^À³
¾aMSCI©u«×½Õ¾ãº¦¤W¥hªº¡AªGµM®t¤£¦h³£ÁÙ¦^¥h¤F¡C
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤p´²¤á10028616  µoªí®É¶¡:2018/6/8 ¤W¤È 08:45:46²Ä 4496 ½g¦^À³
2018 NCCN MPNs GUIDELINES FOR PATIENTS

www.nccn.org/patients/guidelines/mpn/

¦U¦ì¤j¤j¡A¬ÛÃö¤º®e½Ð°Ñ¬Ýºô¯¸¡C

¨ä¤¤PV¬O²Ä32­¶~40­¶

¥Ø«e«ØijªºªvÀø·Ç«h¡A¬O±N¯f¤H¤À¬°¨â¸s¡AHigh risk°ª¦MÀI¸sªº±wªÌ¬O¦~¬ö¤j©ó60·³©Î´¿¸g¦³¦å®ê¯e¯f(blood clot)ªº¯f¤H¡A¦ÓLow risk§C¦MÀI¸sªº±wªÌ«h¬O¨âªÌ³£¤£¨ã³Æªº¯f¤H¡C

¤£¦P¦MÀI¸s°£¦³¨ÇªvÀø¤è¦¡¬O¬Û¦P(¨Ò¦p­°§C¤ß¦åºÞ¯e¯f­·ÀI¦]¤l¡BªA¥ÎAspirin or±Ä¥ÎPhlebotomyµ¥)¡A¦ý°w¹ïHigh risk«h¬O¼W¥[ªA¥ÎHU©Î¤zÂZ¯Àµ¥¤§cytoreduction¡C

±©HU²{¦b¬Othe gold standard¡C

¤½¥q­n¬D¾Ôªº¬OHigh risk+Low risk¥þ¦Y¡A¦Ó¥B¬Othe gold standard¡A¯uªº¤£Â²³æ¡A©Ò¥H·|¤@¨B¤@¨B¨Ó¡A§Æ±æ¦b2019¦~¥H«á¯à§¹¦¨¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤p¥¿¥¿10141351  µoªí®É¶¡:2018/6/7 ¤W¤È 08:31:22²Ä 4495 ½g¦^À³
ÁÂÁ¤pªL¤jªº»¡©ú¡A·P®¦¡C
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤pªL10142678  µoªí®É¶¡:2018/6/7 ¤W¤È 08:20:50²Ä 4494 ½g¦^À³
¤p¥¿¥¿¤j¡A

±zªº²Ä¤@­Ó°ÝÃD¡AªÑªF·|®ÉÁÙ¤£·|ª¾¹D¡C

D180¬OCHMP°w¹ïÁÙ¦³ºÃ¼{ªº³¡¤À´£¥XLoOI(List of Outstanding Issue)¡AµM«á°±¤î­p®Éµ¥«Ý¼t°Ó¸É¥ó©Î¦w±Æ¤fÀY»¡©ú¡C

­YCHMP¦bD180¨S¦³´£¥XLoOI¡A´N·|ª½±µ¨ìD210°µ¥Xµû¦ô·N¨£(opinion)¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡Gavandia10146474  µoªí®É¶¡:2018/6/7 ¤W¤È 12:31:09²Ä 4493 ½g¦^À³
¥t¥~ªÑªF·|¤]·Q¤F¸ÑÃö©ó¥Ó½Ð¬ü°êFDAÃÄÃÒ

¥H©t¨àÃĪº¦W¸q ¥[¤W¬ü°êPV¥Ø«e¨S¦³¤@½uªvÀøÄÝ unmet medical need

¦³¨S¦³¥i¯à¹³¤¤¸Î¤@¼ËÀò±oÀu¥ý¼f¬d¸ê®æ???

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¶È¨Ñ°Ñ¦Ò10146497  µoªí®É¶¡:2018/6/6 ¤U¤È 11:29:04²Ä 4492 ½g¦^À³
·PÁ¤p¥¿¥¿¤jºë¤ß¾ã²z¡A¦³¨t²Î²¼ä©úÁAªº¸ê°T¡C
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤p¥¿¥¿10141351  µoªí®É¶¡:2018/6/6 ¤U¤È 10:49:52²Ä 4491 ½g¦^À³
¥»¤é¤¤¸ÎªÑªF·|ÄÀ¥X¥¿­±°T®§¡A©Ò¦³¶i«×¦pÃÄ«~¾P°â¡B¼Ú·ùÃÄÃÒ¡A¦Ë¥_¥ÍÂå«Ø¼t³£¶W¥X¹w´Á¡A§Y¨Ï5¤ëÀ禬¹s¡A¥~¸ê¥ç¤j¶R394±i¡AªÑ»ù¶}§C¨«°ª¦¬¬õK¡C§Æ±æ¤¤¸Î¯àÄ~Äò©¹¤Wº¦¡A¯à±a¥X¬ÛÃö·sÃĪѪº¤ñ»ùªÅ¶¡¡C¸Ü»¡¦^¨Ó¡AÃĵØÃĪѪF·|¹w­p2018/06/25©ó«n´ä®iÄýÀ]504a·|ij«Ç(¥x¥_¥««n´ä°Ï¸g¶T¤G¸ô1¸¹5F)¥l¶}¡C§Æ±æ¯àÄÀ¥X¥¿­±¥B©ú½Tªº®ø®§¡C

­Y°Ñ¦ÒªÑªF·|¸ê®Æ¡A¾ã²z¦p¤U¡A¥ç§Æ±æªÑªF·|¦³©ú½Tªº»¡©ú¤Î®É¶¡¶i«×¡G

¤@¡BPV ¼Ú¬w¡G¦pªG¤@¤Á¶i®i¶¶§Q±N©ó 107 ¦~¤U¥b¦~¨ú±o¼Ú·ù¤W¥«®Ö­ã¡C

°ÝÃD¡G7¤ë24¤é¡GD180¤Ñ¼f®Ö¬O§_¶·¤fÀY³ø§i©Î®Ñ­±¸É¥ó¦Ó³y¦¨®É¶¡°±¤î¡C

¤G¡B PV ¬ü°ê¡G¾¬±æ¯à¥H³Ì§Öªº®Éµ{¦V FDA ´£¥XÃÄÃҥӽСC

°ÝÃD¡G³ø¯È³ø¾É¸ÑŪ¤£ºÉ¬Û¦P¡G

(¤@)¥¼©w½×¡GPV·sÃĬü°êª½±µ¥Ó½ÐÃÄÃҩθɤT´ÁÁ{§É¥¼©w¡C

(¤G)¤£¶·Á{§É¡G³ø¸üªL°êÄÁ±j½Õ¡AÃĵإӽЬü°êÃÄÃÒ¡u¥u¦³«ç»ò¹L¡A¨S¦³¹L¤£¹Lªº°ÝÃD¡v¡C¥~¶ÇÃĵØP1101¥i¯à­n¸É°µ¬ü°êÁ{§É¤T´Á¡A¹ï¦¹¡A¸â«C¬h¡BªL°êÄÁ³£§_»{¦¹¶µ¶Ç»D¡A¨â¤H¨Ãªí¥Ü¡A¥Ø«eP1101¦b¼Ú¬w§¹¦¨ªºÁ{§É¤T´Á¡BPROUD/CONTI-PV¸ÕÅ窺Á{§É¼Æ¾Ú¡A§¡²Å¦X¬ü°êFDAªº­n¨D¡A»¼¥ó«á±N»PFDA©x­û¦A¶i¦æ°Q½×¡C¥Ø«e¹F¦¨ªº¦@ÃѬO¡A¤£¶·°µÁ{§É¤T´Á¡A¦Ó­Y¶·¸É¥ó«h¦b¤U¥b¦~§¹¦¨¡C

(¤T)¤pµ²¡G§Æ±æªÑªF·|¯à¦³©ú½T°T®§»P¥Ó½ÐÃÄÃҮɶ¡¡C

¤T¡BET ¡G³Ì§Ö 107 ¦~¤W¥b¦~¦V¬ü°ê FDA »¼¥æ²Ä¤T´Á¤HÅéÁ{§É¸ÕÅ窺­pµe®Ñ¡C

°ÝÃD¡G6¤ë©³¥i§_§¹¦¨¡C

¥|¡B¬ü°ê¨u¨£¨xª¢¡G107 ¦~¤W¥b¦~¦V FDA ´£¥X¦³Ãö P1101 ¥Î©óªvÀø¨àµ£ HBV ¤Î HCV/ HBV ¦X¨Ö·P¬V¨xª¢¤§©t¨àÃÄ»{ÃÒ®Ö­ã¡C

°ÝÃD¡G6¤ë©³¥i§_§¹¦¨¡C

¤­¡B HBV e+ ¡G P1101 ¥Î©óªvÀø B ¨x e §Ü­ì¶§©Ê±wªÌ³æ¤@Àøªk¡A¥»¦¸Á{§É¸ÕÅ窺³W¹º±N¥]¬A¤¤¡B¤é¡B¬ü¡B¥x¡B®õ¤ÎÁúµ¥°ê®a¡A¹w­p©ó 107 ¦~¤W¥b¦~¦V TFDA »¼¥æ²Ä¤T´Á¤HÅéÁ{§É¸ÕÅ窺­pµe®Ñ¡A¶}©l±Ò°ÊÁ{§É¦h°ê¦h¤¤¤ß¤§¬ÛÃö¸ÕÅç§@·~¡C

°ÝÃD¡G6¤ë©³¥i§_§¹¦¨¡C

¤»¡BOraxol ªvÀø¨ÅÀù¡G¹w­p 107 ¦~¤W¥b¦~§¹¦¨ÃÄ°Ê/Á{§É¸ÕÅç¡A¥¼¨Ó±N¦X¨Ö Athenex «n¬üÁ{§É¤T´Á´Á¤¤¤ÀªR¸ê®Æ¡A·f°t¬ü°ê¡B­^°ê¡B¿D¬w¤Î¯Ã¦èÄõªk³W °e¼fµ¦²¤¡A¦b¥xÆW¥Ó½ÐÃÄÃÒ¡C

°ÝÃD¡G¥i§_¦³©ú½T®É¶¡¹w¦ô¦ó®É¥Ó½ÐÃÄÃҤΨú±oÃÄÃÒ¡C(³ø¸ü­Y²Å¦X±ø¥ó¡A³Ì§Ö2019¦~¥i±æ¨ú±oÃÄÃÒ¡C)

¤C¡B³Ì«á¡AÃĵإ[ªo¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¶È¨Ñ°Ñ¦Ò10146497  µoªí®É¶¡:2018/6/4 ¤U¤È 05:47:08²Ä 4490 ½g¦^À³
¬O®@¡A¤S»~¸Ñ¤F¤@¦¸¡Asorry¡C
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤pªL10142678  µoªí®É¶¡:2018/6/4 ¤U¤È 05:41:43²Ä 4489 ½g¦^À³
¶È¨Ñ°Ñ¦Ò¤j¡A

±zÀ³¸Ó¬O¥¼²z¸Ñ§Úªº±Ô­z¡A§Ú©Ò«üªºJakafi+IFNsÁp¦XÀøªk¬O°w¹ïMF(Myelofibrosis°©ÅèÅÖºû¤Æ)¡A¦Ü©óPV(Polycythemia Vera)À³¸Ó¤´¬O±Ä³æÃĪºªvÀøµ¦²¤¡C·íµM¥ô¦ó·sÃĪºÃÄÃÒ¨ú±o»P§_³£»Ý¼f·Vªº¬Ý«Ý¡A¤Å¹L«×¼ÖÆ[¬O¥ô¦ó§ë¸êªº·Ç«h¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¶È¨Ñ°Ñ¦Ò10146497  µoªí®É¶¡:2018/6/4 ¤U¤È 05:40:47²Ä 4488 ½g¦^À³
¬ß±æÃĵش£¥Xªºªv¡©Ê¡A¤]¯à¬°EMA±µ¨ü»P«HªA¡C
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡Gavandia10146474  µoªí®É¶¡:2018/6/4 ¤U¤È 05:37:33²Ä 4487 ½g¦^À³
¨ä¹êªÈµ²¦bÀu¶V©Ê©Îµ´¹ïÀu¶Õ¦r­±¤W¸ÑÄÀ ¨ä¹ê·N¸q¤£¤j

­«ÂIÁÙ¬O­n©ñ¦b¹êÅç¼Æ¾Ú¸òÁ{§É¸ÑŪ¤è¦¡

Jakafi response clinical trial ªvÀø«ü¼Ð¥u¦³ ¦å¤ñ®e ¸ò µÊŦ¤j¤p

PROUD-PV + CONTI-PV ªvÀø«ü¼Ð°£¤F ¦å¤ñ®e ¥Õ¦å²y ¦å¤pªO µÊŦ¤j¤p ÁÙ¦³³Ì­«­nªº JAK2 allelic burden

¥Nªí p1101 ¬O¦³potential ¯à°÷®Úªv¯e¯fªº

³o¤~¬O¬°¤°»òp1101 ¯à©ñ¦b¤@½u¥ÎÃÄ ¦Ó jakafi¥u¯à¦b¤G½u

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¶È¨Ñ°Ñ¦Ò10146497  µoªí®É¶¡:2018/6/4 ¤U¤È 05:20:51²Ä 4486 ½g¦^À³
¨ä¹ê·í¤pªL¤j´£¥X¤¬¸É¦¡ªvÀø©MÁp¦X¥ÎÃĪº·sÁͶծɡA§Y¥iÁô¬ù¬Ý¥Xp1101Áö¨ãÀu¶V©Ê¦ý«o«D¨ãµ´¹ïÀu¶Õªº²{ªp¤F¡A¦]¦¹p1101¯à§_¨ú±o¤@½u¥ÎÃĸê®æ¡AÁÙ¬O¼f·V¼ÖÆ[¬Ý«Ý´N¦n¤F¡C
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤p¥øÃZ10142872  µoªí®É¶¡:2018/6/4 ¤U¤È 03:35:33²Ä 4485 ½g¦^À³
¦U¦ì,§Ú«ÜÃhºÃrabbit ªº¯u¥¿¥ø¹Ï

¤§«e³£¨Sµo¹L¤å,

§â¥h¦~¤T¬yªºGºôªº¦A«×µ¹¤j®a¬Ý

Gºô³Ìµh«ëªº¥Í§ÞªÑ

²Ä¤@¬O6446, ²Ä¤G¬O¯E¹©

§Ú§Æ±æ³o­Ó½×¾Â, ¤£­n¦A³Q³o´CÅé©Ò¬V«ü

§â¦³ªº§Q¦h©M§QªÅ®³¨Ó¦A«×ª£§@

¬O¤T¬y¥D¤O±`¥Îªº¤âªk

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤pªL10142678  µoªí®É¶¡:2018/6/3 ¤U¤È 07:39:08²Ä 4484 ½g¦^À³
ÁÂÁªüºµ¤j©M°]°È¦Û¥Ñ¤H¤j¤À¨É¤p§Ìªº©å§@¡A¦]¬°¸Ó¶K¤å¶Z¤µ¤w¦³¤@¬q®É¶¡¡A¦A¸É¥R¨Ç¸ê®Æ©MÆ[¹î¡C

¡´Genetªº¤å³¹¡i±qJakafiªºÁ{§É¨¤«×¨Ó¬ÝÃĵءj¥Z¥X®É¶¡ÂI¡A¬O¥HP1101²Ä¤@¦~Proud-PVªº«D¦H©Ê¼Æ¾Ú¨Óµû½×¡F¤å³¹¥Z¥X«á¨S¦h¤[¡AP1101²Ä¤G¦~Conti-PVµoªí¤FÀu¶V©Ê¼Æ¾Ú¡A«Ü¥i±¤«á¨Ó³£¨S¦A¬Ý¨ìGenet°w¹ïConti-PVªºµ²ªG´£¨Ñ°ª½×¡Cºâ¤F¡AÁÙ¦n¦³¬ü°êMPNÅv«ÂªºDr. Srdan Verstovsek¨Óµû½×¸ÑªRP1101ªºProud/Conti-PV¼Æ¾Úµ²ªG¡C

¡iA revisit of PROUD/CONTI Study¡j

www.youtube.com/watch?v=nDVFEnYu7xk&feature=youtu.be

¡´Dr. Srdan Verstovsek¥¿¬O¡i±qJakafiªºÁ{§É¨¤«×¨Ó¬ÝÃĵءj¤å³¹¤¤Response StudyªºÁ{§É¥D«ùÂå®v¡A¬O·íªìJakafi³Q®Ö­ã¨ú±oPV¤G½u¥ÎÃĪº­«­n±À¤â¡C¹L¥h¦b°ê¥~MPNªÀ¸s¯f¤Íªºµû½×¡ADr. V¹ïPV§C­·ÀI¯f¤H¬O±Ä¨úwatch and waitªº¾ÖÅ@ªÌ¡A»Ý­n¿n·¥ªvÀøªº°ª­·ÀI¯f¤H«h¬O«ùpro-HU©Îpro-JakafiªººA«×¡A§Y¨Ï¯f¤H¥D°Ê­n¨D¬I¥´Pegasys¤]¤£¦P·N¡A³Q¯f¤Í­Ìµû½×¬°¹ï¤zÂZ¯À¤£¤Íµ½ªºÂå®v(2017¦~6¤ë¥H«e)¡C¦ýªñ¤@¦~¨Ó¡ADr. V»P¯f¤Hªº¤¬°Ê(ªí¥Ü¥¼¨ÓÄ@·N¶}¤zÂZ¯À³B¤è)¡B¬ã°Q·|ºt»¡¡B´CÅé³X½Í¡A¹ï¤zÂZ¯À(¤×¨ä¬ORopeg)ªººA«×¦³«Ü¤jªºÂàÅÜ¡C­Ó¤H±À´ú¡A¥LÀ³¸Ó¬Oªñ´Á°Ñ»PÃĵػPFDA·|ijªºKOL¤§¤@¡A©Î³\¤]¬O¥¼¨ÓET¥þ²y¤T´ÁÁ{§Éªº¥D«ùÂå®v¤H¿ï¡C

¡´­Ó¤H¤´µM»{¬°¡AJakafi»PP1101¤£¨£±o¬O¼Ä¤H¡A¤×¨äJakafi²{¦b­±¹ïFedratinib(³QCelgene¥H³Ì°ª70»õ¬üª÷¶R¤U)ªºª½±µ«Â¯Ù¡A¤S¦³¦h­Ó¶}µo¤¤ªºJAK inhibitorsºË·Ç»PJakafi­«Å|ªºMF/PV¥ÎÃıڸs¡AIncyteÀ³¸Ó­n»°§ÖÂX®iJakafiªº¾A¥Î±Ú¸s¡CÁöµMIncyte¥h¦~Á`ºâÁÙ¬O±Ò°Ê¤FJakafi¦bET¤G½u±Ú¸sªº¼Ï¯Ã©Ê¸ÕÅç¡A¦ý¹L¥hProof-of-Concept§Yµo²{Jakafi¹ïETªº®ÄªG¨Ã¤£ÅãµÛ¡A«e°}¤lDr. Claire N. Harrison(­^°êªºMPNÅv«Â)µoªíªº¬ã¨s¡A¤]Åã¥Ü¥XJakafi¹ïHU¤£­@¨ü/§ÜÃĪº¤G½u¯f¤H¡A»PBAT²ÕªºÀø®Ä¨S¦³®t²§¡A¦]¦¹Jakafi­n¦bET¨ú±o»PPV¦P¼Ëªº¦¨¥\¡A¾÷·|®£©È¤£¤j¡C

¡iRuxolitinib vs best available therapy for ET intolerant or resistant to hydroxycarbamide¡j

www.bloodjournal.org/content/130/17/1889?ijkey=dd903b75306df9924de2b153bf44173af17f9957&keytype2=tf_ipsecsha&sso-checked=true

¡´¨º»ò¦bMPN»â°ì¡AJakafi¥i¥HÂX®i¥Ø¼Ð±Ú¸sªº¾÷·|¦b­þ¸Ì¡H­º¥ý­nª¾¹D¡AJakafiÁöµM¬°MFªº²Ä¤@½u¥ÎÃÄ¡A¦ý¥u®Ö­ã¦bintermediate-2 risk©Mhigh risk±Ú¸s¡Alow risk©Mintermediate-1 risk¥Ø«e¤´µL®Ö­ã¥ÎÃÄ¡A¥Ñ©óMF¯e¯fªº¶iµ{³t«×¸û§Ö¡A¥B¤wÄÝÄY­«»Ý¿n·¥ªvÀøªº¯e¯f¡A¥Ø«e¤£½×¬O¨Ï¥ÎJAK§í¨î¾¯©Î¤zÂZ¯ÀªvÀøMF¦U¦³¨äÀu¯ÊÂI¡A³¡¤ÀÂå®v©M¯f¤H±H±æ©óJakafi+IFNaªº¦X¨ÖÀøªk¡C³o­Ó¤ë¼Ú¬w¦å²G¾Ç¦~·|(EHA)±N¦³¤@½gCOMBI Study(Jakafi+IFNa)ªº¤@¦~ªì¨Bµ²ªGµoªí¡AºK­nµ²ªG«ü¥X°w¹ïlow/intermediate-1 riskªºMF¯f¤H¡AJakafi+IFNa¬O¥i¦æ¥B¦³®Äªº(¸Ô²Ó¼Æ¾Ú¥i°Ñ¦ÒºK­n)¡A¥i¾Ú¦¹¹ªÀy¥¼¨Óªº¤T´ÁÁ{§É¡C¦]¦¹¡A­Ó¤H«Ü´Á«Ý¥¼¨Ó¯à¬Ý¨ìIncyteÄâ¤âÃĵئ@¦P¶}µoearly MFªº¦X¨ÖªvÀø¤è®×¡C

¡iSAFETY AND EFFICACY OF COMBINATION THERAPY OF INTERFERON £DLPHA-2 AND RUXOLITINIB IN POLYCYTHEMIA VERA AND LOW-/INTERMEDIATE-1-RISK MYELOFIBROSIS ¡V A ONE YEAR FOLLOW-UP UPDATE OF A PHASE II STUDY¡j

learningcenter.ehaweb.org/eha/2018/stockholm/215880/stine.ulrik.mikkelsen.safety.and.efficacy.of.combination.therapy.of.interferon.html?f=ce_id=1346*ot_id=19067*media=3*marker=167

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡Gavandia10146474  µoªí®É¶¡:2018/6/2 ¤U¤È 08:38:33²Ä 4483 ½g¦^À³
¥t¥~¤@´£ incyte ´X¥GÀ禬¥u¦³¨Ó¦Û Jakafi

¥þ²±®É´Á ªÑ»ù150¬üª÷ ¾ã­Ó¤½¥q¥«­È±Nªñ¥x¹ô¤@¥ü

epacadostat »P MSD Keytruda¦X¨ÖªvÀøªº¸ÕÅ祢±Ñ

¨ì¥Ø«e¥Ø«eªÑ»ù60´X¤¸ ´X¥G¸y±Ù ¦ýÁÙ¦³±Nªñ140»õ¬üª÷ªº¥«­È¬ù4200»õ·s¥x¹ô

ÃĵØÃĥثe¥«­È¥u¦³400»õ¤£¨ì ¦pªGropeg ®³¥X¨Ó ¸ò jakafi ¹ï¤ñ

Áö»¡¥Ø«e°êµo°òª÷¸ò¤jªÑªFÁÙ«ù¦³¤j¦h¼Æ«ùªÑ

À³¸Ó¨S¦³³Q¨ÖÁʪº¥i¯à©Ê (¤½¥q¬£ªÖ©w¤]¤£·|©ñ¹L³o­Ó¤jª÷Âû)

¤½¥q¥«­È¥Ø«e¬O§_¹L«×§C¦ô??

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡Gªüºµ10136469  µoªí®É¶¡:2018/6/2 ¤U¤È 04:11:39²Ä 4482 ½g¦^À³
¥t¥~¡AÃĵتº§C¦¨¥æ¶q¨ä¹ê·t¥ÜµÛÄw½XªºÃ­©w

±q2017¦~6¤ë3¤é¨ì2018¦~6¤ë1¤éªºªÑÅv¤À´²ªí¨Ó¬Ý

«ù¦³400±i¥H¤WªºªÑªFÁ`­p«ù¦³±i¼Æ¥Ñ

127,172±i¼W¥[¬°132,192±i¡A

µ¥©ó³Ìªñ¤@¦~¦³¶W¹L5000±iªºÄw½X¥Ñ´²¤á¬y¨ì¤j¤á¤â¸Ì

µ¥¨ì¯u¥¿ªº§Q¦h¸¹¨¤ÅT°_¡A¥Lªºº¦¶ÕÀ³¸Ó¬O·|¥O¤H¨í¥Ø¬Û¬Ýªº¡C

¦Ó©Ò¿×¯u¥¿ªº§Q¦h¡A­Ó¤H»{¬°¬O¨ú±oEMA¡BFDAÃÄÃÒ¡A¶}©l¦³¤FÀ禬Àò§Q¡A

©¡®ÉÃĵرN·n¨­¤@Åܦ¨¬°¦¨ªøªÑ¡A

ªø½u¦hÀY´N¦¹®i¶}¡A

¥u­n©ê±o°÷¤[¡A´N¥i¥H¬Ý¨ì¥Ø«eªºªÑ»ùÅܦ¨¤@¦~ªºEPS¡A

ªÑ»ù·|¨ì¦h¤Ö¦Û¤v·Q¹³

¤§«e¤w¸g¦³»¡¹L¡A¤µ¦~8¤ë¤U¦¯D210®ÉCHMPªº·N¨£­Y¹w§i±N¨ú±o­nÃÒ¡A

¥i¯à´N¬O¤@­ÓIJ´C¡A

¤£¥Î¦Aµ¥¤[¤F!

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡Gªüºµ10136469  µoªí®É¶¡:2018/6/2 ¤U¤È 03:25:08²Ä 4481 ½g¦^À³
³æ­p¬ü°ê¥«³õ¡BPV³o¶µ¾AÀ³¯g¡AP1001´N¯à°^ÄmÃĵبC¦~100¤¸¥H¤WªºEPS

°²³]¨C¤H¨C¦~ÃÄ»ù84000¬ü¤¸¡]ªL°õ¦æªø¦bªk»¡¤W´£¨ìªº¼Æ¦r¡^¡B¦³20000¯f±w¨Ï¥Î¡]v.s.¥Ø«eoff-label¨Ï¥Î¤zÂZ¯Àªº¯f±w¦³14000¤H¡^¡A³o¼Ë¤@¦~´N¦³16.8»õ¬ü¤¸À禬¡A¬ù·í©ó500»õ¥x¹ôªºÀ禬

¤£§t¬ãµo¶O¥ÎªºÀç¯q²v°²³]¬°60%¡A³o¼Ë¦©°£¬ãµo¶O¥Î«eªºÀç·~§Q¯q´N¦³300»õ¡F°²³]¦]¬°®i¶}ETÁ{§É¡A¤@¦~ªº¬ãµo¶O¥Î¼W¥[¬°20»õ¡A³o¼Ë¦©°£¬ãµo¶O¥Î«áªºÀç·~§Q¯q´N¬O280»õ¡F¦©°£Àç©Òµ|17%¡Aµ|«á¯Â¯q232»õ¡AEPS´N¬ù100¤¸¡C

¦pªG¦A¥[¤W¼Ú¬w¡B¤é¥»¡B¤¤°êµ¥¥«³õªº°^Äm¡A¥Ø«eªºªÑ»ù«Ü¥i¯à´N¬O¥¼¨ÓªºEPS¡I

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡Gavandia10146474  µoªí®É¶¡:2018/6/2 ¤U¤È 02:12:47²Ä 4480 ½g¦^À³
to rabbit:

Gºô³o½g®³¨Ó¶ÂÃĵØÃĬO«D±`¥X¦Wªº ¬Û«H¤j®a³£Åª¹L¤F ¸Ì­±ªº½èºÃ¨ä¹ê¦³¥¦ªº¹D²z¦b

¦ý¨º½g¤å³¹¬O°w¹ï PROUD-PV ¸ÕÅç

³Ì·sªº CONTI-PV ¥[¤W¤§«e PROUD-PV ¦@24­Ó¤ëªºÁ{§É¸ÕÅ禭¤wÃÒ¹ê

¦b ²Ä21-24¤ë®É¤wÃÒ¹ê¨ä¬Û¸û©ó HU

¤£½×¬O CHR©Î¬OµÊ¸~¤j±¡§Î ¤w¦³ superiority

§ó¤£­n»¡¹ï JAK2 allele burden ¤U­°²v±Nªñ70%»·Àu©ó HU

³oªí¥Ü¬Æ»ò? ³o¥Nªípv ¬O¦³¾÷·|³Qªv¡ªº ¦Ó«Dªí­±¤W³æ¯Â¦å²G¾ÇÀˬd­Èªº§ïµ½.....

¥t¥~ ¬°¦ó¤£®³¨Ó¸ò Jakafi ¬Û¤ñ ¦b¤T´Á¶}©l®É jakafi ®Ú¥»ÁÙ¥¼³Q FDA approved ³o¤£¬O¤j®a³£ª¾¹Dªº¶Ü?

¥t¥~¯E¹©¦­¦bphase iii off label¸Ñª¼¥¢±Ñ

ÃĵØÃĦ­¤w¦¨¥\ ²{¦b¦b¨«ÃÄÃÒ®Öµoµ{§Ç ³o¨â¥ó¨Æ¤]¯à²V¬°¤@½Í¶Ü?

¦pªG¦U¦ì»{¬°ÃĵØÃĬO¤@¶¡³Q¹L«×§j±·ªº¤½¥q ¨S¦³market oppurtunity

¦bÃÄÃÒ¨ú±o«eÁÙ¯àºû«ù²{¦b180¤¸ªºªÑ»ù?

¥t¥~§Ú»¡ªºeps 100 ¤]µ´¹ï¤£¬O¤£¥i¯à

¦]¬°jakafi ¦b MPN ªº¥«³õ´N¬O³o»ò¦h ¦Ó¥BÁͶլO¦~¦~¦¨ªø

¦óªp©t¨àÃĬO¦³¨C¦~¸ò«OÀI¤½¥qÁp¨¹¬F©²­«½Í»ù¿úªº¾÷·|ªº (·íµM¬O¨C¦~½Õº¦ jakafi´N¬O¦p¦¹)

§ó¤£­n»¡ PV ÁÙ¦³«D±`¤jªº¥«³õªÅ¶¡¨Ã¨S¦³³Q«õ±¸

¦]¬°¶W¹L80%¯f¤HªvÀøÁÙ¬O¥H off-lable use ªº HU/IFN ¸ò aspirin ©ñ¦å¬°¥D

°²¦p ¯u¥¿ªº²Ä¤@½u¥ÎÃijQ FDA approve

Ãø¹D p1101 ¤£¯à¶W¶V jakafi ¨ººØ¥H§ÜÃĩʲ£¥Í¤~¯à¨Ï¥Îªº¤G½u¥ÎÃĪº¥«³õ??

¨C¦~¬ù450»õ¥x¹ô ³o¬O³æ¯ÂªºÅÞ¿è¦Ó¤w ¨Ã¤£»Ý­n¤Ó½ÆÂøªº¥«³õ¦ôºâ

§A§ìÀç¯q²v 60-70% ¦n¤F ¥[¤W¼Ú¬wÁȪº ¤@¦~eps 100 ¤£¥i¯à¶Ü??

«Ü¦h¤H¤]½èºÃÃĵØÃĦb¬ü°ê¥«³õªº¦æ¾P¯à¤O

¦ý¨ä¹ê³QFDA»{ÃÒªº first-line ´N¤w¸g¬O³Ì±j¤jªº¦æ¾P¤F

¬Æ¦Ü³s¦æ¾P³£¤£»Ý­n ²Ä¤@½u´N¬O·|¹ý©³§ïÅÜ©Ò¦³Âå®v¥Ø«eªvÀøªº¥ÍºA

§A¤£¶}²Ä¤@½uÃÄ ¯f¤H¬Æ¦Ü¯f¤H®aÄݬO·|½èºÃÂå®vªº

¥t¥~©t¨àÃĦb¬ü°ê¬O¦³ªk«ß«O»Ù «OÀI¤½¥q¤£±oµ¹¯f¤H©Ú«Oªº ³o¬O¨Æ¹ê

¦óªp²{¦b¦bÀ°ropeg ­I®Ñªº ¤£´X¥G³£¬O¦å²G¾Ç²Ä¤@½uªºÅv«ÂÂå®v¶Ü

¬ü°ê MPN ¾Ç·|¥D®u

ÁÙ¦³MD anderson (¥þ¥@¬É³Ì³»¦yªºÀù¯gªvÀøÂå°|)Srdan Verstovsek (jakafi±À¤â)

Ãø¹D³o¨Ç¤Hªº¨­¤À¦a¦ìÁ¿ªº¸Ü ¤ñGºô½s¿èÁÙ¤£¦p??

³o¨Ç¦³ÀY¦³Áyªº¤j¦ÑÄ@·NÀ°ropeg ­I®Ñ

¦pªGÃĦ³ºÃ¼{©Î¤£¦n ¬O¤£¥i¯à®³¥ÛÀY¯{¦Û¤vªº¸}ªº

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GKid10147031  µoªí®É¶¡:2018/6/2 ¤W¤È 10:55:44²Ä 4479 ½g¦^À³
¬P¬P°{Ã{ªº¥ú¨~¡@°l´M¤w§Ñ°O¦h¤Ö¥ú¦~

¤é©]¥æ·|ªº«b¨º¡@¶À©üµuªº¹³¤@¥y»}¨¥

±q¨Ó¤£¨D®É¶¡¬°§ÚÀÁ²L

¥u¬ß¬¡ªº¨C¤@¤Ñ

³£¯à¦³§A¡@Åý§Ú«ä©À

¬y®ö¡@¬y®ö¡@¬y®ö

·R­ì¨Ó¬O¤ù®ü¬v

ÄÆÄÆÀúÀú¡@§Ú±æ²´±ý¬ï

¤d¸U·øµó¿O³£¬°§ÚÂI«G

©t³æ¡@©t³æ

·R±²¨«§Aªº¼Ò¼Ë

©R¹B¬O§A¡@¨è¦b§Ú¤â´x

³o¤@¦¸§Úµ´¤£©ñ¤â

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G°]°È¦Û¥Ñ¤H10132540  µoªí®É¶¡:2018/6/2 ¤W¤È 10:42:57²Ä 4478 ½g¦^À³
to rabbit, ½Ð°Ñ¦Ò¤U¦C¸ê®Æ¡A­Ó¤Hı±o¼gªº¤£¿ù¡C

·|­û¡G¤pªL10142678 µoªí®É¶¡:2017/9/23 ¤U¤È 06:18:42²Ä 2937 ½g¦^À³

¬Q¤ÑGºôµoªí¤F¤@½g¡i±qJakafiªºÁ{§É¨¤«×¨Ó¬ÝÃĵءj¡A§@ªÌ¦WºÙ¬°²Ä¤@¦¸¬Ý¨ì¡A¤£ª¾¹D¬O¯u¦W©Î¤S¬O¥t¤@­ÓÃÀ¦W¡C¤å³¹¤º®e¤´µMªÈµ²¦bProud-PVªºÁ{§É«D¦H©Ê(non-inferiority)»PHUÃÄ»ù¹ïP1101¾P°â¯à¤Oªº½èºÃ¡CÃĵتºProud-PV¼Æ¾Ú³£µoªí¤F¤j¥b¦~¥H¤W¡A¦bConti-PV¨â¦~´Á¼Æ¾Ú§Y±Nµoªí«e¤i¡BEMA¬d¼t§¹¦¨¤é·í¤Ñ¡AGºôªº¼¶¤å¤S¦Ñ½Õ­«¼u¤F¤@¦¸¡C

½Ð¥ý¦Û¦æ°Ñ¾\¸Ó¤å³¹¡A­Ó¤Hªº¬Ýªk¦p¤U¡G

¡´ Gºô¥ý¥HJakafi·íªìªºÁ{§É¸ÕÅçRelief Study»PResponse Study¨Ó¤ñ¸û¨Ã±j½ÕJakafiªº¯à¤O¡CJakafiªºReliefe Study (NCT01632904)¡A¬O¥HÁ`Åé¯gª¬µû¤À(Total Symptom Score, TSS)§ïµ½50%¥H¤W§@¬°¥D­n«ü¼Ð¡AÁ`Åé¯gª¬µû¤Àªº­Ó§O¯gª¬¥]¬A¯h­Â¡Bæ±Äo¡B¦Ù¦×¯kµh¡Bµs¦½µ¥¶µ¥Ø¡A¨Ã¥H­Ó§O¯gª¬¶µ¥Øµû¤À§ïµ½50%¥H¤W§@¬°¦¸­n«ü¼Ð¡CReliefe Study¸ÕÅçµ²ªG¡A¥D­n«ü¼ÐTSS§ïµ½50%¥H¤W¬°Jakafi=43.4% (n=53), HU=29.6% (n=54)¡A¦bÀu¶V©Ê¤ñ¸û®Ép=0.139¥¼¹F²Î­pªºÅãµÛ¡F­Y¦p¸Ó¤å³¹©Ò´£§ï¬°«D¦H©Ê«á¡A½T¹ê·|¹F¨ì²Î­pªºÅãµÛ¡C

¡´¦ý¬O¡A³o­ÓRelief Study¦³«Ü­«­n¶Ü? ÁöµM¥L¬Oª½±µ¸òHU¤ñ¸û¡A¦ý¬O¥D­n/¦¸­n«ü¼Ð¬OªA¥ÎÃĪ««áªº¯gª¬¤ÏÀ³¡A¨Ã¤£¬O¤ñ¸ûÃĪ«ªºÀø®Ä(¨Ò¦p¦å²G¤ÏÀ³©Î¤À¤l¤ÏÀ³)¡A¨Ó¬Ý¤@¬qIncyte°w¹ïRelief¸ÕÅçµ²ªGµo¥¬ªº·s»D½Z¨ä¤¤¤@¬q¸Ü¡C¡uRELIEF not included in, nor required for, polycythemia vera (PV) sNDA submission; data expected to be presented at an upcoming scientific meeting¡v¥H¤Î¡usNDA submitted to FDA for PV in June 2014 based on the pivotal Phase III RESPONSE trial demonstrating superior clinical benefit of ruxolitinib over best available therapy in patients resistant to, or intolerant of, hydroxyurea¡v¡C¤]´N¬O»¡¤£ºÞRelief¸ÕÅ禳µL¹F¼Ð¡A³£µLÃöÃÄÃÒ(¤£½×²Ä´X½u)ªº¨ú±o»P§_¡A¯u¥¿Ãö¥GÃÄÃÒ¨ú±o»P§_ªºÃöÁä©ÊÁ{§É¸ÕÅç(pivotal trial)¬OResponse Study¡C

¡´±µ¤U¨Ó±´°QResponse Study (NCT01243944)ªº¸ÕÅç³]­p¡A¬O°w¹ï¨Ï¥ÎHUªvÀø¦ý¤£­@¨ü(intolerant)©Î§ÜÃÄ(resistant)ªº¯f¤H¡A´Â²Ä¤G½u¥ÎÃĪº¸ÕÅç³]­p¡C¬°¤°»òJakafi¥u¥HPV¤G½u¥ÎÃĬ°¥Ø¼Ð? Gºô¤å³¹»¡¬O¡¨Jakafi®Ú¥»¤£·Q»PHUÄvª§ÃÄ»ù¡K..¡¨ªº»¡©ú¦ü¥G¹L©ó¥DÆ[¡A¦n¹³¬O¦bÀ°Incyteµo¨¥¦üªº¡C®Ú¾Ú¤åÄm¹ïHU²£¥Í¤£­@¨ü©Î§ÜÃĩʪº¯f¤H¬ù25%¡A¦pªG¦³¾÷·|·m°ß¤@®Ö¥iªº¤@½u¥ÎÃÄ¡A¬°¦ó«o¥uÄ@·N¥Ó½Ð¤G½u¥ÎÃÄ? ­Ó¤H»{¬°ªº¥i¯à©Ê¬O¥Ó½ÐPV¤G½u¥ÎÃĦ¨¥\¾÷²v·¥°ª¡A³o¥i¥H±q±µ¤U¨Ó±´°QResponse Studyªº¸ÕÅç³]­p¨Ó±ÀºV¡F¦Ó¥B¦]¬°ÁÙ¨S¦³®Ö¥iªº¤@½u¥ÎÃÄ¡AÁÙ¦³¾÷·|¥H¥é³æ¥~(off-label)¤è¦¡§@¬°¤@½uªvÀø¤è¦¡¡C

¡´Gºô¤å³¹»¡¡uResponseªº¹êÅç³]­p«D±`ªº±j®«¡A¬O¥HBAT(³Ì¨Î¥iÀò±o¦aÀøªk)°µ¹ï·Ó²Õ¡K¡K¡v¡C¥EÅ¥¤§¤U¦ü¥Gı±oResponse¸ÕÅç«Ü±j? Jakafi¦bResponse¸ÕÅ礤¾î±½¤FBAT²Õ§O? BAT²Õ§O¬Æ¦Ü¥]¬A¤F¤zÂZ¯À(IFN)¡A©Ò¥HJakafi¤ñ¤zÂZ¯ÀÁÙ±j? ¤£¹Lµ¥µ¥¡A¦pªG¥J²Ó¬Ý¤@¤UBAT²Õ§O¯f¤HªºªvÀø¤è¦¡¡A¬O¥ÑÁ{§ÉÂå®v©Ò¿ï¾Ü¡A¥]¬A¤FHU¦û59%(n=66)¡BIFN¦û12%(n=13)¡Banagrelide¦û7%(n=8)¡Bpipobroman¦û2%(n=2)¡BIMIDs¦û4%(n=5)¡BÆ[¹î¦û15%(n=17)¡C­º¥ý­nª¾¹D¡AResponse Studyªº¹êÅç²Õ&¹ï·Ó²Õ¡A¦¬ªº³£¬O¹ïHU¤£­@¨ü©Î²£¥Í§ÜÃĪº¯f¤H°Ú! BAT²Õ§O59%ªº¯f¤H(n=66)³ºµMÁÙ¬OÄ~Äòµ¹¤©HUªvÀø(©ú©ú´N¤w¸g¤£­@¨ü©Î§ÜÃĤF!)¡AÁÙ¦³15%ªº¯f¤H(n=17)³ºµM¬O¤£ªvÀø¥uÆ[¹î(³o¤]¥s°µBAT?)¡Aµ¥©ó¬OBAT¹ï·Ó²Õ¦³59%+15%=74%ªº¯f¤H¥¼¾Ô´N¥ý§ë­°¤F¡A³Ì«áªº¸ÕÅçµ²ªGJakafi²Õ¾î±½BAT²Õ¤]¤£¥O¤H·N¥~¡C©Ò¥HResponse Studyªº¹êÅç³]­p¯uªº«D±`ªº±j®«¶Ü? ³o¬OGºôªº¤å³¹¤¤¨S¦³´£¨ìªº¡A§Ú·Q§@ªÌ¦pªG¤£¬O¬G·NÁ׽͡A´N¬O±M·~¤£¨¬¥H¬Ý¥X¦¹²Ó¸`¡C(©êºp¡A§Ú¤]¨Ó»Ä¤@¤U)

¡´JakafiªºPV¤G½uÃÄÃÒ¨ú±o®É¡AMPNforum´N¦³¤@½g½èºÃResponse¸ÕÅç³]­p¤½¥­©Êªº¤å³¹¡iPV and Jakafi ¡V Fair trial?¡j¬JµM¸ÕÅç³]­p¬O¤£¤½¥­ªº¡A¬°¤°»òFDAÁÙ¬O®Öµo¤FÃÄÃÒ? ¥Ñ©ó·í®ÉPV§¹¥þ¨S¦³®Ö¥iªº¥ÎÃÄ¡AÄݩ󥼺¡¨¬ªºÂåÀø»Ý¨D(unmet medical needs)¡A¯f¤Hoff-label¨Ï¥ÎHUªvÀø¤£­@¨ü/§ÜÃÄ«á¡A´N¨S¦³ÃĪ«¥i¥HªvÀø¤F¡A³o¬OJakafi°w¹ï¤w¨Ï¥ÎHUªvÀø¤£­@¨ü/§ÜÃĪº¯f¤H¡A¤£ºÞÀø®Ä¬O°ª¬O§C¡A¥u­n¨S¦³ÄY­«¦w¥þ©ÊªººÃ¼{¡AFDA³£¤£±o¤£µ¹ÃÄÃÒ¡CResponse StudyªºÁ{§É¥D«ùÂå®vDr. Srdan Verstovsek¦b¦^ÂÐMPNforum½èºÃªº¦^µª¬O¡G¡uThat investigators would still use hydroxyurea reflects a lack of good alternative therapies. ¡v©Ò¥H¦bunmet medical needsªº¯e¯f¤¤¡AªÈµ²¦b¸ÕÅç³]­pªºÀu¶V©Ê©M«D¦H©Ê¡B½ÖPK½Ö¡B¼Æ¾Úº}¤£º}«G¡A¤£¨£±o¬Oµ´¹ïªº­«­n¡C(´N¦p¦P¨xÀù¼Ð¹vÃĪ«¹p¨F¥ËNexavarªºORR¬°3%¡A3%¬Ý°_¨Ó¤£°ª°Ú¡A¦ý¦³¾÷·|±Ï¦^3%ªº¤HÁÙ¬O«Ü¦³»ù­È°Ú¡A¦]¦¹ÁÙ¬O­È±oµ¹¤©ÃÄÃÒ¡A¤£µM¨S¦³¨ä¥Lªº¿ï¾Ü«á¥i¯à´NÙTÙT¤F~~)

¡´±µ¤U¨Ó±´°QGºô¦h¦¸ªº½èºÃHU«K©yªºÃÄ»ù·|¼vÅTÃĵØP1101ªº¾P°â¯à¤O¡A¤å³¹µ²»y¬Æ¦Ü»¡¡G¡u¡K­YP1101¤W¥««áÂå¥Í¤j·§¤£·|¿ï¾Ü¨ä¥L¨Ï¥Î¤zÂZ

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡Gªüºµ10136469  µoªí®É¶¡:2018/6/2 ¤W¤È 10:40:52²Ä 4477 ½g¦^À³
Rabbit¤j¤j

Ãö©ó§A­«´£GºôªºÂ¤峹¡A¤pªL¤j¦b²Ä2922½g¶K¤å¤w¦³§¹¾ã¦^À³¡A

¦b¦¹­É¥Î¤@¤U¤pªL¤jªº¤å³¹...

¬Q¤ÑGºôµoªí¤F¤@½g¡i±qJakafiªºÁ{§É¨¤«×¨Ó¬ÝÃĵءj¡A§@ªÌ¦WºÙ¬°²Ä¤@¦¸¬Ý¨ì¡A¤£ª¾¹D¬O¯u¦W©Î¤S¬O¥t¤@­ÓÃÀ¦W¡C¤å³¹¤º®e¤´µMªÈµ²¦bProud-PVªºÁ{§É«D¦H©Ê(non-inferiority)»PHUÃÄ»ù¹ïP1101¾P°â¯à¤Oªº½èºÃ¡CÃĵتºProud-PV¼Æ¾Ú³£µoªí¤F¤j¥b¦~¥H¤W¡A¦bConti-PV¨â¦~´Á¼Æ¾Ú§Y±Nµoªí«e¤i¡BEMA¬d¼t§¹¦¨¤é·í¤Ñ¡AGºôªº¼¶¤å¤S¦Ñ½Õ­«¼u¤F¤@¦¸¡C

½Ð¥ý¦Û¦æ°Ñ¾\¸Ó¤å³¹¡A­Ó¤Hªº¬Ýªk¦p¤U¡G

¡´ Gºô¥ý¥HJakafi·íªìªºÁ{§É¸ÕÅçRelief Study»PResponse Study¨Ó¤ñ¸û¨Ã±j½ÕJakafiªº¯à¤O¡CJakafiªºReliefe Study (NCT01632904)¡A¬O¥HÁ`Åé¯gª¬µû¤À(Total Symptom Score, TSS)§ïµ½50%¥H¤W§@¬°¥D­n«ü¼Ð¡AÁ`Åé¯gª¬µû¤Àªº­Ó§O¯gª¬¥]¬A¯h­Â¡Bæ±Äo¡B¦Ù¦×¯kµh¡Bµs¦½µ¥¶µ¥Ø¡A¨Ã¥H­Ó§O¯gª¬¶µ¥Øµû¤À§ïµ½50%¥H¤W§@¬°¦¸­n«ü¼Ð¡CReliefe Study¸ÕÅçµ²ªG¡A¥D­n«ü¼ÐTSS§ïµ½50%¥H¤W¬°Jakafi=43.4% (n=53), HU=29.6% (n=54)¡A¦bÀu¶V©Ê¤ñ¸û®Ép=0.139¥¼¹F²Î­pªºÅãµÛ¡F­Y¦p¸Ó¤å³¹©Ò´£§ï¬°«D¦H©Ê«á¡A½T¹ê·|¹F¨ì²Î­pªºÅãµÛ¡C

¡´¦ý¬O¡A³o­ÓRelief Study¦³«Ü­«­n¶Ü? ÁöµM¥L¬Oª½±µ¸òHU¤ñ¸û¡A¦ý¬O¥D­n/¦¸­n«ü¼Ð¬OªA¥ÎÃĪ««áªº¯gª¬¤ÏÀ³¡A¨Ã¤£¬O¤ñ¸ûÃĪ«ªºÀø®Ä(¨Ò¦p¦å²G¤ÏÀ³©Î¤À¤l¤ÏÀ³)¡A¨Ó¬Ý¤@¬qIncyte°w¹ïRelief¸ÕÅçµ²ªGµo¥¬ªº·s»D½Z¨ä¤¤¤@¬q¸Ü¡C¡uRELIEF not included in, nor required for, polycythemia vera (PV) sNDA submission; data expected to be presented at an upcoming scientific meeting¡v¥H¤Î¡usNDA submitted to FDA for PV in June 2014 based on the pivotal Phase III RESPONSE trial demonstrating superior clinical benefit of ruxolitinib over best available therapy in patients resistant to, or intolerant of, hydroxyurea¡v¡C¤]´N¬O»¡¤£ºÞRelief¸ÕÅ禳µL¹F¼Ð¡A³£µLÃöÃÄÃÒ(¤£½×²Ä´X½u)ªº¨ú±o»P§_¡A¯u¥¿Ãö¥GÃÄÃÒ¨ú±o»P§_ªºÃöÁä©ÊÁ{§É¸ÕÅç(pivotal trial)¬OResponse Study¡C

Incyte·s»D½Z¡G

www.businesswire.com/news/home/20140723006286/en/Incyte-Announces-Top-Line-Results-RELIEF-Trial-Ruxolitinib

¡´±µ¤U¨Ó±´°QResponse Study (NCT01243944)ªº¸ÕÅç³]­p¡A¬O°w¹ï¨Ï¥ÎHUªvÀø¦ý¤£­@¨ü(intolerant)©Î§ÜÃÄ(resistant)ªº¯f¤H¡A´Â²Ä¤G½u¥ÎÃĪº¸ÕÅç³]­p¡C¬°¤°»òJakafi¥u¥HPV¤G½u¥ÎÃĬ°¥Ø¼Ð? Gºô¤å³¹»¡¬O¡¨Jakafi®Ú¥»¤£·Q»PHUÄvª§ÃÄ»ù¡K..¡¨ªº»¡©ú¦ü¥G¹L©ó¥DÆ[¡A¦n¹³¬O¦bÀ°Incyteµo¨¥¦üªº¡C®Ú¾Ú¤åÄm¹ïHU²£¥Í¤£­@¨ü©Î§ÜÃĩʪº¯f¤H¬ù25%¡A¦pªG¦³¾÷·|·m°ß¤@®Ö¥iªº¤@½u¥ÎÃÄ¡A¬°¦ó«o¥uÄ@·N¥Ó½Ð¤G½u¥ÎÃÄ? ­Ó¤H»{¬°ªº¥i¯à©Ê¬O¥Ó½ÐPV¤G½u¥ÎÃĦ¨¥\¾÷²v·¥°ª¡A³o¥i¥H±q±µ¤U¨Ó±´°QResponse Studyªº¸ÕÅç³]­p¨Ó±ÀºV¡F¦Ó¥B¦]¬°ÁÙ¨S¦³®Ö¥iªº¤@½u¥ÎÃÄ¡AÁÙ¦³¾÷·|¥H¥é³æ¥~(off-label)¤è¦¡§@¬°¤@½uªvÀø¤è¦¡¡C

¡´Gºô¤å³¹»¡¡uResponseªº¹êÅç³]­p«D±`ªº±j®«¡A¬O¥HBAT(³Ì¨Î¥iÀò±o¦aÀøªk)°µ¹ï·Ó²Õ¡K¡K¡v¡C¥EÅ¥¤§¤U¦ü¥Gı±oResponse¸ÕÅç«Ü±j? Jakafi¦bResponse¸ÕÅ礤¾î±½¤FBAT²Õ§O? BAT²Õ§O¬Æ¦Ü¥]¬A¤F¤zÂZ¯À(IFN)¡A©Ò¥HJakafi¤ñ¤zÂZ¯ÀÁÙ±j? ¤£¹Lµ¥µ¥¡A¦pªG¥J²Ó¬Ý¤@¤UBAT²Õ§O¯f¤HªºªvÀø¤è¦¡¡A¬O¥ÑÁ{§ÉÂå®v©Ò¿ï¾Ü¡A¥]¬A¤FHU¦û59%(n=66)¡BIFN¦û12%(n=13)¡Banagrelide¦û7%(n=8)¡Bpipobroman¦û2%(n=2)¡BIMIDs¦û4%(n=5)¡BÆ[¹î¦û15%(n=17)¡C­º¥ý­nª¾¹D¡AResponse Studyªº¹êÅç²Õ&¹ï·Ó²Õ¡A¦¬ªº³£¬O¹ïHU¤£­@¨ü©Î²£¥Í§ÜÃĪº¯f¤H°Ú! BAT²Õ§O59%ªº¯f¤H(n=66)³ºµMÁÙ¬OÄ~Äòµ¹¤©HUªvÀø(©ú©ú´N¤w¸g¤£­@¨ü©Î§ÜÃĤF!)¡AÁÙ¦³15%ªº¯f¤H(n=17)³ºµM¬O¤£ªvÀø¥uÆ[¹î(³o¤]¥s°µBAT?)¡Aµ¥©ó¬OBAT¹ï·Ó²Õ¦³59%+15%=74%ªº¯f¤H¥¼¾Ô´N¥ý§ë­°¤F¡A³Ì«áªº¸ÕÅçµ²ªGJakafi²Õ¾î±½BAT²Õ¤]¤£¥O¤H·N¥~¡C©Ò¥HResponse Studyªº¹êÅç³]­p¯uªº«D±`ªº±j®«¶Ü? ³o¬OGºôªº¤å³¹¤¤¨S¦³´£¨ìªº¡A§Ú·Q§@ªÌ¦pªG¤£¬O¬G·NÁ׽͡A´N¬O±M·~¤£¨¬¥H¬Ý¥X¦¹²Ó¸`¡C(©êºp¡A§Ú¤]¨Ó»Ä¤@¤U)

¡´JakafiªºPV¤G½uÃÄÃÒ¨ú±o®É¡AMPNforum´N¦³¤@½g½èºÃResponse¸ÕÅç³]­p¤½¥­©Êªº¤å³¹¡iPV and Jakafi ¡V Fair trial?¡j¬JµM¸ÕÅç³]­p¬O¤£¤½¥­ªº¡A¬°¤°»òFDAÁÙ¬O®Öµo¤FÃÄÃÒ? ¥Ñ©ó·í®ÉPV§¹¥þ¨S¦³®Ö¥iªº¥ÎÃÄ¡AÄݩ󥼺¡¨¬ªºÂåÀø»Ý¨D(unmet medical needs)¡A¯f¤Hoff-label¨Ï¥ÎHUªvÀø¤£­@¨ü/§ÜÃÄ«á¡A´N¨S¦³ÃĪ«¥i¥HªvÀø¤F¡A³o¬OJakafi°w¹ï¤w¨Ï¥ÎHUªvÀø¤£­@¨ü/§ÜÃĪº¯f¤H¡A¤£ºÞÀø®Ä¬O°ª¬O§C¡A¥u­n¨S¦³ÄY­«¦w¥þ©ÊªººÃ¼{¡AFDA³£¤£±o¤£µ¹ÃÄÃÒ¡CResponse StudyªºÁ{§É¥D«ùÂå®vDr. Srdan Verstovsek¦b¦^ÂÐMPNforum½èºÃªº¦^µª¬O¡G¡uThat investigators would still use hydroxyurea reflects a lack of good alternative therapies. ¡v©Ò¥H¦bunmet medical needsªº¯e¯f¤¤¡AªÈµ²¦b¸ÕÅç³]­pªºÀu¶V©Ê©M«D¦H©Ê¡B½ÖPK½Ö¡B¼Æ¾Úº}¤£º}«G¡A¤£¨£±o¬Oµ´¹ïªº­«­n¡C(´N¦p¦P¨xÀù¼Ð¹vÃĪ«¹p¨F¥ËNexavarªºORR¬°3%¡A3%¬Ý°_¨Ó¤£°ª°Ú¡A¦ý¦³¾÷·|±Ï¦^3%ªº¤HÁÙ¬O«Ü¦³»ù­È°Ú¡A¦]¦¹ÁÙ¬O­È±oµ¹¤©ÃÄÃÒ¡A¤£µM¨S¦³¨ä¥Lªº¿ï¾Ü«á¥i¯à´NÙTÙT¤F~~)

¡iPV and J

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡Grabbit10136567  µoªí®É¶¡:2018/6/2 ¤W¤È 09:49:47²Ä 4476 ½g¦^À³
±qJakafiªºÁ{§É¨¤«×¨Ó¬ÝÃĵØ

www.genetinfo.com/investment/featured/item/11139.html?limitstart=0

¥Í§Þ§ë¸ê²Ä¤@¯¸-Genet ªº¤å³¹°Ñ¦Ò°Ñ¦Ò¡A¼ÖÆ[¬O¦n¨Æ¡A§Ú¤]¹ï¯E¹©¼ÖÆ[¹L¡A¯¬ÃĤͤ߷Q¨Æ¦¨¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¦n¹B10137114  µoªí®É¶¡:2018/6/2 ¤W¤È 08:28:00²Ä 4475 ½g¦^À³
EPS¬O­n¥Î¹w¦ôªº¡A¦Ó«D¶È¶È¬O·Q¹³¡C

¬O§_¥i¥H¤À¨É±zı±o100,200ªºeps¬O«ç»ò¨Óªº¡H

¯¬ºÖ±z

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¶È¨Ñ°Ñ¦Ò10146497  µoªí®É¶¡:2018/6/1 ¤U¤È 10:35:16²Ä 4474 ½g¦^À³
¯¬ºÖ§A¡A§Æ±æ§A¤ß·Q¨Æ¦¨
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡Gavandia10146474  µoªí®É¶¡:2018/6/1 ¤U¤È 09:22:18²Ä 4473 ½g¦^À³
¦b³o¤è­±§Ú¬OµL¥i±ÏÃĪº¼ÖÆ[

§Ú¬Û«H­YEMA¨úÃÒ ÃĵØÃĪºÃzµo¤Oµ´¹ï¬O»·»·¶W¹L¤¤¸Îªº

²¦³º ¤@½u¥ÎÃÄ¥«³õ¥÷ÃB®t²§¤Ó¤j

¼ç¦bªº¯f±w±Nªñ¬O¤¤¸Î¥|½uÃĪº¤Q­¿

Jakafi 2017 MPN ¬ü°ê¥«³õ±µªñ300»õ 2018¦~¹w¦ô 450»õ

¥ú¬OÃĵØÃĦbpv¤@½u¥ÎÃĪº¦a¦ì´NÅý¤H¦³¦h¤j·Q¹³ªÅ¶¡

­«ÂIÃĵØÃĬO¤@°¦ªÑ¥»¥u¦³20»õªº¤½¥q... eps 100? 200?

¹w¦ô 2019¦~ªìªÑ»ù¥ý©é°ê¥¨ 2020 FDA¨úÃÒ¦A¬D¾Ô¤j¥ß¥ú

²{¦b¶R¶iªÑ²¼´N·í§@©w¦s©ñµÛ ¬Ý³£¤£­n¬Ý

¤@¦~«á¬Û«H·|¦³«D±`Â׫pªºªG¹ê

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GKid10147031  µoªí®É¶¡:2018/6/1 ¤U¤È 01:59:02²Ä 4472 ½g¦^À³
·f¹L¸Î§Ìªº¨®¡A¤¤¶¡©È§¤¿ù¨®¤W¤U¨®¤£¤Ö¦¸¡A¿ù¹L¤£¤Ö­·´º¡A³o¦¸Ãĵب®¨Ó¤F¡A´È¤l¤@©w§¤¨ì¼ö
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GKid10147031  µoªí®É¶¡:2018/6/1 ¤U¤È 01:50:48²Ä 4471 ½g¦^À³
³o¨â¤Ñ¥~¸ê¤]¶}©l¶R¶W¤F¡A¤£¬O¶Ü?
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤p¥øÃZ10142872  µoªí®É¶¡:2018/6/1 ¤U¤È 01:06:43²Ä 4470 ½g¦^À³
ªÑ»ù¿éµ¹­è®³¨ìÃÄÃÒªº¸Î§Ì´Nºâ¤F

ÁÙ§Ö­n¿éµ¹5¦~«á¤~®³ÃÄÃÒªº¯E­ô

³oºØ´N¬OªÑ©Ê

¤]´N¬O¥Ø«e«ùªÑªÌ,©M·Ç³Æ¶R¤JªºÆ[±æªÌ

¬Û¤¬¨¤¤O«áªºµ²ªG

§Ú¤@¸ô¬Ý¦n, ¦ý²{¦b¤£§K¦³ÂI¾á¤ß

¦]¬°¬Ý¥xªÑ, Ãþ¦üªº¤½¥q¨Ã¤£¤Ö

Ãø©Çªk¤H¤£Ä@·N¶i¨Ó

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
²Ä¤@­¶¤W¤Q­¶¤W¤@­¶242526272829303132¤U¤@­¶¤U¤Q­¶

         

¡@

§Ú¡@¡@­n¡@¡@¦^¡@¡@À³¡@¡@¥»¡@¡@¸Ü¡@¡@ÃD

·| ¡@­û¡G

  

§@ ªÌ ¡G

 

¬ÛÃöªÑ²¼¤½¥q¦WºÙ ¡G

ÃĵØÂåÃÄ

¤º¡@ ®e¡G

¡@
½Ð¥ýµn¤J ­Y±z©|µL·|­û¨­¤À¡A½Ð¥ý¥Ó½Ð±b¸¹ ¡@
¡@

°Q½×°Ï¬ÛÃö³W©w¡G
    1.­Y±b¸¹¶¢¸m¹L¤[¨t²Î·|¦Û°Êµn¥X¡A«Øij¦b¼g¦n¤å³¹¨Ã¥B©|¥¼µo°e¤§«e¥ý¦æ½Æ»s¡A¥H§Kµo°e¥¢±Ñ«á¾É­P¤º¤å®ø¥¢¡I
    2.½Ð¤Å°Q½×ªÑ²¼¶R½æ©Î´£¤Î¦¨¥æ»ù¦ìµ¥¨Æ©y¡A¤Z¬O¯d¤U¬ÛÃö¥æ©ö°T®§¡A¥»ºô±N¦Û°Ê§R°£¡A¹HªÌ±NµLªkÄ~Äò°Ñ»P°Q½×¡I
    3.ÄY¸T¯d¤UÁpµ¸¤è¦¡¡A½Ñ¦pLINE¡BFB¡BE-mail¡B¹q¸Ü..µ¥¡A©Î¥H¥ô¦ó©ú¥Ü¡B·t¥Üµ¥¤âªk¶i¦æÁpµ¸¡A¹HªÌ±NµLªkÄ~Äò°Ñ»P°Q½×¡I
    4.¬°ÁקK®ö¶Oºô¸ô¸ê·½¡A½Ð¤Å±N¬Û¦P¤º®e³sÄòµo¦b¦h­Ó¤£¦P¥DÃD¤º¡A©ÎªÌ³sÄòµo°e¦h­Ó·s¥DÃD¡A­Y¦³¦¹Ãþ¬~ª©¤§¦æ¬°±NµLªkÄ~Äò°Ñ»P°Q½×¡I
    5.ÄY¸T·N¹ÏÂǥΥ»ºô¥­¥x¤½µM´²¥¬¤å¦r©ó²³¡A¦Ó«üÂÖ¡B«V°d©Î¶Ç­z¨¬¥H·´·l¥L¤H¦WÅA¤§¨ÆªÌ¡A­Y¦]¦Ó¯A¤Îªk«ß°ÝÃD¡A·§»P¥»¤½¥qµLÃö¡A·q½Ð¿í¦u¡C

·q½Ð´L­«¥»ºô¤§¸gÀç²z©À¨Ã¿í¦uª©³W¡AÁÂÁ¡C


¼s§i¦X§@ ¥¼¤W¥«ÂdªÑ²¼¬d¸ß ¥¼¤W¥«ºô¯¸¾ÉÄý ¥¼¤W¥«ÂdªÑ²¼±MÃD ¿³ÂdªÑ²¼±MÃD ¥¼¤W¥«ªÑ²¼-¶°¹Î¤ÀÃþ ²§·~Âà§ë¸ê¥Í§Þ·~ ¤U³æ±Ð¾Ç
¥¼¤W¥«|¥¼¤W¥«ªÑ²¼|³Ì±M·~ªº  ¥xÆW¥¼¤W¥«ªÑ²¼  °]¸gºô¯¸-Copyright©2022¡£¥²´Iºô¡¤ §K¥I¶OªA°È±M½u:0800-035-178   ªA°È«H½c:postmaster@berich.com.tw
¥»ºô¯¸¬° ¥¼¤W¥«ÂdªÑ²¼¬d¸ß,¥¼¤W¥«ªÑ²¼§Y®É·s»D,¥¼¤W¥«¤½¥q¤½§i,¿³ÂdªÑ²¼¶R½æ,·Ç¤W¥«ªÑ²¼,¤¤ÅҪѠ ¬ÛÃö¸ê°T¤À¨É¥æ¬yªÀ¸sºô¯¸,¸ê®Æ¶È¨Ñ°Ñ¦Ò,¨Ï¥ÎªÌ½Ð¦Û¦æ·r°u!
¥»ºô¯¸¤£¤¶¤J·|­û¶¡¤§¥¼¤W¥«ªÑ²¼¶R½æ,³æ¯Â´£¨Ñ  ¥¼¤W¥«ªÑ²¼¦æ±¡,«ùªÑÂàÅý,¥¼¤W¥«ªÑ²¼¹L¤á¿Ô¸ß  ¶È´£¨Ñ¥¼¤W¥«ªÑ²¼¥æ©ö¥­¥xµ¹·|­û¨Ï¥Î,¨Ì¥»¸ê®Æ¥æ©ö«á¬ÕÁ«¦Û­t!